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CHAPTER 1 INTRODUCTION 
Sections 1.1 and 1.2 are adapted with permission from Barrett T.M., Fiore K.E., 
Liu C., James Petersson E. (2019) Thioamide-Containing Peptides and Proteins. 
In: Murai T. (eds) Chemistry of Thioamides. Springer, Singapore. Copyright 2020 
Springer Nature.  
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§ 1.1 Properties, Synthesis, and Incorporation of Thioamides into Peptides
and Proteins 
Properties of Thioamides 
The modification of the peptide backbone has long been of interest to 
biological and medicinal chemists.  Numerous methods for backbone modification 
with peptide bond analogs exist, including esters, thioesters, N-methyl amides, 
thioamides, selenoamides, alkenes, and fluoroalkenes, along with many others1.  
Chalcogen amide modification is of particular interest as they are nearly isosteric 
with the native oxoamide and retain many key features, including hydrogen 
bonding donor and acceptor capabilities.  However, due to the instability of seleno- 
and telluroamide modifications, thioamides are by far the most widely studied of 
these chalcogen backbone modifications. 
While the thioamide substitution is appealing as an oxoamide isostere, it 
does have different physiochemical properties, many of which can be understood 
by considering that the thioamide populates resonance structure B in Figure 1.1 to 
a greater degree than resonance structure A.   
Figure 1.1 Applications of thioamides.  
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The increased single bond character in the thiocarbonyl results from a 
poorer orbital overlap with the carbonyl carbon’s π bonding orbitals, making the 
thiocarbonyl bond slightly longer than the oxocarbonyl bond, with a lower bond 
dissociation energy2.  The increased C=N double bond character explains the 
higher rotational barrier for the thioamides, and the resulting quaternary 
ammonium character explains the larger dipole moment of the thioamide as well 
as the lower N-H pKa of the thioamide3-4.  The decrease in pKa correlates with 
stronger N-H hydrogen bond donation by the thioamide5-6.  While one might think 
that the larger dipole moment of the thioamide would make it a better hydrogen 
bond acceptor as well, the larger van der Waals radius of sulfur makes the partial 
negative charge more diffuse and again reduces orbital overlap, significantly 
weakening the hydrogen bond accepting ability of thioamides7.  Thioamides exhibit 
higher reactivity as both nucleophile and electrophile8-9.  Thioamides are also 
known to have greater affinities than oxoamides for soft metals, such as Cu(I), 
Ag(I), Hg(II), and others10.  In addition to these effects on covalent and non-
covalent interactions, thioamidation red-shifts the π→π* absorption and decreases 
the oxidation potential of an oxoamide3, 11.  These two properties respectively allow 
thioamides to participate in Förster  resonance energy transfer (FRET) and photo-
induced electron transfer (PeT) mechanisms when combined with appropriate 
donor fluorophores12.  All of these properties are summarized in Table 1.1 and 
inform our understanding of the roles of thioamides in natural peptides as well as 




Table 1.1 Physical properties of thioamides. 
Property Oxoamide Thioamide 
vdW radius (Å)13 1.40 1.85 
C=X length (Å)2 1.23 1.71 
Electronegativity14 3.44 2.58 
C=X…H-N BE (kcal mol-1)6 6.1 4.8 
N-H pKa3 17 12 
π→π* absorption (nm)11 200 270 
EOx (V vs. SHE)3 3.29 1.21 
Abbreviations: vdW radius refers to the van der Waals radius. BE refers to bond energy.  EOx is 
the oxidation potential versus a standard hydrogen electrode (SHE). 
 
Synthesis of Thioamides and Thioamino acid Precursors 
The first reported synthesis of a thioamide was performed in 1815 by Gay-
Lussac, where cyanogen and hydrogen sulfide were used to form 
cyanothioformate and dithiooxoamide15.  However, the products of this reaction 
are not very useful for the synthesis of thioamide functionalized molecules.  One 
of the first methods used to create a variety of different thioamides was the 
Willgerodt-Kindler reaction, which allowed thioamides to be synthesized from 
ketones, aldehydes, isothiocyanates, and amides16.  A key development in the field 
was the advent of Lawesson’s reagent (1, 2,4-Bis-(4-methoxyphenyl)-1,3,2,4-
dithiadiphosphatane-2,4-dithione) and the use of tetraphosphorous decasulfide 
(P4S10), which have since served as standard reagents for synthesizing thioamides 





Figure 1.2 Previous routes to thioamides.  Left: Thionating agents to generate 
thioamides in small molecules.  Right: Thioamide incorporation into peptides using 
thioacids and azides (EWG: electron-withdrawing group) or activated thiocarbonyl 
solid phase peptide synthesis (SPPS) reagents. 
 
Recently, interest in creating thioamides for uses as biological probes, metal 
frameworks, and other applications has led researchers to investigate newer, 
easier methods to synthesize thioamides.  These include methods for synthesizing 
thioamides from methylarenes, aldehydes, ketones, thiols, alkynyl bromides, 
oximes, and carboxylic acids19-25.  There has also been an effort to investigate 
milder conditions to form thioamides, by decreasing the reaction temperature, 
removing metals, and performing the reactions in different solvents26-28.  Methods 
that utilize Lawesson’s reagent, elemental sulfur, and P4S10 produce toxic 
byproducts, so there have been several efforts to create newer, safer thionating 
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reagents (Figure 1.2).  To this end, Bergman and coworkers were able to isolate 
and use a pyridine-P4S10 complex in acetonitrile to thionate a variety of scaffolds29.  
Interestingly, Yadav and coworkers were able to thionate aldehydes and ketones 
using O,O-diethyl dithiophosphoric acid (2)25.  Similarly, Kaboudin and coworkers 
reported a method that utilizes ammonium phosphorodithioates (3) in the direct 
conversion of carboxylic acids to thioamides20.  Due to the difficulty in purifying 
byproducts from reactions with Lawesson’s reagent, Ley et al. developed a solid 
phase thionating reagent (4) that is able to convert secondary and tertiary amides 
to thioamides30.  This solid-phase thionating reagent can be removed from the 
reaction mixture using a simple fritted funnel, which makes purification significantly 
easier.  In an alternative approach, Kaleta and co-workers have created fluorinated 
derivatives of Lawesson’s reagent (5) that can be removed from the reaction by 
extraction31-32. 
 
Incorporation of Thioamides into Peptides 
For the incorporation of thioamides into peptides, the use of reagents that 
are compatible with standard peptide synthesis methods is highly desirable.  To 
our knowledge, the first synthesis of a thiopeptide was completed in 1911 by 
Johnson and Burnham, where they produced thioimidated glycine derivatives by 
reactions of nitriles with hydrogen sulfide33.  However, it was not until 1973 that the 
first thioamide derivative of a complex peptide was made, when du Vigneaud and 
coworkers synthesized a thioamide analogue of oxytocin34.  They first synthesized 
thioglycinamide by thionating N-benzoyl-glycinamide with P4S10.  The 
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thioglycinamide was then incorporated into a tripeptide fragment using solution 
phase peptide synthesis.  Finally, this tetrapeptide was coupled to the cyclic core 
of oxytocin.  The incorporation of thioamides into short peptide fragments for later 
inclusion into a larger peptide paved the way for the rational synthesis of 
thiopeptides. 
Direct thionation of peptides has also been reported as a method for 
incorporation of thioamides into the backbone of peptides2, 35.  In these examples, 
short peptides containing α-aminoisobutyric acid (Aib) or β-amino acids are directly 
thionated with 1.  However, in some cases, a mixture of thionated products is 
observed.  Additionally, Heimgartner et al. reported the synthesis of thionated 
dipeptides containing Aib by the “azirine/thiazolone” method, which incorporates 
thioamino acids into a peptide through a ring opening reaction36.  Initially, 
epimerization of the α-carbon of the amino acid selected for thionation made this 
method problematic.  Later, it was reported that the use of HCl/ZnCl2 during the 
migration of the thioamide from Aib to the n+1 residue abolished epimerization, 
leading to stereochemically pure thiopeptides37.  However, the need for including 
Aib in the peptide sequence still limited the utility of this method. 
Thioacids (6) have also been used to install thioamides into peptides, both 
using peptide coupling reagents and reactions with electron-poor azides (7).  
Studies by Williams and coworkers elaborated the mechanistic pathways leading 
to either oxoamide or thioamide incorporation through reactions with azides38.  
More recently, Hackenberger’s group determined that the ratio of oxoamide-to-
thioamide peptides could be controlled through optimization of the azide moiety 
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and the pH of the reaction39.  It was found that electron-poor azides and acidic 
reaction conditions gave the best conversion to the desired thioamide peptide, but 
that selectivity was still limited to 11:1 (Figure 1.2).  Thioacids have also been 
activated for peptide incorporation using benzotriazol-1-yl-
oxytripyrrolidinophosphonium hexafluoro-phosphate (PyBOP) and bis(2-oxo-3-
oxazolidinyl)phosphinic chloride coupling reagents40-41.  Activation with PyBOP 
was performed on fluorenylmethoxycarbonyl (Fmoc) protected amino acids, which 
enabled easy integration with common solid phase peptide synthesis (SPPS) 
procedures, unlike the previous methods.  However, it was found that these 
coupling procedures must be optimized for each amino thioacid, due to the 
potential for epimerization. 
In order to efficiently incorporate thioamides into peptides made by SPPS, 
Belleau and coworkers established a method using thiobenzimidazolones (8) as 
chemoselective thioacylating agents that were stable and storable (Figure 1.2)42.  
While this was a valuable first account of a chemoselective thioacylating agent, 
there were a few drawbacks to this method, including a small loss (2%) of 
enantiometic purity and a reactive benzimidazole byproduct (9), reducing the 
overall yield to 20%.  After this report, several others reported similar thioacylating 
reagents such as fluorobenzimidazolones (10), thioacyl-N-phthalimides (11), 
benzotriazoles (12), and nitrobenzotriazole (13) derivatives (Figure 1.2)43-44.  The 
nitrobenzotriazole thioacylation method reported by Rapoport and coworkers is 
now by far the most widely used route for high yielding syntheses of thioamide 
precursors that can be stored and coupled with no observable epimerization43. 
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We and others have successfully synthesized Fmoc thioacylbenzotriazole 
monomers (17a/17b) of Ala, Ile, Leu, Phe, Pro, and Val utilizing N-Boc-1,2-
phenylenediamine (15a) and L- and D-Ala, Arg, Asp, Asn, Cys, L- and D-Glu, Gln, 
Gly, His, Ile, Leu, Lys, L- and D-Phe, Pro, Ser, L- and D-Tyr, and Val, as well as 
D-Trp and L-4-hydroxyproline (Hyp), utilizing 4-nitro-1,2-phenylenediamine (15b) 
as amidating reagents (Figure 1.3)45-57.  Fmoc protection of the α-amine was used 
due to its compatibility with SPPS methods that do not require HF for sidechain 
deprotection and resin cleavage.  These thioamino acid monomers are stable to 
storage conditions for several months and can be used without further purification 
after the ring closing step.  Incorporation follows standard Fmoc SPPS procedures, 
excepting that no additional coupling reagent is required for addition of the 
thioacylbenzotriazole monomer.  Typical yields of thioamide-containing peptides 
are about 25-50% of the corresponding oxoamide sequence.  While this is 
undesirable, the methods are sufficiently robust that they have been used to 
synthesize a variety of thiopeptides of up to about 40 amino acids in length, 
including yeast transcription factor GCN4-p1, villin head piece variant HP35, 
glucagon-like peptide 1 (GLP-1), gastric inhibitory peptide (GIP), and various β-
hairpins48, 50, 58-60.  To our knowledge, the longest peptide sequence synthesized 
by SPPS is the B1 fragment of protein (GB1, 56 amino acids) synthesized by both 





Figure 1.3 Thioacylbenzotriazole monomers for solid phase peptide synthesis 
(SPPS).  Top: Synthesis of benzotriazolide and nitrobenzyltriazolide thioamino 
acid precursors: (i) 1. N-methylmorpholine, isobutyl chloroformate, THF, -10°C, 2. 
N-Boc-1,2-phenylenediamine or 4-nitro-1,2-phenylenediamine; (ii) Na2CO3, P4S10, 
THF; (iii) For benzyltriazolide: Trifluoroacteic acid (TFA), then NaNO2, 5% 
H2O/AcOH, 0°C; For nitrobenzyltriazolide: NaNO2, 5% H2O/AcOH, 0°C.  Bottom: 
SPPS with thioamides.  Deprotect: 20% piperidine is used in deprotections prior to 
thioamide incorporation, 2% DBU is used following thioamidation to decrease the 
amount of epimerization.  Couple: For thioamides, Fmoc-Aa-Bt (17a) or Fmoc-Aa-
Nbt (17b); for other amino acids, Fmoc-Aa-OH, (2-(1H-benzotriazol-1-yl)-1,1,3,3-
tetramethyluronium hexafluorophosphate (HBTU), N,N-diisopropylethylamine 
(DIPEA).  Cleave: TFA and other additives, TFA concentrations limited to reduce 
Edman degradation like reactions. 
 
The lower yields of thioamide-containing peptides are caused by side 
reactions that can arise during SPPS due to the fact that thioamides are more 
reactive than oxoamides with both nucleophiles and electrophiles.  Specifically, in 
the acidic conditions of resin cleavage, an Edman degradation-like reaction can 
cause backbone cleavage at the n+1 position (Figure 1.4).  To avoid this, one must 
consider shortening cleavage times, which must be balanced with a need to fully 
deprotect all acid-labile protecting groups.  Another side-reaction that can occur is 
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a S-to-O exchange when water and base are present (Figure 1.4).  In order to 
avoid this, our laboratory and others have used anhydrous methylene chloride in 
the coupling step of the thioamino acid precursor47.  Finally, epimerization of the 
α-carbon of the thioamide residue is a serious issue that can arise during the Fmoc 
deprotection steps subsequent to incorporation (Figure 1.4).  This epimerization is 
possible due to the lower pKa (~13) of the thioamide α-carbon (see a detailed 
analysis in the Supporting Information of Szantai-Kis, Walters et al. 2017)62.  In 
order to decrease the amount of epimerization, Chatterjee and coworkers 
decreased the concentration of piperidine used in their Fmoc deprotection solution 
and shortened the reaction time54.  While this led to a noticeable decrease in 
epimerization of the thioamide, they also noted that the yield of their peptide 
synthesis decreased significantly due to incomplete Fmoc deprotection.  Our 
laboratory has also investigated methods for decreasing the epimerization of the 
thioamide.  Specifically, we have used a 2% solution of a more hindered base, 1,8-
diazabicyclo[5.4.0]undec-7-ene (DBU), in our deprotection solutions for removal of 
all Fmoc groups subsequent to thioamide incorporation62.  When treated for a 
shorter time with the DBU solution, there is a significant decrease in the amount of 
epimerization of the thioamide. Very recently, other methods have been developed 
to overcome the issue of epimerization of the thioamide. Khatri and co-workers 
developed a method using a solution of 2% DBU along with 5% piperazine. 
Peptides were treated twice for 60 seconds each, which led to 36% epimerization 
of thioamidated phenylalanine, but full deprotection of the Fmoc group. The 
VanVeller group has also come up with two protection strategies, which make 
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epimerization of the thioamide near impossible. First, Camacho and co-workers 
treated thioamidated peptides with MeI and DIPEA in order to protect the thioamide 
as the thioimidate. After treatment with Fmoc deprotection conditions and the 
usage of hydrogen sulfide to yield the deprotected thiopeptide, it was determined 
that there was less than 0.01% epimerization with this protection technique63. Due 
to concerns about the applicability of using hydrogen sulfide to convert the 
thioimidate to the thioamide, Camacho and co-workers quickly followed up this 
work by developing an azidobenzyl protecting group that could be deprotected with 






Figure 1.4 Side reactions of thioamides.  A cleavage reaction similar to Edman 
degradation occurs through reaction of the thioamide with the n+1 amide in acidic 
conditions (i.e. during resin cleavage).  S-to-O exchange can occur in basic 
aqueous conditions due to the lower N-H pKa of the thioamide.  Epimerization can 
occur with piperidine during Fmoc deprotection due to the decreased Cα-H pKa of 
the thioamide. 
 
Due to the difficulty that can come with incorporating thioamides by SPPS, 
a few groups have studied incorporating thioamides enzymatically. Unverzagt and 
coworkers utilized chymotrypsin in the enzymatic incorporation of thiodipeptides 
into growing peptide chains65.  While this work was only limited to the synthesis of 
short peptides, it could be applicable to longer sequences upon optimization of the 
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enzyme and protecting groups that are utilized.  More recently, Mitchell and 
coworkers have examined the usage of thiazole/oxazole-modified microcin 
(TOMM) cyclodehydratases to install thioamides (and other amide modifications) 
into the backbone of peptides and proteins, a method they call azoline-mediated 
peptide backbone labeling66.  Through the use of the Balh cyclodehydratase, Cys, 
Ser, and Thr residues can be cyclized onto the carbonyl of the n-1 residue to form 
an azoline.  After treatment with KHS, the azoline ring is opened to afford a 
thioamide N-terminal to the Cys, Ser, or Thr residue.  While this reaction is limited 
in sequence scope, the elucidation of thioamide biosynthesis pathways may lead 
to more practical enzymatic methods for installing thioamides, for example by use 
of YcaO enzymes. YcaO enzymes are a class of enzymes that installs the post-
translational modifications (PTMs) on the ribosomally synthesized and post-
translationally modified peptides (RiPPs) is the YcaO superfamily.  This 
superfamily utilizes ATP to phosphorylate and activate the carbonyl of the peptide 
backbone for the generation of PTMs such as azoline heterocycles and azole 
PTMs67.  It is also responsible for the thioamidation of McrA and thioamide-
containing thiopeptides, as well as thioviridamide and its associated molecules. At 
this time, SPPS methods remain the most practical way of installing thioamides 
into peptides of up to about 40 amino acids and coupling of peptide segments must 




Incorporation of Thioamides into Proteins 
While thioamides can be incorporated into peptides through SPPS, there is 
currently no way to incorporate backbone thioamides into full length proteins 
ribosomally.  Therefore, thioamides must be incorporated into proteins through the 
use of native chemical ligation (NCL) or expressed protein ligation (EPL)68.  Briefly, 
NCL refers to the reaction of a peptide fragment containing a C-terminal thioester 
(18) with a peptide fragment containing an N-terminal Cys or Cys analog (19) to 
yield a peptide product linked by a “native” amide bond.  The key step in the 
reaction is the initial engagement of the two fragments through 
transthioesterification, as shown in Figure 1.5.  While this step is reversible under 
the reaction conditions, the subsequent S-to-N acyl shift is not, and the ligated 
product (20) can then be desulfurized to form the final synthetic protein (21) if a 
Cys is not desired at the ligation site.  Desulfurization of Cys provides Ala, and a 
variety of other β- or γ- thiol analogs can be used to produce other amino acids, 
so that one’s choice of ligation site is not significantly limited when designing a 
protein retrosynthesis69.  EPL allows one to produce one of the two fragments by 
expression and purification from cells to avoid unnecessary synthesis of long 
stretches of natural amino acids.  When we began our study of the applicability of 
NCL to synthesize thioamide-containing proteins, there were no previous 
published efforts, and in fact Fischer and coworkers had stated that "the presence 
of thioxo-peptide bonds is not compatible with the subsequent synthesis of the 
thioester which is necessary for the ligation procedure,” presumably referring to 
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HF-based SPPS methods70.  Thus, much of our early effort was devoted to finding 
NCL conditions whereby thioamides would not undergo significant side reactions. 
 
 
Figure 1.5 Native chemical ligation (NCL).  NCL generally requires a peptide with 
a C-terminal thioester (18) and a peptide and an N-terminal Cys (19) or Cys analog 
(Y = amino acid sidechain).  Thioamide incorporation is compatible with both the 
C-terminal thioester portion as well as the N-terminal Cys portion.  In the first step, 
a transthioesterification reaction between the C-terminal thioester and the N-
terminal Cys generates an initial covalent intermediate species.  Next, an 
intramolecular S-to-N acyl shift forms the ligated product (20) with a “native” amide 
bond at the Cys ligation site.  Finally, the Cys can be desulfurized to form Ala in 
the final product protein (21).  Cys analogs are desulfurized to form the 
corresponding natural amino acid.  In the presence of a thioamide, desulfurization 
can be performed with the use of organic radical initiator VA-044 and the use of 
thioacetamide as a sacrificial additive to prevent S-to-O exchange of the thioamide. 
 
We synthesized short peptides for test ligations where LeuS was placed in 
either the N- or C-terminus of fragments with a variety of sequences and lengths46.  
In general, we observed that thioamides were well-tolerated in both the C-terminal 
thioester and N-terminal Cys containing peptide for NCL, with only a few 
sequence-specific issues.  For example, we found that thioamides are not tolerated 
at the n-1 position in relation to the C-terminus of the fragment due to cyclization 
caused by the increased electrophilicity of the thioester.  Side product formation 
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was observed when Cys disulfides were reduced with tris(2-
carboxyelthyl)phosphine (TCEP), but this was shown to be avoidable upon 
sparging solvents with argon in order to prevent prior disulfide formation.  No side 
reactions were observed when thiol reducing agents were used.  Thus, we found 
that one of the most significant barriers to overcome was the need for a robust 
method for the synthesis of thioamide-containing thioester fragments. 
Our initial investigations utilized PyBOP to form the C-terminal thioester (22, 
Figure 1.6), which requires that the sidechain protecting groups remain intact for 
activation.  This can lead to decreased solubility and epimerization of the C-
terminal residue at long reaction times, limiting the sequences and sizes of 
thioester peptides that can be made using this method.  To avoid this issue, we 
investigated using a method developed by Kawakami and MacMillan that would 
form the thioester through intramolecular cyclization (Figure 1.6)71.  In this method, 
a tripeptide sequence containing Csb-Pro-Gla (23, where Csb is a t-butyl thiol 
protected cysteine and Gla is glycolic acid) is appended to the C-terminus of the 
peptide of interest through SPPS on Rink amide resin71-72.  Upon cleavage of the 
peptide from resin and subsequent treatment with TCEP, the free Cys residue 
undergoes an N-to-S acyl shift with the backbone carbonyl of the n-1 residue, 
yielding a free amine that is able to attack the O-ester of the Gla residue to form a 
diketopiperazine thioester (24).  This thioester can either be used directly in a 
ligation reaction or can undergo transthioesterification with other thiols to yield a 
different thioester.  We utilized this method to create a hexameric peptide 
containing LeuS with the Csb-Pro-Gla sequence that, upon cleavage from the 
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resin, could be used in a one-pot Csb deprotection, cyclization, and ligation 
reaction with very little side product observed46. 
 
Figure 1.6 Thioamide-containing peptide thioester synthesis.  PyBOP Activation: 
After cleavage of a peptide (22) from 2-chlorotrityl resin with mild acid, leaving 
sidechain protecting groups intact, benzotriazol-1-yl-oxytripyrrolidinophosphonium 
hexafluorophosphate (PyBOP) can be used to activate the carboxy terminus to 
form the thioester (18) for use in ligation.  Csb In situ Activation: Using a Csb-Pro-
Gla linker (23, where Csb is t-butyl thiol protected cysteine and Gla is glycolic acid), 
after disulfide reduction, the free Cys is able to attack the Gla ester linkage to form 
a diketopiperazine thioester (24) for use in ligation.  The diketopiperazine thioester 
can be exchanged by treatment with a thiol additive.  N-Acyl Benzimidazolinone 
(Nbz, 26): Using resin with a cleavable 3,4-diaminobenzyl (Dbz, 25) linker, the 
peptide C-terminus can be transformed into an N-acyl benzimidazolinone upon 
treatment with 4-nitrophenylchloroformate.  Nbz can be displaced by treatment 
with a thiol.  Acyl Hydrazide: After synthesis on hydrazine-loaded 2-chlorotrityl 
resin and cleavage from the solid phase, the C-terminal acyl hydrazide (27) can 
be reacted with sodium nitrite in acid to form the C-terminal acyl hydrazide (28), 




Our group has also examined the utility of Dawson’s N-acyl 
benzimidazolinone (Nbz) method to synthesize a thioamide with a C-terminal Nbz 
group (26, Figure 1.6)45, 73.  3,4-Diaminobenzyl (Dbz, 25) resin was used to 
synthesize a ValS containing peptide fragment.  After peptide synthesis, 4-
nitrophenylchloroformate was used to form the N-acylurea of the Nbz group.  When 
treated with an N-terminal Cys containing peptide, ligation proceeded with 90% 
conversion.  Despite the high conversion, we were only able to obtain an isolated 
yield of 15% of the desired peptide.  This is likely due to the side reactivity that the 
Dbz resin can undergo at its secondary amino group.  In order to address this 
issue, many reports suggest that the usage of allyloxycarbonate (Alloc) protection 
of this amine can avoid branching and byproducts.  However, the removal of Alloc 
groups requires Pd0, which desulfurizes thioamides74-75.  We investigated a variety 
of other Fmoc SPPS thioester generation methods, including use of Botti and 
Muir’s α-hydroxy Cys analog (Chb),76-77 which performed very well in ligations, but 
was less desirable because the Chb required a five step synthesis before resin 
loading78.  Therefore, we were intrigued by Liu’s 2011 report of the use of C-
terminal acyl azides as latent thioesters79. 
We investigated the compatibility of thioamides with C-terminal acyl azides 
(28) in the synthesis of GB1, a 56 amino acid protein that is frequently used as a 
model system in protein structure investigations.  The synthesis of C-terminal acyl 
azides starts by treating 2-chlorotrityl resin with a 5% hydrazine in DMF solution.  
This forms a C-terminal hydrazide (27) which is stable during the entirety of the 
peptide synthesis and cleavage.  Prior to ligation, the C-terminal hydrazide can be 
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converted to the acyl azide through treatment with NaNO2 in acidic buffer.  Then 
this acyl azide can be converted to the thioester in situ using a thiol (often 4-
mercaptophenylacetic acid) in a neutral to basic buffer solution (Figure 1.6)79.  We 
successfully utilized this method in the ligation of GB1 constructs containing 
thioamides at positions 5, 6, and 780.  Utilizing the C-terminal acyl azides to access 
the C-terminal thioester, we were able to synthesize thioamide-containing GB1 
constructs with 30-40% yields, after purification. 
Our laboratory has also investigated the compatibility of thioamides with 
methods that are used for multi-part ligations.  For a central fragment that will 
undergo two ligations, the N-terminal Cys needs to be protected so that it will not 
react with C-terminal thioesters in an intramolecular fashion to cyclize or in an 
intermolecular fashion to oligomerize.  In 2006, Kent and coworkers described a 
protection method where the Cys could be reversibly masked as a thiazolidine 
(Thz, Figure 1.7)81.  Once the C-terminal thioester has been ligated, the N-terminal 
Thz can be treated with methoxylamine to reveal an N-terminal Cys that can be 
used in another NCL reaction.  There was some concern that there might be 
cleavage of the peptide at the thioamide bond due to treatment with a nucleophile 
like methoxylamine. However, we were able to demonstrate that Thz protection 
was compatible with the three-part ligation of a thioamide-containing peptide with 




Figure 1.7 Thioamide expressed protein ligation (EPL).  Thiazolidine Protected 
Cys.  Proteins expressed with an N-terminal Met-Cys sequence and an unnatural 
amino acid (29) are obtained with the Met residue cleaved by methionine 
aminopeptidase and the N-terminal Cys converted to a thiazolidine (Thz) by 
reaction with endogenous aldehydes.  Treatment with methoxylamine opens the 
Thz ring, exposing the Cys residue for ligation (30).  Cys Masking:  After ligation 
(31), Cys can be masked as mimics of other amino acids by reaction with alkyl 
halides (32); bromoethylamine yields a Lys mimic, iodoacetic acid or 
iodoacetamide yield a Glu or Gln mimic, respectively.  Aminoacyl Transferase 
(AaT): AaT and a Met tRNA synthetase (MetRS) can be employed to append an 
S-protected homocycteine (Hcs) to the N-terminus of an expressed protein with a 
terminal Arg (33) or Lys (not shown) residue.  This segment (34) can be used in a 
ligation reaction with a thioester (18) and then masked with methyl iodide to form 




In the pursuit of chemically synthesized proteins, EPL has been an 
important advance, utilizing the expression of large portions of proteins that can 
be used in NCL with shorter, synthetic peptides82.  We have successfully used EPL 
to incorporate thioamides into α-synuclein (αS), calmodulin (CaM), and GB1, with 
99% retention of the thioamide61, 83-84.  However, we are also interested in double-
labeling proteins with thioamide-fluorophore pairs for FRET studies.  In order to 
achieve this, we have used unnatural amino acid mutagenesis to incorporate 
cyanophenylalanine (Cnf) into αS9-140 expressed as in E. coli.  To obtain an N-
terminal Cys, we can express the protein with an N-terminal polyhistidine tag for 
purification by Ni2+ affinity chromatography.  After this step, the His tag can be 
removed using the appropriate protease, to reveal an N-terminal Cys for ligation.  
We have also had success utilizing the endogenous methionine aminopeptidase 
in E. coli to cleave Met from an appended N-terminal Met-Cys sequence.  The N-
terminal Cys reacts with endogenous aldehydes to form Thz (29, Figure 1.7).  
Deprotection with MeONH2•HCl reveals the N-terminal Cys on the protein for 
ligation.  After purification of the deprotected expressed fragment (30), a short 
peptide containing PheS was ligated for 24 hours, resulting in double-labeled 
protein.  However, this method still required installation of a non-native Cys residue 
in order to perform the chemistry required for ligation. Our group has also shown 
that C-terminal thioesters can be obtained from expressed proteins by simply 
incubating an intein containing protein with MESNa (2-mercaptoethanesulfonate), 
which will cleave the intein leaving a C-terminal thioester for ligation. 
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Requirement of a ligation site Cys in order to perform NCL or EPL was a 
significant initial limitation of the methods which has been largely eliminated 
through methods for desulfurization of Cys or Cys surrogates after ligation.  It has 
been shown that β- or γ- thiol analogs of many of the natural amino acids can be 
used in NCL reactions, with selective desulfurization following, in order to obtain a 
traceless ligation85.  The Raney Ni conditions used in early NCL desulfurization 
reactions were not compatible with thioamides, leading to desulfurization and 
backbone cleavage86.  The organic radical initiator VA-044 (2,2’-Azobis[2-(2-
imidazolin-2-yl)propane]dihydrochloride) developed by Danishefsky was reported 
to be selective for desulfurization at Cys, even in the presence of possibly reactive 
PTMs87.  Our group was able to demonstrate that thioamides are also compatible 
with the usage of VA-044 for selective desulfurization, provided that thioacetamide 
is used as a sacrificial scavenger (Figure 1.5)86.  This was then successfully 
applied to the synthesis of a thioamide-containing analogue of GB1. 
In addition to desulfurization, reactions which convert Cys to mimics of other 
amino acids are also valuable ways of masking the ligation site Cys.  Previously, 
it has been reported that Cys can be reacted with bromoethylamine in order to 
yield a Lys mimic88-89.  In this reaction, the protein is dissolved in pH 8.6 Tris buffer 
and reacted with bromoethylamine in order to obtain the alkylated Lys mimic (32, 
R = CH2NH2, Figure 1.7).  In our hands, this reaction has proven to be compatible 
with thioamides in the semi-synthesis of GB1 constructs.  Cys can also be masked 
to produce Gln/Glu mimics at the site of ligation.  In our synthesis of thioamide-
containing CaM constructs, a Gln was mutated to a Cys to allow for ligation to 
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occur.  After ligation, this free Cys containing CaM was treated with iodoacetamide 
in order to yield the Gln mimic61. Similarly, iodoacetic acid can be used in order to 
create a Glu mimic at the ligation site90.  Our group has observed that these 
masking techniques are compatible with thioamide inclusion provided that Cys 
alkylation times are limited.  These findings allow for a larger sequence space of 
thioproteins to be synthesized using ligation techniques.  
Finally, we have shown that some Cys analogs can be enzymatically 
transferred to the N-terminus of proteins, used in ligation, and then converted to 
other amino acids (Figure 1.7).  Homocysteine (Hcs) can be used in this manner, 
as treatment with CH3I upon completion of protein synthesis converts it to Met91.  
In order to also expand the scope of possible EPL reactions, our group developed 
a method to enzymatically incorporate Hcs into proteins92.  Utilizing the E. coli 
enzyme Leucyl/Phenylalanyl Amino Acyl Transferase (AaT), a protein with N-
terminal Lys or Arg (33) can be functionalized with S-(thiomethyl)homocysteine 
(Hcm)93-95.  After transfer, the Hcm can be converted to Hcs through TCEP 
deprotection (34), which allows for subsequent reaction with a C-terminal thioester 
(18).  Hcs can then be converted to Met with CH3I (35).  We have shown that this 
can be used with unnatural mutagenesis in the expressed protein fragment to 
generate Cnf-labeled αS containing an AspS using Met5 as the ligation site.  AaT 
can also be used to transfer selenocysteine (Sec) to proteins with N-terminal Lys 
or Arg.86  Sec can be used in NCL reactions and selectively deselenized to Ala 
using TCEP without desulfurizing Cys residues in the ligated protein.  Sec can also 
be converted to Ser96.  These experiments demonstrate the value of being able to 
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functionalize protein N-termini with traceless ligation handles.  Our laboratory has 
investigated mutation of AaT to remove the limitation of specificity for N-terminal 
Lys or Arg (Unpublished Results), and recently Rozovsky and Wang have 
developed a tRNA synthetase for Sec incorporation, which provides a more 
general method for Sec insertion at ligation sites97. 
Taken together, these developments have enabled the synthesis of large 
proteins containing thioamides in combination with other unnatural amino acid 
modifications.  We are interested in using these methods to synthesize a variety 
of thioamide-containing proteins in order to get structural data, such as 2D NMR 
spectra or a crystal structure, to determine the effect of this substitution on the 
global structure of the system within which it is place.  Our laboratory recently 
published work on determining ways to incorporate sidechain thioamides into 
peptides and proteins as a way to utilize thioamides as biophysical probes with 
less potential for disrupting the secondary structure of the protein98.  This method 
is particularly interesting as there is the possibility that sidechain thioamides can 
be incorporated ribosomally into the protein of interest99. 
 
§ 1.2 Previous Studies Examining the Effects of Thioamides on the 
Stabilization of Peptides and Proteins 
Thioamide Substitution Effects on Proteolysis 
Proteases play an important role in drug development since they are 
involved in many biological signaling pathways, and underlie a variety of 
diseases100.  Inhibitors of well-established protease targets such as angiotensin-
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converting enzyme and HIV protease have shown significant therapeutic 
success101.  Thioamides introduced at the scissile bond of protease substrates or 
inhibitors have been applied to study catalytic mechanisms of proteolysis with the 
potential to develop improved protease inhibitors or to stabilize injectable peptides.  
Throughout our discussion, we will refer to the thioamide position in terms of the 
common protease nomenclature where P1 is the amino acid at the position of 
cleavage, or scissile bond, and the other neighboring amino acids in the substrate 
are designated P3, P2, P1, P1', P2', P3', from the N-terminus to the C-terminus 
(Figure 1.8).  Typically, only these 3-4 flanking amino acids are relevant to 
protease recognition of substrates. 
 
Figure 1.8 Thioamide proteolysis scheme.  Proteolysis occurs at the position of 
the red slash.  Amino acids surrounding the scissile bond are denoted P3, P2, P1, 
P1', P2', or P3' as shown.  Thioamide substitutions at these sites can be used to 
probe effects on proteolysis.  X = O or S. 
 
Thioamide Probes of Protease Mechanism 
Numerous proteases have been investigated through thioamide 
modifications, including representatives of the major protease classes – Ser, Cys, 
metallo-, and Asp proteases – which are categorized based on their catalytic 
mechanism.  The zinc metalloprotease carboxypeptidase A (CPA) is one of the 
most well studied proteases to date, in terms of thioamide effects 102-105.  A peptide 
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substrate containing a thioamide linkage at the scissile bond (P1) was found to be 
less efficiently cleaved by CPA105.  In addition, thioamide incorporation near the 
scissile bond of substrates yielded peptides with a similar KM, but a greater than 
10-fold decrease in kcat compared to the corresponding oxoamide substrates.  
These results suggested a mechanism involving a rate-determining step requiring 
C-N bond rotation, wherein the higher rotational barrier of the thioamide would slow 
reaction102-103.  In a subsequent study, other metal ions, including Cd(II), Mn(II), 
Co(II) and Ni(II), were substituted for the native zinc to study their effects on the 
cleavage of oxoamide and P1 thioamide substrates104.  It was found that 
thioamidation led to a large increase in the rate of Cd(II) CPA cleavage relative to 
the oxoamide substrate, but a large decrease in relative activity was observed with 
Mn(II) CPA.  This was explained in that sulfur and oxygen functional groups are 
classified as soft and hard ligands respectively and similarly Cd(II) and Mn(II) are 
classified as soft and hard metals. Empirically, hard metals tend to form stable 
complexes with hard ligands, and soft metals act similarly with soft ligands.  Thus 
the favorable soft/soft thioamide/Cd(II) combination had a 100-fold increase in 
kcat/KM in comparison to Mn(II) CPA (Table 1.2).  These results reflect the 
mechanism for peptide bond hydrolysis in which the metal atom interacts with the 
substrate C=X group at the scissile bond during catalysis. 
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Table 1.2 Protease inhibition by thioamides at the scissile bond (P1). 
Thioamide Substrate Enzyme Thio/Oxo kcat/KM* 
Bz-Gly-GlyS-Phe 
Zn(II) CPA 
6.00 × 10 -4 
Z-GlyS-Phe 0.18 
Z-Gly-AlaS-Phe 3.67 × 10 -3 







9.44 × 10 -4 





* kcat/KM value of thioamide substrate vs. corresponding oxoamide substrate.  
†Bz: benzoyl; Z: N-carbobenzoxy; GlyS: thioglycine; AlaS: thioalanine; PheS: thiophenylalanine; 
LysS: thiolysine; ArgS: thioarginine; CPA: Carboxypeptidase A; AIE: isophthalic acid dimethyl 
ester.  
CPA data from Bond et al.104  Papain data from Cho et al.106 
 
Cho et al. studied the ability of papain and trypsin to catalyze the hydrolysis 
of thioamide and corresponding oxoamide substrates using dipeptides106.  They 
found that both the oxo- and thioamide substrates were cleaved by papain, while 
a thioamide at P1 significantly suppressed the proteolysis rates of typsin as 
compared to the oxopeptides.  According to Roberts et al., the classical “oxyanion 
hole” might be destabilized in the case of the tetrahedral intermediate formed 
during thioamide cleavage due to the longer C=S bond and poorer hydrogen bond 
accepting ability of the thioamide107.  Thus, Cho. et al. concluded that the 
stabilization of the oxyanion plays an important role for trypsin, but not papain, 
which may reflect broader rules for P1 thioamide peptide cleavage by serine vs. 
cysteine proteases106.  However, Foje and Hanzlik reported that papain cleavage 
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of Phe-Gly-NH-R dipeptides with a thioamide at P1 depended on the identity of the 
R group, demonstrating that the active site interactions are more subtle108. 
In another example, Fischer and coworkers investigated dipeptidyl 
peptidase-4 (DPP-4) using AlaS-Pro-pNA as substrate, where the enzyme 
hydrolyzes the bond between Pro and para-nitroaniline (pNA)109.  They found a 
1,100-fold decrease of kcat/Km compared to the oxoamide, which they attributed to 
the decrease of kcat, caused by the increased rotational barrier of the thioamide.  
Recently, our laboratory built on this observation in studying GLP-1 and GIP60, 
natural substrates of DPP-4.  A thioamide substitution at either of the two terminal 
positions increased the peptide half-life in an in vitro proteolysis assay from 2 
minutes to greater than 12 hours.  Competition experiments with an alternate DPP-
4 substrate revealed that thioamide GLP-1 was not a competitive inhibitor, 
seemingly in conflict with Fischer’s finding of a primary kcat effect.  This may be 
due to the fact that the 36 residue GLP-1 peptide cannot be repositioned in the 
active site to accommodate the thioamide, whereas the AlaS-Pro-pNA can, but in 
a way that is not optimal for catalysis.  Examination of the crystal structure of DPP-
4 with a peptide substrate reveals bifurcated hydrogen bonds with the carbonyls 
of the two N-terminal amino acids (Figure 1.9)110.  Thioamidation would disrupt 
these interactions, preventing productive binding of substrates (although the 
rotational barrier may still play a role).  Our laboratory is currently evaluating 
thioamide effects on other proteases by scanning thioamide incorporation around 
the scissile bond, and this systematic approach, coupled with the increased 
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availability of protease crystal structures, should provide additional mechanistic 
insight. 
 
Figure 1.9 Structural analysis of the impact of thioamide substitution on DPP-4 
substrate recognition.  Left: An image of the DPP-4 (cyan) active site with a GLP-
1 N-terminal fragment (purple) bound, modeled based on the neuropeptide Y 
bound DPP-4 structure in PDB entry 1R9N110.  The P2, P1, and P1' carbonyl 
oxygens are highlighted as yellow, orange, and grey spheres, respectively.  Key 
interactions with DPP-4 are shown as dashed lines.  Right: A schematic 
representation of the P2, P1, and P1' binding sites.  The DPP-4 cleavage site is 
shown as a red slash. 
 
Thioamide Inhibitors of Protease Activity 
Given the observed resistance to proteolysis for certain thioamide positions, 
there have been attempts to introduce them into protease substrates or other 
peptides to create inhibitors of proteases such as papain, a variety of proline 
specific peptidases, leucine aminopeptidase (LAP), and HIV-1 protease111-115.  
Most of the thioamide inhibitors were found to be competitive inhibitors with weak 
binding affinities.  Thioamide modified inhibitors were studied for the first time by 
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Lowe and Yuhavong in 1971111.  A papain substrate was modified by introducing 
a thioglycine at the scissile bond, and weak competitive inhibition was observed, 
with a KI 100-fold greater than the KM of the corresponding oxoamide substrate.  
Moreover, Stöckel-Maschek characterized amino acid thiazolidides (dipeptides 
with thiazolidine units) as DP II protease inhibitors and found that a thioamide 
modification could improve its inhibitory effect116.  Interestingly, in the thioamide 
positional scanning from P3 to P2' of an HIV-1 protease substrate by Chimeleski 
and coworkers, the thioamide at the P2' position rather than P1 position produced 
the most significant inhibition effect (Table 1.3)117.  Moreover, in the study of the 
positional effect of thioamide on prolyl oligopeptidase by Schutkowski et al., two 
series of tetrapeptide-p-nitroanilides, Ala-Gly-Pro-Phe-pNa and Ala-Ala-Pro-Phe-
pNa, along with all possible thioamide derivatives were examined118.  They found 
that a thioamide introduced at the P2 position enhanced kcat/KM 5-fold in the Gly 
series substrates, while it resulted in a 1.7-fold decrease in the Ala series 
substrates.  Studies such as this highlight the need for greater mechanistic 
understanding of thioamide effects to be able to use them rationally in inhibitor 
design. 
Table 1.3 Positional effects of thioamides on the inhibition of HIV-1 protease. 
Thioamide Position IC50 (μM) 





Data from Yao et al.117. 
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§ 1.3 Thioamide Applications in Peptide and Protein Imaging Agents 
Due to the stability thioamides impart on peptide and protein substrates, we 
believed they could be used to stabilize peptide and protein-based imaging agents. 
Peptide and protein-based imaging agents have gained increased usage over the 
years because of their many benefits over anti-body and nanoparticle imaging 
agents. Typically, peptides and small proteins are smaller in molecular weight, 
have good diffusion into tissue, low background signal due to renal clearance of 
the imaging agent that is freely circulating, and low to no immunogenicity119. 
Peptides and proteins are also advantageous as a starting point for imaging agents 
because they typically have known receptors that they interact with at high affinity 
and specificity120. With technologies such as solid phase peptide synthesis, 
recombinant protein expression, and phage display optimizing sequences for 
peptide and protein-based imaging probes is streamlined more now than ever121. 
To date, several peptide or protein-based imaging agents have been used in the 
clinic to help surgeons and physicians care for their patients (Figure 1.10). 
 
Figure 1.10 Design and Usage of Peptide and Protein-based Imaging Agents. Left: 
Example design of peptide or protein-based imaging agent. Center: Imaging agent 
will have an in vivo target, likely a GPCR or surface receptor. Right: Example image 
of what is seen intraoperatively when the imaging agent is used (adapted from 




It is unclear where the development of peptides and proteins as targeting 
moieties for imaging agents started, but the first peptide that gained traction for 
development was somatostatin, a 28 amino acid peptide that interacts with a 
number of somatostatin receptors (SSTRs) that are over expressed in cancer119. 
One of the biggest hurtles in pursuing somatostatin as a targeting moiety is that it 
is endogenous to the body and susceptible to proteolytic cleavage. To address 
this, many analogues were made including the cyclic peptide octreotide (D-Phe1-
Cys2-Phe3-D-Trp4-Lys5-Thr6-Cys7-Thr8-ol)123. An Indium labeled octreotide 
imaging peptide became the first peptide-based radiopharmaceutical approved by 
the United States Department of Food and Drug Administration. The work with 
somatostatin also brought about new knowledge in the development of peptides 
as the basis for imaging agents. Previously, it was thought that agonists of the 
receptors of interest would be the best imaging agents due to their receptor-
mediated internalization. However, work with somatostatin showed that 
antagonists typically occupy the receptor longer and have no effect on the activity 
of the receptor119. Another peptide that has become the “gold standard” for the 
targeting moiety of peptide-based imaging agents is the RGD family of peptides. 
RGD peptides are not agonists, but they do target αVβ3 integrins which are over 
expressed and activated in endothelial cells during tumor angiogenesis123. After 
the moderate success of somatostatin- and RGD-based imaging agents, several 
other peptides became of interest as targeting moieties including gastrin, GLP-1, 
and NPY. As previously discussed with somatostatin, these peptides also had 
issues of stability due to being native peptide sequences. In order to overcome 
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these issues, many avenues for stabilization were developed. Some favorites 
include, incorporation of D-amino acids or beta-amino acids as well as the 
replacement of the carbonyl in the amide bond with an alkene isostere121.  
While peptide-based imaging agents that are always “on” are useful for 
many purposes, researchers were still interested in creating activatable probes 
with which they could image cancer cells. One of the first activatable probes that 
was developed was based on a substrate of matrix metalloprotease-13 (MMP-13), 
which is one of many MMPs overexpressed in cancer cells123. Spectroscopy 
studies with this construct in cells with and without the protease showed an >30-
fold recovery of the fluorescence signal only in cells containing the protease. This 
probe could also be used to monitor, image, and analyze cancer development in 
a rat model.  
Peptides are not the only naturally occurring scaffolds that have been used 
as targeting moieties for imaging agents. Small proteins (molecular weight less 
than 60kDa) have also been developed for use as imaging agents. Even though 
proteins are larger than many of the peptides previously discussed, they are still 
small enough that they do not have poor absorption properties124. In fact, several 
recombinant antibody-binding fragments (Fabs) and single-chain variable 
fragment antibodies (scFvs) are in late-stage clinical development. Even though 
the size of Fabs and scFvs are smaller in comparison to full-length antibodies, 
there is still a need for size reduction, which is why HER antibodies and affibodies 
are being developed. Interestingly, cytokines and chemokines are being of interest 
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in order to develop imaging agents that allow the immune reactions to tumors be 
imaged and detected124. 
 
§ 1.4 Prospectus 
Thioamides are a single-atom oxygen-to-sulfur substitution that can be 
placed in the backbone of peptides and proteins that impart significantly different 
chemiophysical properties than their oxoamide counterpart. These properties 
allow thioamides to be used in a number of different applications, including its use 
as a medicinal peptide modifier, biophysical/functional probe, and many others. Us 
and many others have observed that thioamide incorporation near, or at, the 
scissile bond in peptide substrates of different proteases will decrease the 
proteolysis rate of that peptide. However, this phenomenon had not been studied 
systematically and only observed in a handful proteases. In this thesis, I will 
address the systematic study of the positional effects of thioamides on substrates 
of both cysteine and serine proteases. Next, I will discuss how we utilized our 
knowledge of the positional effects thioamides have on the protease kallikrein in 
order to develop a stabilized peptide, TB1-RS6, to image NPY Y1 receptors that 
are overexpressed in breast cancer. Then, I will discuss our work on the 
optimization of TB1-RS6 to afford an imaging peptide with specific desired 
properties. Finally, I will discuss our work on the expression of full-length peptide 
hormones for eventual in vivo imaging applications. Taken together, this work 




CHAPTER 2 FLUORESCENT PROBES FOR STUDYING THIOAMIDE 
POSITIONAL EFFECTS ON PROTEOLYSIS REVEAL INSIGHT INTO 
RESISTANCE TO CYSTEINE PROTEASES  
 
Adapted with permission from C. Liu, T. M. Barrett, X. Chen, J. J. Ferrie, E. J. 




§ 2.1 Introduction 
Thioamide substitution, a single atom O-to-S modification of the peptide 
backbone, has been shown to reduce the rate of proteolysis when incorporated at 
or near the scissile bond.102, 104, 106, 108, 115, 117-118, 125-127  For example, our laboratory 
described the introduction of thioamides into glucagon-like peptide-1 (GLP-1) and 
gastric inhibitory polypeptide (GIP), two therapeutically relevant peptide substrates 
of dipeptidyl peptidase 4 (DPP-4).60  A single thioamide near the scissile bond 
provided up to 750-fold enhancement of peptide stability compared to the all-amide 
peptide without significantly altering cellular activity, and a thioamide modified 
GLP-1 was active in rats.  A recent report by Chatterjee and coworkers 
demonstrated that thioamide incorporation in macrocyclic integrin agonists can 
increase their serum half-life by 3-fold while maintaining or even increasing 
potency toward MBA-MD-231 and U87 MG cancer cell lines.56  Studies such as 
these show that thioamides can be highly useful for the stabilization of peptides 
toward key proteolytic events for in vivo applications.  However, despite numerous 
investigations of proteases using thioamide peptides, few systematic studies have 
been performed to study the positional effects of thioamide substitution on 
proteolysis.117-118 
 
§ 2.2 Synthesis of Fluorescent Probes 
Our laboratory has previously developed a thioamide-based fluorescent 
protease sensor system which we envisioned using to better understand the 
effects of thioamides on proteolysis.128  This system, based on our extensive 
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studies of thioamides as fluorescence quenchers,12, 47 involved placing a thioamide 
and a fluorophore on opposite sides of the scissile bond, so that a fluorescence 
turn-on would be observed once proteolysis occurs.  To study the positional effects 
of thioamides on cysteine proteases, we generated a peptide substrate labeled 
with a fluorophore, 7-methoxycoumarin-4-yl-alanine (μ), at both the C-terminus 
and N-terminus with the thioamide placed at the position to be tested (Figure 2.1).  
With this design, no matter where the thioamide is located, quenching by one of 
the fluorophores will be relieved when the peptide is cleaved, so that proteolysis 
can be monitored by a fluorescence change.  In the case of the P1 thioamide, 
successful proteolysis should lead to dequenching of both fluorophores, since the 
thionoacid resulting from initial thioamide hydrolysis would undergo further 
reactions with water to form the carboxylic acid.102, 104 Figure 2.1 shows the 
fluorescence turn-on scheme for the P2 thioamide construct (others are shown in 
Figure 2.6).  Our sensor design provides a general method for testing thioamide 
positional effects using real-time fluorescence to monitor cleavage kinetics, a 
significant improvement over earlier designs that either required chromatographic 





Figure 2.1 Design of Thioamide Positional Scanning Probes. Peptides contain 7-
methoxycoumarinylalanine (µ) residues at the termini, and amide (X=O) or 
thioamide (X=S) residues between.  The red line represents the cleavage site.  
Amino acid residues are denoted as P3 to P3' from the N-terminus to the C-
terminus.  P2 peptide fluorescence turn-on shown corresponds to Figure 2.2 inset. 
 
§ 2.3 Positional Effects of Thioamides on Papain and Cathepsin Family 
Proteases 
For an initial demonstration of our method, we investigated cysteine 
proteases in order to compare our results to previous, more limited studies of 
thioamide effects on these enzymes and show the value of an exploration of many 
positions and proteases, enabled by our sensor design.106, 130  Cysteine proteases 
are primarily localized in the cytosol or lysosome, and mediate general functions 
such as catabolism of intracellular proteins as well as specialized functions like 
selective activation of extracellular protein degradation131.  The papain family 
cysteine proteases, which include parasite proteases (cruzain and falcipains), 
plant enzymes (bromelain and papain), and human cysteine cathepsins (Cts B, C, 
F, H, K, L, O, S, V, W, X), are the most abundant cysteine proteases.  They play 
important roles in many biological and pathological events.132-135  Thus, the ability 
to manipulate cysteine proteases by inhibiting them, making peptides resistant to 
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them, or designing sensors for them can have valuable applications in biology and 
medicine. 
 We studied papain as well as Cts B, K, S, and V (31-59% homologous, 
Figure 2.20).  For these experiments, a series of peptides, μLLK/AAAμ and its 
thioamide analogs, were synthesized using slightly modified solid phase methods, 
employing thioacylbenzotriazole monomers to introduce the thioamides as 
previously described.136-137  The sequence was designed to be recognized by all 
five cysteine proteases and cleaved at the position indicated by “/”, based on our 
own previous study and comprehensive sequence/activity studies of these 
proteases by Ellman and coworkers.128, 138  We generated variants where the 
thioamide was scanned from the P3 position to the P3' position, using the standard 
protease nomenclature as depicted in Figure 2.1.  For example, the P1 substrate 
has the sequence μLLKSAAAμ, where the position of the thioamide is indicated by 
a superscript “S.” 
 In our initial steady state protease assay, each peptide substrate was 
incubated at 7.5 µM in the presence or absence of a protease in a concentration 
determined to lead to complete cleavage of the Oxo control substrate (µLLKAAAµ) 
within 30 min.  While the thioamide substrates were designed to have a turn-on of 
fluorescence, we found that the oxoamide substrate was also conveniently 
fluorogenic, presumably due to relief of quenching through a homo-FRET (Förster 
resonance energy transfer) mechanism.139  Thus, for all substrates, fluorescence 
intensity was monitored over time to determine cleavage kinetics (see Figure 2.2 
Inset and Figures 2.7-2.11 in Materials and Methods for primary data).  Matrix-
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assisted laser desorption ionization mass spectrometry (MALDI MS) was used to 
identify the Oxo peptide fragments generated by proteolysis and confirm that 
significant cleavage took place only at the designed site, between Lys and Ala 
(Figure 2.12).  In the absence of protease, no significant change in fluorescence 
was observed, and no degradation was observed by MALDI MS.  By monitoring 
the increase in fluorescence over time until proteolysis was complete, we could 
convert the fluorescence data to product formation rates, as detailed in the 
Methods and Materials section.  The normalized proteolysis rate data shown in 
Figure 2 allow one to easily visually compare the effects of thioamidation at each 
position for each protease.  While all proteases were affected by at least one 
thioamide position, the magnitude of the effects at each position were greatly 
variable according to the protease.  For a more quantitative comparison, the 
normalized initial rates of each peptide with each protease are reported in Table 
2.1 Initial Rates of Peptide Cleavage by Cysteine Proteases.a. 
 We found that thioamides which were far away from the scissile bond, at 
the P3 and P3' positions, had little effect on the peptide half-life.  Thioamides near 
the scissile bond conferred different levels of resistance to proteolysis.  Similar to 
previous results from Cho et al. and Asbóth et al., we found that papain proteolysis 
was dramatically slowed by a P1' or P2 thioamide, while only slightly affected by 
the P1 thioamide.106, 130  However, this result is clearly not applicable to all cysteine 
proteases.  While all five proteases were slowed to a similar extent by P1' 
thioamidation, the effect of P2 thioamidation was variable.  Cts B was not affected 
by the P2 thioamide and was only affected by the P1' thioamide.  The activities of 
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Cts K, S, and V were reduced by thioamides at all positions except P3 and P3'.  
Cts K and S were significantly retarded by P1 thioamides, in contrast to our papain 
data and the previously published results.106, 108 
 
Figure 2.2 Thioamide Positional Effects on Proteolysis Rates. Top Left Inset: 
Primary fluorescence data for Oxo control peptide and P2 thioamide peptide (both 
defined in Figure 2.1) in the presence (+) and absence (–) of papain.  Top Right: 
Background-corrected, normalized fluorescence traces for papain proteolysis of 
Oxo control peptide and P3, P2, P1, P1', P2', and P3' thioamide peptides (defined 
in Figure 2.1), colored black, purple, blue, green, orange, red, and pink as shown.  
Bottom: Fluorescence traces for proteolysis by cathepsins (Cts) B, K, S, and V.  All 
traces are the average of three trials.  Experimental details and primary 




Table 2.1 Initial Rates of Peptide Cleavage by Cysteine Proteases.a 
Peptide Papain Cts B Cts K Cts S Cts V 
P3 1.01 ± 0.10 0.99 ± 0.05 1.27 ± 0.05 1.21 ± 0.13 1.10 ± 0.09 
P2 0.10 ± 0.01b 1.18 ± 0.07 0.09 ± 0.01 0.16 ± 0.01 0.17 ± 0.01 
P1 0.58 ± 0.04 0.87 ± 0.05 0.07 ± 0.01 0.05 ± 0.01 0.19 ± 0.01 
P1' 0.10 ± 0.01b 0.22 ± 0.02 0.07 ± 0.01 0.05 ± 0.01 0.11 ± 0.01 
P2' 1.38 ± 0.11 0.78 ± 0.05 0.09 ± 0.01 0.12 ± 0.01 0.32 ± 0.02 
P3' 1.18 ± 0.09 0.70 ± 0.04 1.18 ± 0.05 1.03 ± 0.11 1.13 ± 0.11 
aAll rates normalized to rate of cleavage of Oxo peptide.  Raw rate data are reported in Table 
2.5 in Methods and Materials.  bWhen bisphasic cleavage was observed, only the slower rate is 
shown here.  Rates for both phases are shown in Table 2.5 in Methods and Materials. 
 
§ 2.4 Enzyme Kinetic Analysis of Papain with Thiopeptide Substrates 
To probe the mechanism of thioamidation effects, we chose to study papain 
in more depth because significant, but site-selective effects were observed, and 
because more structural data are available for substrates of papain than Cts B, K, 
S, or V (see below).  We studied papain proteolysis at various concentrations of 
the Oxo, P2, and P1' peptides to determine Michaelis-Menten kinetic parameters.  
We found that the catalytic efficiency (kcat/KM) for papain cleavage of the thioamide 
peptides was about 10-fold lower than that of the Oxo peptide (Figure 2.3).  For 
both the P2 and P1' peptides, the reduction in kcat/KM resulted from a combination 
of a 2-fold change in KM and a 5-fold change in kcat.  Thus, it seems that the P2 or 
P1' thioamide has a minor effect on binding to papain, and a more significant effect 
on adopting a productive cleavage conformation.  This may be caused by the 
higher rotational barrier of the thioamide (thioamide: 22 kcal/mol, amide: 14 
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kcal/mol) to which some previous studies have attributed thioamide protease 
resistance.4, 127  It may also be due to hydrogen bonding effects  (see below). 
 
Figure 2.3 Michaelis-Menten Analysis of Papain Activity on Thioamide Peptides. 
Various concentrations of Oxo, P2, or P1' peptide were incubated in the presence 
of 1.2 µM papain.  Primary fluorescence data are shown in Figure 2.13. 
 
The kcat effect contrasts with our finding that thioamides at the P2 or the P1 position 
of DPP-4 substrates primarily affect binding, and thus the thioamide peptides do 
not serve as competitive inhibitors of DPP-4.60  In this case, binding without 
proteolysis could make the P2 and P1' thioamide peptides competitive inhibitors of 
other papain substrates, so we assessed their inhibition of the proteolysis of a 
commercial chromogenic papain substrate, L-pyroglutamyl-L-phenylalanyl-L-
leucine-p-nitroanilide (PFLNA).  However, 50 µM concentrations of the thioamide 
peptides did not significantly inhibit PFLNA proteolysis (Figure 2.15 and Table 2.8), 
indicating that they are not potent competitive inhibitors, as expected based on 
their KMs.  Solubility problems at higher concentrations prevented us from 
determining whether they functioned as weak (KI >100 µM) competitive inhibitors. 
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 In order to better understand the thioamide positional effects, we conducted 
peptide docking simulations and examined existing X-ray structures of papain with 
covalent peptide inhibitors bound.  While several papain structures are available 
in the Protein Data Bank (PDB) with inhibitors mimicking P3, P2, and P1 
interactions (PDB IDs 1PAD, 1CVZ, 1PPP), only one structure (PDB ID 1BP4) 
exists with an inhibitor mimicking P1', P2', and P3' interactions.140-143  We found 
that the geometry obtained with Rosetta FlexPepDock was consistent with the X-
ray structures and shed further light on the P1' interaction.144  The docked structure 
is shown in Figure 2.4, highlighting interactions of carbonyl groups with papain 
which may be disrupted by thioamide substitution.  Additional papain structures 
are shown in Methods and Materials (Figures 2.16-2.18, Figures 2.22-2.27, and 
Figures 2.29-2.30). 
 The P1' carbonyl (Figure 2.4, orange) interacts with His159, which serves as 
the catalytic base, deprotonating Cys25 for nucleophilic attack on the P1 amide 
bond.  Thioamidation could weaken stabilizing interactions with the protonated 
form of His159, leading to the decrease in kcat for the P1 thioamide peptide.  The P2 
amide (Figure 2.4, blue) makes both hydrogen bond donor (with the Asp158 
backbone carbonyl) and acceptor (with the Gly66 amide N-H) interactions.  
Thioamidation could weaken the acceptor interaction and strengthen the donor 
interaction, repositioning the P2 site closer to Asp158, altering active site geometry 
and again leading to a decrease in kcat.  The mild, two-fold effect on proteolysis of 
the P1 thioamide (Figure 2.4, green) can be attributed to disruption of hydrogen 
bonding interactions with the “oxyanion hole” Gln19 sidechain and Cys25 backbone 
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amides, repositioning the scissile bond prior to nucleophilic attack and/or 
destabilizing the tetrahedral intermediate.108  The variability of the positioning of 
the P1 carbonyl and Gln19 sidechain in the model (Figure 2.4) and papain X-ray 
structures (Figures 2.22-2.23 and Figures 2.28-2.30) implies that this interaction 
flexible and helps to explain its small effect.  The P3, P2', and P3' positions (Figure 
2.4 and Figures 2.16-2.18, purple, red, pink, respectively) are relatively solvent 
exposed, with few interactions, consistent with their lack of effect on proteolysis. 
Analysis of Cts B, K, S, and V structures (Figures 2.24-2.27) with inhibitors 
bound to the non-prime side demonstrates that the P2 amide makes hydrogen 
bonds comparable to those in the docked structure (Figure 2.4) in all cases.  
However, the carbonyl hydrogen bond acceptor in Cts B is found in a flexible 
Gly197-Gly198 sequence, which could tolerate the thioamide perturbation.  In the 
other proteases, the corresponding carbonyl is found in a rigid Val/Leu-Asp/Asn 
sequence, such as the Val157-Asp158 site in papain (Figure 2.4).  This may explain 
why Cts B is not affected by P2 thioamidation.  In this way, prediction of thioamide 
effects on proteolysis must account not only for altered binding interactions, but 





Figure 2.4 Interactions of Substrate Carbonyls in Papain Active Site.  Docked 
structure of LLKAAA peptide shows carbonyl interactions of the P3 (purple), P2 
(blue), P1 (green), P1' (orange), and P2' (red) residues.  Key hydrogen bonds 




§ 2.5 Future Directions 
In summary, we studied the positional effects of thioamide substitution on 
proteolysis by the homologous cysteine proteases papain, Cts B, Cts K, Cts S and 
Cts V.  For all five proteases, P1' thioamidation significantly affected proteolysis, 
indicating that this may be a modification that can be used to stabilize injectable 
peptides toward cleavage by cysteine proteases in a manner similar to our GLP-1 
and GIP DPP-4 stabilization.60  In all cases except for Cts B (lowest homology to 
other Cts enzymes, Figure 2.20), other thioamide positions also had a 10-fold or 
greater effect, allowing for flexibility in one’s placement of a thioamide for 
stabilization if one found that a P1' thioamide compromised bioactivity of the 
peptide.  No protease tested was affected by a thioamide at the P3 or P3' position.  
48 
 
This finding is useful because it allows one to place a thioamide at either of these 
positions to make turn-on sensors for papain-family cysteine proteases without 
fear of disrupting protease activity.  Thus, our study exemplifies how a systematic 
approach enabled by our sensor peptide design, in combination with modelling 
based on available structural information, establishes rules for employing 
thioamides in both peptide medicinal chemistry and fluorescent biosensor 
applications.  The generality of our sensor peptide strategy will allow us to perform 
similar studies on other protease classes to provide broad sets of such rules for 
peptide chemists. In the next chapter, the positional effects of thioamides on serine 
proteases will be discussed, along with applications towards developing stabilized 
imaging peptides. Currently, our group is focusing efforts on using the cysteine 
and serine protease data to develop a machine learning algorithm that will help in 
the prediction of thioamide locations for different applications, including probe 
design and stabilizing peptide substrates. We are also interested in examining the 
effects of thioamide incorporation on Cathepsin L, specifically with the goal of 
developing thiopeptide-based inhibitors.  
 
§ 2.6 Methods and Materials 
General Information.  Fluorenylmethoxycarbonyl-β-(7-methoxycoumarin-4-yl)-
Ala-OH was purchased from Bachem (Torrance, CA, USA).  All other 
fluorenylmethoxycarbonyl (Fmoc) protected amino acids and 2-(1H-benzotriazol-
1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU) were purchased 
from Novabiochem (currently EMD Millipore; Billerica, MA, USA).  Piperidine was 
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purchased from American Bioanalytical (Natick, MA, USA).  Sigmacote®, N,N-
diisopropylethylamine (DIPEA), papain (crude powder; from papaya latex; 1.5 – 10 
units/mg solid), cathepsin B (Cts B, solution; from human liver, ≥1,500 units/mg 
protein), cathepsin K (Cts K, 0.5 mg/mL, recombinant, expressed in E. coli, ≥90% 
pure by SDS-PAGE), cathepsin S (Cts S, 0.2 mg/mL, recombinant, expressed in 
FreeStyle™ 293-F cells, ≥90% pure by SDS-PAGE), cathepsin V (Cts V, 0.38 
mg/mL, recombinant, expressed in FreeStyle™ 293-F cells, ≥90% pure by SDS-
PAGE) and papain substrate pyroglutamyl-phenylalanyl-leucyl-p-nitroanilide 
(PFLNA) were purchased from Sigma-Aldrich (St. Louis, MO, USA).  See 
manufacturer definitions of unit activity at sigmaaldrich.com.  All other reagents 
were purchased from Fisher Scientific (Pittsburgh, PA, USA) unless specified 
otherwise. Milli-Q filtered (18 MΩ) water was used for all solutions (EMD Millipore).  
Peptides were purified with a Varian ProStar High-Performance Liquid 
Chromatography (HPLC) with a diode array detector (currently Agilent 
Technologies; Santa Clara, CA, USA), and analyzed with an Agilent 1100 Series 
HPLC system.  Peptide mass spectra (MS) were collected with a Bruker Ultraflex 
III matrix-assisted laser desorption ionization (MALDI) mass spectrometer 
(Billerica, MA, USA).  Nuclear magnetic resonance (NMR) spectra were collected 
with a Bruker DMX 500 MHz instrument.  High resolution electrospray ionization 
mass spectra (ESI-HRMS) were obtained on a Waters LCT Premier XE liquid 
chromatograph/mass spectrometer (Milford, MA).  Low resolution electrospray 
ionization mass spectra (ESI-LRMS) were obtained on a Waters Acquity Ultra 
Performance LC connected to a single quadrupole detector mass spectrometer.  
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Time-course UV-Vis absorbance and fluorescence were obtained with a Tecan 
Infinite® M1000 PRO plate reader (San Jose, CA, USA).  Stopped flow 
fluorescence measurements were made on a KinTek AutoSF-120 instrument 
(Snow Shoe, PA, USA). 
 
Synthesis of Thioamide Precursors.  Thioalanine and thioleucine 
nitrobenzotriazole precursors were synthesized according to published 
procedures.80 
 
Figure 2.5 Thiolysine Precursor Synthesis. 
 
Synthesis of Nα-Fmoc-Nε-Boc-L-lysine-2-amino-5-nitroanilide (S1). Under 
argon atmosphere, Fmoc-Lys(Boc)-OH (2.3412 g, 5 mmol, 1 equiv.) was dissolved 
in 50 mL of anhydrous tetrahydrofuran (THF) and chilled to -10 °C in a salt ice bath 
(1:3 NaCl/ice).  Under magnetic stirring, N-methylmorpholine (NMM, 1.10 mL, 10 
mmol, 2 equiv.) and isobutylchloroformate (IBCF, 0.65 mL, 5 mmol, 1 equiv.) were 
added to the solution dropwise by a syringe.  The reaction was stirred for 15 min 
at -10 °C.  4-nitro-1,2-pheylenediamine (0.7657g, 5 mmol, 1 equiv.) was added 
and the reaction was allowed to proceed at -10 °C for 2 h, then at room temperature 
overnight.  Upon completion, the solvent was removed by rotary evaporation.  The 
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residue was dissolved in 40 mL of ethyl acetate and extracted against 40 mL each 
of 1 M Na2HPO4, brine, 5% NaHCO3, and brine.  The aqueous layers were 
combined and extracted against 100 mL ethyl acetate.  All the organic layers were 
combined, and the solvent was removed by rotary evaporation.  Silica flash 
chromatography provided the product as a red powder (2.95 g, 4.9 mmol, 98% 
yield) in 70% purity (determined by HPLC). Rf = 0.71 in 95:5 v/v ethyl 
acetate/petroleum ether.  1H NMR (500 MHz, DMSO-d6): δ 9.32 (s, 1H), 8.16 (s, 
1H), 7.88 – 7.83 (m, 3H), 7.82 (d, J = 2.6 Hz, 1H), 7.72 – 7.67 (m, 2H), 7.63 (d, J 
= 7.0 Hz, 1H), 7.38 (t, J = 7.4 Hz, 3H), 7.29 (t, J = 7.4 Hz, 2H), 6.73 (d, J = 9.1 Hz, 
2H), 4.27 (d, J = 6.8 Hz, 2H), 4.20 (t, J = 7.0 Hz, 1H), 4.10 (q, J = 7.4 Hz, 1H), 2.89 
(d, J = 4.2 Hz, 3H), 1.76 – 1.67 (m, 1H), 1.62 (d, J = 9.6 Hz, 1H), 1.33 (s, 12H), 
1.30 – 1.22 (m, 1H).  13C NMR (126 MHz, DMSO-d6): δ 172.18, 156.77, 156.06, 
149.68, 144.32, 144.21, 141.19, 135.95, 128.10, 127.52, 125.76, 123.54, 122.33, 
122.11, 121.66, 120.57, 114.09, 77.81, 66.19, 55.71, 47.15, 39.15, 31.60, 29.74, 
28.73, 23.42, 22.97. ESI+-HRMS: m/z calculated for C32H37N5O7 [M+Na]+ 
626.2385, found 626.2591. 
 
Synthesis of Nα-Fmoc-Nε-Boc-L-lysine-2-amino-5-nitroanilide (S2). 
Anhydrous Na2CO3 (0.1590 g, 1.5 mmol, 0.75 equiv.) and P4S10 (0.6668 g, 1.5 
mmol, 0.75 equiv.) were dissolved in 20 mL of dry THF and stirred at room 
temperature under argon for 1-2 h until the mixture turned into a clear pale yellow 
solution.  Compound S1 (1.2065 g, 2 mmol, 1 equiv.) was added to the solution 
and allowed to react overnight at room temperature under argon atmosphere.  
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Upon completion, the solvent was removed by rotary evaporation.  The crude was 
purified by flash chromatography in ethyl acetate/petroleum ether (4:6 v/v) to yield 
a bright yellow foam (0.4931 g, 0.65 mmol, 33% yield) in 87% purity (determined 
by HPLC).  Rf = 0.34 in 45:55 v/v ethyl acetate/petroleum ether; 1H NMR (500 MHz, 
CDCl3): δ 9.55 (s, 1H), 8.04 (s, 1H), 7.99 (d, J = 11.8 Hz, 1H), 7.74 (dd, J = 2.4, 
7.6 Hz, 2H), 7.55 (t, J = 7.1 Hz, 2H), 7.37 (q, J = 6.8 Hz, 2H), 7.28 – 7.24 (m, 3H), 
6.65 (d, J = 9.8 Hz, 1H), 6.11 (s, 1H), 4.77 (s, 2H), 4.54 (s, 1H), 4.39 (s, 1H), 4.32 
(t, J = 8.8 Hz, 1H), 4.17 (t, J = 7.1 Hz, 1H), 3.15 (s, 2H), 1.93 (d, J = 42.4 Hz, 2H), 
1.52 (d, J = 24.7 Hz, 4H), 1.42 (s, 9H).  13C NMR (126 MHz, DMSO-d6) δ 208.33, 
156.96, 156.07, 151.12, 144.33, 144.06, 141.17, 135.78, 128.14, 128.12, 127.56, 
127.53, 125.90, 125.75, 125.43, 125.16, 122.84, 120.58, 114.35, 77.83, 66.37, 
61.90, 47.09, 33.97, 29.75, 28.76, 23.38.  ESI+-HRMS: m/z calculated for 
C32H37N5O6S [M+Na]+ 642.2357, observed 642.2362. 
 
Synthesis of Nα-Fmoc-Nε-Boc-L-lysine-nitrobenzotriazolide (S3). Compound 
S2 (0.3531 g, 0.57 mmol, 1 equiv.) was added in 5 mL of 5% glacial acetic acid in 
water at 0 °C until fully dissolved.  With stirring, NaNO2 (0.0590 g, 0.86 mmol, 1.5 
equiv.) was added in small portions over 5 min.  The reaction was allowed to stir 
for 30 min at 0 °C, then quenched with 25 mL of ice cold water, resulting in a yellow 
precipitate.  The precipitate was collected by filtration, rinsed with cold water, and 
dried on vacuum for 30 min.  A yellow solid was yielded as the final product (0.3244 
g, 0.5075 mmol, 89% yield) in 75% purity (determined by HPLC).  Note: The 
characterization provided below is for a purified sample, but S3 is often taken on 
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to peptide synthesis as the crude mixture.  Rf = 0.83 in 1:1 v/v ethyl 
acetate/petroleum ether.  1H NMR (500 MHz, DMSO-d6): δ 8.92 (s, 1H), 8.32 – 
8.22 (m, 2H), 8.06 (d, J = 8.0 Hz, 1H), 7.89 – 7.82 (m, 2H), 7.78 (d, J = 8.3 Hz, 
1H), 7.68 (s, 2H), 7.53 (d, J = 7.6 Hz, 2H), 7.33 (dt, J = 34.8, 6.9 Hz, 7H), 7.21 – 
7.11 (m, 1H), 6.67 (d, J = 20.7 Hz, 1H), 4.22 (dd, J = 24.9, 7.1 Hz, 3H), 1.50 (s, 
1H), 1.33 (s, 15H).  ESI-LRMS: m/z calculated for C32H34N6O6S [M+Na]+ 653.2153, 
observed 653.2166. 
 
Peptide Synthesis and Purification.  Each peptide was synthesized on a 25 μmol 
scale on 2-chlorotrityl resin manually using established protocols.86  Prior to use, 
the glass peptide reaction vessel (RV) was coated with Sigmacote® and dried 
under vacuum.  For a typical synthesis, 2-chlorotrityl resin was added to a dry RV 
and swelled in 5 mL dimethylformamide (DMF) for two successive 30 min periods 
with magnetic stirring.  Between each reaction, the resin was washed extensively 
with adequate DMF.  For the first amino acid coupling, 5 equiv. of Fmoc-protected 
amino acid was dissolved in 1.5 mL of DMF and added to the RV, following an 
addition of 10 equiv. of DIPEA.  The reaction was allowed to stir for 30 min.  After 
washing with DMF, the resin was incubated with 2 mL of a 20% piperidine solution 
in DMF for 20 min under stirring for deprotection.  The same deprotection 
procedure was followed for all the subsequent standard amino acids.  For a typical 
coupling reaction, 5 equiv. of amino acid and 5 equiv. of HBTU were dissolved in 
DMF, and added to the RV, with an addition of 10 equiv. of DIPEA.  Thioamide 
precursors were introduced with slightly different coupling and deprotection 
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procedures.  Two equiv. thioamide precursor in 1.5 mL of dry dichloromethane 
(DCM) was added to the RV with 2 equiv. DIPEA, and stirred for 45 min.  For 
deprotection of thioamide Fmoc groups, 20% piperidine in DMF was added to the 
RV for successive 5 min and 15 min incubations with resin under magnetic stirring.  
Upon completion of the synthesis, the resin was dried with DCM under 
vacuum.  Peptides were cleaved off of resin by treatment with a 3 mL fresh 
cleavage cocktail of DCM, trifluoroacetic acid (TFA), water, and triisopropylsilane 
(TIPSH) (65:30:2.5:2.5 v/v) for two successive 30 min periods on a rotisserie.  After 
each treatment, the cocktail solution was expelled from the RV with nitrogen and 
reduced to a volume of less than 1 mL by rotary evaporation.  The crude cleavage 
solution was stored at -80 °C until purification.  The solution was then diluted with 
CH3CN/H2O (1:1 v/v) and then purified on a Vydac 218TP C18 semi-prep column 
(Grace/Vydac; Deerfield, IL, USA) by HPLC using the following gradients (Table 
S1, Table S2) at a flow rate of 12 mL/min.  MALDI MS was used to confirm peptide 
identifies (Table S3).  Purified peptides were dried on a lyophilizer (Labconco; 
Kansas City, MO, USA) or in a vacuum centrifuge (Savant/Thermo Scientific; 
Rockford, IL, USA).  If needed, peptides were subjected to multiple rounds of 





Table 2.2. Peptide Purification Methods and Retention Times. 
Peptide Gradient Retention Time 
Oxo: μLLKAAAμ 1 35 min 
P3: μLSLKAAAμ 1 33 min 
P2: μLLSKAAAμ 1 35 min 
P1: μLLKSAAAμ 1 35 min 
P1': μLLKASAAμ 2 28 min 
P2': μLLKAASAμ 2 28 min 
P3': μLLKAAASμ 2 28 min 
Abbreviations: μ: 7-methoxycoumarinylalanine; AS: thioalanine; LS: thioleucine; KS: thiolysine. 
 
Table 2.3. HPLC Gradients for Peptide Purification. 
Gradient 
No.  




Time (min) %B 
1 00:00 002  2 00:00 002 
06:00 002  06:00 002 
08:00 015  08:00 020 
37:00 040  28:00 040 
40:00 100  31:00 100 
45:00 100  36:00 100 
50:00 002  41:00 002 
Solvent A: 0.1 % TFA in water; Solvent B: 0.1 % TFA in acetonitrile. 
 
Table 2.4. Calculated and Observed Masses of Peptides. 
Abbreviations: μ: 7-methoxycoumarinylalanine; AS: thioalanine; LS: thioleucine; KS: thiolysine. 
Peptide 
[M+H]+ [M+Na]+ [M+K]+ 
Calc Obs Calc Obs Calc Obs 
μLLKAAAμ 1076.53 1075.81 1098.51 1097.79 1114.49 1113.77 
μLSLKAAAμ 1092.51 1092.44 1114.49 1114.42 1130.46 1130.39 
μLLSKAAAμ 1092.51 1092.42 1114.49 1114.40 1130.46 1130.37 
μLLKSAAAμ 1092.51 1092.87 1114.49 1114.85 1130.46 1130.84 
μLLKASAAμ 1092.51 1092.43 1114.49 1114.41 1130.46 1130.38 
μLLKAASAμ 1092.51 1092.38 1114.49 1114.36 1130.46 1130.43 
μLLKAAASμ 1092.51 1092.52 1114.49 1114.51 1130.46 1130.47 
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Reporter Construct Design.  The thioamide peptides were designed to report on 
proteolysis at the scissile bond through relief of quenching of one or both of the 
methoxycoumarin (Mcm or µ) amino acids as shown in Figure 2.6.  This scaffold 
can therefore be used for real-time fluorescence monitoring of proteolysis rates 
regardless of the position of the thioamide.  This real-time analysis capability is in 
contrast to chromatographic assays, which although general, can only be used to 
monitor select timepoints.  Commonly used C-terminal nitroanilide (NA) or 
aminomethylcoumarin (AMC) assays provide real-time data but cannot be used to 





Figure 2.6 Mechanism of Fluorescence Turn-on in Reporter Peptides.  Top: 
Peptides contain 7-methoxycoumarinylalanine (Mcm, µ) residues at the termini, 
and amide (X=O) or thioamide (X=S) residues between.  Inset: Nitroanilide (NA) 
or aminomethylcoumarin (AMC) sensors only provide information on non-prime 
side effects.  Bottom: Cleavage at the scissile bond will lead to relief of thioamide 
quenching of one of the two methoxycoumarin groups in the P3, P2, P1', P2', or 
P3' thioamide peptides.  Cleavage at the scissile bond in the P1 peptide will lead 
to relief of quenching for both methoxycoumarin groups since the thionoester 
cleavage product will be rapidly hydrolyzed to the carboxylic acid. 
 
Steady State Protease Assays.  In a typical trial, a 7.5 μM peptide solution was 
incubated in the presence or absence of 0.12 μM papain in a buffer of 2.0 mM 
ethylenediaminetetraacetic acid (EDTA), 5.00 mM L-cysteine, 300 mM NaCl, pH 
6.2 at 27 °C, or in the presence or absence of the appropriate concentration of Cts 
B (4.133 nM), Cts K (53.19 nM), Cts S (135.1 nM) and Cts V (25.7 nM) in 12.3 mM 
Na2HPO4, 87.7 mM NaH2PO4, 100 mM NaCl, 5 mM DTT, 1 mM EDTA, pH 6.0 at 
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27 °C.  The fluorescence was monitored as a function of time at 390 nm with an 
excitation wavelength of 325 nm on the Tecan M1000 plate reader.  Three 
independent trials were performed for each assay to ensure reproducibility.  These 
data are shown in Figures 2.7-2.11.  MALDI MS analysis of Oxo peptide proteolysis 
by all five proteases confirmed that cleavage occurred at the expected position, 
indicated by the slash, µLLK/AAAµ.  Masses for these peaks are reported in Table 
2.6.  The data from the trials were averaged and cleavage percentages were 
calculated by dividing the fluorescence change of each time point by the 
fluorescence change of complete cleavage (measured up to 6 h).  Initial rates were 
determined by fitting a line to early timepoints (first 2 min) and later timepoints 
(between min 10 to 20) if a biphasic curve was observed.  These are reported in 








Figure 2.7 Proteolysis of Papain Monitored by Fluorescence.  Peptides (7.5 µM) 
were incubated in the presence or absence of 0.12 µM papain in 2.0 mM EDTA, 
5.00 mM L-cysteine, 300 mM NaCl buffer (pH 6.2) at 27°C.  Three independent 
trials are shown overlayed.  For each peptide, the colored trace corresponds to 
fluorescence in the presence of protease and the grey trace corresponds to 








Figure 2.8 Proteolysis of Cts B Monitored by Fluorescence.  Peptides (7.5 µM) 
were incubated in the presence or absence of 4.13 nM Cts B in 12.3 mM Na2HPO4, 
87.7 mM NaH2PO4, 100 mM NaCl, 5 mM DTT, 1 mM EDTA buffer (pH 6.0) at 27°C.  
Three independent trials are shown overlayed.  For each peptide, the colored trace 
corresponds to fluorescence in the presence of protease and the grey trace 








Figure 2.9 Proteolysis of Cts K Monitored by Fluorescence.  Peptides (7.5 µM) 
were incubated in the presence or absence of 53.19 nM Cts K in 12.3 mM 
Na2HPO4, 87.7 mM NaH2PO4, 100 mM NaCl, 5 mM DTT, 1 mM EDTA buffer (pH 
6.0) at 27°C.  Three independent trials are shown overlayed.  For each peptide, 
the colored trace corresponds to fluorescence in the presence of protease and the 








Figure 2.10 Proteolysis of Cts S Monitored by Fluorescence.  Peptides (7.5 µM) 
were incubated in the presence or absence of 135.1 nM Cts S in 12.3 mM 
Na2HPO4, 87.7 mM NaH2PO4, 100 mM NaCl, 5 mM DTT, 1 mM EDTA buffer (pH 
6.0) at 27°C.  Three independent trials are shown overlayed.  For each peptide, 
the colored trace corresponds to fluorescence in the presence of protease and the 








Figure 2.11 Proteolysis of Cts V Monitored by Fluorescence.  Peptides (7.5 µM) 
were incubated in the presence or absence of 25.7 nM Cts V in 12.3 mM Na2HPO4, 
87.7 mM NaH2PO4, 100 mM NaCl, 5 mM DTT, 1 mM EDTA buffer (pH 6.0) at 27°C.  
Three independent trials are shown overlayed.  For each peptide, the colored trace 
corresponds to fluorescence in the presence of protease and the grey trace 




Table 2.5 Initial Rates of Peptides Cleavage by Cysteine Proteases. 
Peptides Papain CtsB CtsK CtsS Cts V 
Oxo 448 ± 30 477 ± 26 491 ± 17 644 ± 44 731 ± 43 
P3 451 ± 33 473 ± 05 623 ± 9 781 ± 66 803 ± 49 
P2 
149 ± 9a 
561 ± 19 42 ± 2 101 ± 5 126 ± 4 
50 ± 4b 
P1 260 ± 5 413 ± 3 34 ± 1 30 ± 1 137 ± 5 
P1' 
606 ± 71a 
104 ± 6 32 ± 2 32 ± 1 82 ± 2 
46 ± 2b 
P2' 618 ± 26 371 ± 11 43 ± 5 80 ± 2 232 ± 8 
P3' 528 ± 17 336 ± 11 581 ± 9 662 ± 56 822 ± 67 
All rates in nM•min-1.  aCleavage rate during first two min.  bCleavage rate during 10-20 min. 
 
 
Figure 2.12 MALDI MS Analysis of Oxo Peptide Cleavage.  Oxo peptide 
(µLLKAAAµ) was cleaved between residues K and A by all proteases.  
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Calculated Observed Calculated Observed 
Papain 
μLLK 618.35 618.43 640.33 640.50 
AAAμ 477.20 477.75 499.18 - 
Cts B 
μLLK 618.35 618.52 640.33 640.19 
AAAμ 477.20 477.94 499.18 - 
Cts K 
μLLK 618.35 618.48 640.33 640.53 
AAAμ 477.20 477.82 499.18 - 
Cts S 
μLLK 618.35 618.52 640.33 640.59 
AAAμ 477.20 477.75 499.18 - 
Cts V 
μLLK 618.35 618.46 640.33 640.52 
AAAμ 477.20 477.83 499.18 - 
 
Papain Michaelis-Menten Kinetic Analysis.  Various concentration of peptides, 
ranging from 5 μM to 150 μM, were reacted with 1.2 μM papain in 2.0 mM EDTA, 
5.00 mM L-cysteine, 300 mM NaCl buffer, pH 6.2, at 27°C in a 96-well plate for P1' 
or P2.  Note that performing Oxo digestion under these conditions resulted in rates 
that were too fast to be accurately monitored and performing the thioamide peptide 
cleavage at lower papain concentrations resulted in slow deactivation of the 
enzyme through autoproteolysis.  Therefore, Oxo peptide digestion was monitored 
using a stopped flow apparatus (see below).  For P1' or P2, the fluorescence of 
the reaction was monitored as a function of time at 390 nm with an excitation 
wavelength of 325 nm on the Tecan plate reader.  Three independent trials were 
performed for each assay to ensure reproducibility (Figure 2.13).  We note that 
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solubility problems were encountered at 150 µM for the P1' thioamide peptide.  In 
order to convert the fluorescence data to reaction progress in terms of 
concentration (μM/min), a conversion factor was calculated by taking the ratio of 
endpoint fluorescence (at long time points of up to 6 h) and substrate 
concentration. 
For Auto-SF-120 stopped flow measurements of the Oxo peptide, 200 µL 
of peptide solution at twice the desired concentration was rapidly mixed with a 2.4 
μM solution of papain in 2.0 mM EDTA, 5.00 mM L-cysteine, 300 mM NaCl buffer 
(pH 6.2) at 27 °C.  Due to the 1:1 mixing of the stopped-flow instrument, this would 
lead to a reaction of peptide at the desired concentration with 1.2 μM papain. 
Fluorescence emission was recorded as a function of time at 390 (± 18) nm, with 
excitation at 325 nm.  Three technical replicates were averaged together for each 
trial to ensure reproducibility.  Concentration of product was determined by 
normalizing to the minimum and maximum fluorescence signals (after reactions 
reached completion) during each trial. 
For both plate reader (P1' or P2) and stopped flow (Oxo) data, the initial 
rates (v0) at each concentration were determined by linear fits, and these rates 
were used to generate the Michaelis-Menten plot shown in Figure 2.3.  Data for 
the P1' peptide at 150 µM were omitted due to solubility problems that led to 
inconsistent data.  These curves were fit to the following equation in Prism 
(Graphpad Software; La Jolla, Ca) to determine VMax and KM.  Turnover number 
(kcat) was calculated by dividing VMax by the enzyme concentration. 
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                                    (Equation 2.1) 
 
 
Table 2.7 Kinetic Parameters Obtained from Papain Michaelis-Menten Analysis. 
Substrates 
VMax 






(µM-1 ∙ min-1) 
Oxo 76.7 ± 4.9 27.5 ± 4.6 63.9 ± 4.0 2.32 ± 0.42 
P2 15.1 ± 0.4 48.2 ± 3.4 12.6 ± 0.4 0.26 ± 0.02 





Figure 2.13 Papain Proteolysis Michaelis-Menten Analysis.  Peptides (Oxo, P2, or 
P1') at varying concentrations were incubated in the presence of 1.2 µM papain in 
2.0 mM EDTA, 5.00 mM L-cysteine, 300 mM NaCl buffer (pH 6.2) at 27 °C either 
in a plate reader (P2 and P1') or rapid-mixing instrument (Oxo).  Initial rates from 
these data were used to develop the activity plot shown in Figure 2.3. 
 
Protease Steady State Kinetics For papain, various concentrations of papain 
substrate PFLNA (6 μM, 10 μM, 20 μM, 30 μM, 60 mM, 100 mM, 150 mM and 200 
mM) were reacted with 1.2 μM papain in 2.0 mM EDTA, 5.00 mM L-cysteine, 300 
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mM NaCl buffer (pH 6.2) at 27 °C in a 96-well plate.  50 μM of P2 or P1' thiopeptide 
was incubated with 1.2 μM papain for 15 min at 27 °C to allow for full binding before 
adding the papain substrate.  Reactions were monitored by UV-Vis absorbance at 
410 nm.  Three trials were performed to ensure reproducibility.  The absorbance 
was converted to the product concentration of p-nitroaniline based on the 
extinction coefficient of p-nitroaniline as 9800 M-1∙cm-1.145  The initial reaction rate 
was calculated by extracting the slope of a linear fit of the first 2 min of the progress 
curve (Figure 2.15).  The average of reaction rates from three trials were calculated 
and fitted to Equation 2.1. (Figure 2.15) to obtain VMax and KM values.  The 2-fold 
or less decrease in VMax in the presence of the thioamide peptides can be attributed 
to cleavage of those peptides over the course of the assay, reducing the effective 
enzyme concentration. 
 
Table 2.8 Kinetic Parameters from Papain Inhibition Analysis. 
Inhibitors None 50 µM P2 50 µM P1' 
VMax (µM ∙ min-1) 0.67 ± 0.05 0.32 ± 0.02 0.47 ± 0.02 






Figure 2.14 Papain Inhibition Analysis.  Papain substrate PFLNA treated at 
different concentrations with and without the presence of inhibitor (P2 and P1’ 
peptides at 50 µM). PFLNA was incubated in the presence of 1.2 µM papain in 2.0 
mM EDTA, 5.00 mM L-cysteine, 300 mM NaCl buffer (pH 6.2) at 27°C either in a 






Figure 2.15 Papain Proteolysis Inhibition Analysis.  Left: Various concentrations 
of the PFLNA substrate were incubated with 1.2 µM papain in 2.0 mM EDTA, 5.00 
mM L-cysteine, 300 mM NaCl buffer (pH 6.2) at 27 °C in the presence or absence 
of 50 µM concentrations of the P2 or P1' thioamide peptides.  Averages of three 





Structure Analysis: Modeling of LLKAAA Peptide Binding to Papain.  The 
interaction between the µLLKAAAµ “Oxo” peptide and papain was modeled using 
PyRosetta and the Rosetta Modeling Suite.146-147  The PDB structure 1BP4 was 
used as a starting structure for papain following excision of the covalent inhibitor 
and two independent simulation approaches were used to dock the LLKAAA 
peptide.140  The LLKAAA peptide was prepared in PyRosetta and was manually 
aligned in PyMOL with the covalent inhibitor in the 1BP4 structure to place the 
scissile bond (K/A) in proximity to the active site Cys residue.147-148  In both 
approaches, constraints between Gln19 and Cys25, which form the oxyanion hole 
as described in Cordara et al, and the P1’ Lys carbonyl oxygen along with a 
constraint between Cys25 and the Lys carbonyl carbon were employed to enhance 
the number of peptide decoys effectively docked to the appropriate location on the 
enzyme (a flat-harmonic potential with an energy of zero from 2 to 4 Å with a 
standard deviation of 1 Å dictating the harmonic profile outside of the zero-energy 
region).149  Likewise, the distance between the Cys25 sulfur and the peptide Lys 
carbonyl carbon was constrained with a flat-harmonic potential set to zero between 
1 and 3 Å and a standard deviation of 1 Å. 
The first approach utilized the FlexPepDock refinement protocol within 
Rosetta, which performs a Monte-Carlo simulation with a gradient-based 
minimization rigid body docking search with on-the-fly optimization of both the 
peptide and enzyme sidechains, allowing for flexible exploration of peptide 
backbone torsions.144  Fragment libraries consisting of 3mer and 5mer fragments 
were constructed using Rosetta’s FragmentPicker application employing the quota 
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method.150  The FragmentPicker was supplied with predictions from the Jufo and 
PsiPred servers.150-152  The refine FlexPepDocking protocol was run using the 
default parameters sampling 1000 decoys with constraints set with a weight of 100 
Rosetta Energy Units (REUs).144  The 10 lowest energy structures, according to 
the FlexPep score, were visualized in PyMOL.144, 148  As shown in Figure 2.16, all 
10 output structures feature the same binding interactions at sites from the N-
terminus through the P2' Ala residue, with the final P3' residue demonstrating 
flexibility. 
The second approach was to “relax” the starting structure with the 
previously designed constraints employed with a weight of 10 REU.  A total of 100 
trajectories were sampled, performing 10 FastRelax protocol executions per 
trajectory.153  In brief, the general Relax protocol consists of interlaced sidechain 
repacking alongside gradient-based minimization of both backbone and side-chain 
torsion angles, with an initially suppressed van der Waals repulsion term, which 
increases in weight with each Relax cycle and returns to its default weight during 
the final cycle.153  Each FastRelax was performed as a dualspace relax using the 
“ref2015_cart” score function, performing the latter stages of the protocol in 
cartesian space.154  Minimizations were performed using the 
“lbfgs_armigo_nonmonotone” minimization method allowing for minimization of the 
bond angles.  The ten lowest energy structures observed during the search were 
all nearly identical in terms of peptide conformation (<0.5 Å RMSD across all 
peptide atoms) in spite of extensive variation in protein backbone and sidechain.  
These are shown overlaid in Figure 2.17 and are shown separately in Figure 2.18.  
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The energy in REU of each of the structures is plotted as a function of RMSD 
relative to the lowest energy structure in Figure 2.18.  The peptide-enzyme 
hydrogen bonds observed in the “Relax” outputs were also observed in the 
FlexPepDock outputs, bolstering our confidence in these simulated docking 
interactions.  The average hydrogen bond distances for all contacts made by the 
backbone amides in the 10 lowest energy structures are reported in Figure 2.18.  





Figure 2.16 Overlay of Lowest Energy Structures from “FlexPepDock” Simulations 
of Papain.  The 10 lowest energy structures of papain in complex with docked 
LLKAAA have minimal variations in carbonyl interactions of the P3 (purple), P2 
(blue), P1 (green), P1' (orange), P2' (red), and P3' (pink) residues.  Note: Protein 
backbone structure is static in these simulations. 
 
Figure 2.17 Overlay of Lowest Energy Structures from “Relax” Simulations of 
Papain.  The 10 lowest energy structures of papain in complex with docked 
LLKAAA have minimal variations in carbonyl interactions of the P3 (purple), P2 
(blue), P1 (green), P1' (orange), P2' (red), and P3' (pink) residues.  In spite of 





Figure 2.18 Lowest Energy Structures from “Relax” Simulations of Papain.  Top: 
The 10 lowest energy structures of papain in complex with docked LLKAAA have 
minimal variations in carbonyl interactions of the P3 (purple), P2 (blue), P1 (green), 




Figure 2.19 Energy and Amide Hydrogen Bond Data from 10 Lowest Energy 
Structures. Left: A plot of the energy (in Rosetta Energy Units, REU) as a function 
of the RMSD of each structure relative to the lowest energy structure from the 
Relax simulations.  Right: Average O-to-H distances for amide hydrogen bonds 
from the 10 structures shown. 
 
Structure Analysis: Existing Inhibitor-Bound X-Ray Structures.  The following 
cysteine protease X-ray structures from the Protein Data Bank (PDB, 
https://www.rcsb.org) were used in analyzing active site interactions of papain (PDB 
IDs 1PPP,143 1PAD,141 1CVZ,142 1BP4140), Cts B (PDB ID 1GMY155), Cts K (PDB 
ID 1BGO156), Cts S (PDB ID 1MS6157), and Cts V (PDB ID 1FH0158).  All structures 
were aligned using MacPyMOL (pymol.org148) and sidechains within 4.0 Å of the 
inhibitor molecule were rendered as sticks.  Oxygens in carbonyl groups, or 
equivalent atoms in reactive groups (e.g., nitrile nitrogen) linked to the active site 
Cys, were rendered as spheres and colored according to the substrate carbonyl 
that they mimic (P3: purple, P2: blue, P1: green, P1': orange, P2': red, P3': pink).  
Figure 2.21 shows an overlay of several structures, highlighting the similarity in 
sidechain positioning in spite of sequence differences among papain and Cts B, K, 
S, and V.  This point is important as it demonstrates that the differences in 
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thioamide effects are not likely to be due to dramatically different sidechain 
interactions in the protease active sites. 
The fact that Cts B is tolerant of thioamidation at positions except for P2 can 
be attributed to the substantial difference in the Cts B sequence, with several much 
longer loops inserted around the active site (Figure 2.24 and sequence alignment 
in Figure 2.20).  As noted in the main text, it is not clear from these structures why 
Cts B is insensitive to thioamidation at the P2 position since all of the P2 carbonyls 
make similar hydrogen bonding interactions with the protein.  However, sequence 
alignment (Figure 2.20) shows that the P2 amide N-H partners with a hydrogen 
bond acceptor Gly residue in CtsB found in a Gly-Gly motif, which could be 
sufficiently flexible to tolerate the change in geometry introduced by thioamidation.  
The corresponding position in papain and the other Cts enzymes is an Asp or Asn 
residue, which is locked into a more rigid position by sidechain hydrogen bonds 
and a bulky neighboring Leu or Val residue.  The P2 carbonyl partner is a Gly 
residue in all Cts and papain structures, so the hydrogen bond acceptor 
functionality of the thioamide is unlikely to be the source of the differential effect of 
P2 thioamidation on Cts B. 
A comparison of Figure 2.23, Figure 2.25, and Figure 2.27 shows that the 
positioning of the P1 and P2 carbonyl oxygens is consistent in several 
papain/inhibitor structures, with identical P1 (Gln19 and Cys25) and P2 (Gly66 and 
Asp158) hydrogen bonding networks.  In contrast, the position of the P3 carbonyl is 
variable, with no hydrogen bonds made to papain in the 1PPP (Figure 2.22) or 
1CVZ (Figure 2.23) structures.  This provides a structural rationale for why P3 
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thioamidation does not affect papain cleavage rates, in spite of the hydrogen 
bonding interaction observed in the 1PAD structure (Figure 2.23).  In the Cts S 
(1MS6, Figure 2.26) and Cts V (1FH0, Figure 2.27) structures, the P3 hydrogen 




Papain       -IPEY----VDWRQKGAVTPVKNQGSCGSCWAFSAVVTIEGIIKIRTGNL--NEYSEQEL 53 
Cathepsin B  KLPASFDAREQWPQCPTIKEIRDQGSCGSCWAFGAVEAISDRICIHTNAHVSVEVSAEDL 60 
Cathepsin K  -APDS----VDYRKKGYVTPVKNQGQCGSCWAFSSVGALEGQLKKKTGKL--LNLSPQNL 53 
Cathepsin S  -LPDS----VDWREKGCVTEVKYQGSCGACWAFSAVGALEAQLKLKTGKL--VSLSAQNL 53 
Cathepsin V  -LPKS----VDWRKKGYVTPVKNQKQCGSCWAFSATGALEGQMFRKTGKL--VSLSEQNL 53 
               *       :: :   :. :: * .**:****.:. ::.  :  :*.     . * ::* 
 
Papain       LDCDRR---SYGCNGGYPWSALQLVA-QYGIHYRNTYP-------YEG---------VQR 93 
Cathepsin B  LTCCGS-MCGDGCNGGYPAEAWNFWTRK-GLVSGGLYESHVGCRPYSIPPCEHHVNGSRP 118 
Cathepsin K  VDCVS---ENDGCGGGYMTNAFQYVQKNRGIDSEDAYP-------YVG---------QEE 94 
Cathepsin S  VDCSTEKYGNKGCNGGFMTTAFQYIIDNKGIDSDASYP-------YKA---------MDQ 97 
Cathepsin V  VDCSRP-QGNQGCNGGFMARAFQYVKENGGLDSEESYP-------YVA---------VDE 96 
             : *      . **.**:   * :    : *:     *        *               
 
Papain       YCR---------------SREKGPYAAKTDGVRQV-QPYNEGALLYSIA-NQPVSVVLEA 136 
Cathepsin B  PCTGEGDTPKCSKICEPGYSPTYKQ-DKHYGYNSYSVSNSEKDIMAEIYKNGPVEGAFS- 176 
Cathepsin K  SCM---------------YNPTGKA-AKCRGYREI-PEGNEKALKRAVARVGPVSVAIDA 137 
Cathepsin S  KCQ---------------YDSKYRA-ATCSKYTEL-PYGREDVLKEAVANKGPVSVGVDA 140 
Cathepsin V  ICK---------------YRPENSV-ANDTGFTVV-APGKEKALMKAVATVGPISVAMDA 139 
              *                         .            *  :   :    *:.  ..  
 
Papain       AGKDFQLYRGGIFVGPCG--NKVDHAVAAVGYG--------PNYILIKNSWGTGWGENGY 186 
Cathepsin B  VYSDFLLYKSGVYQHVTGE-MMGGHAIRILGWGVENG----TPYWLVANSWNTDWGDNGF 231 
Cathepsin K  SLTSFQFYSKGVYYDESCNSDNLNHAVLAVGYGIQKG----NKHWIIKNSWGENWGNKGY 193 
Cathepsin S  RHPSFFLYRSGVYYEPSCT-QNVNHGVLVVGYGDLNG----KEYWLVKNSWGHNFGEEGY 195 
Cathepsin V  GHSSFQFYKSGIYFEPDCSSKNLDHGVLVVGYGFEGANSNNSKYWLVKNSWGPEWGSNGY 199 
                .* :*  *::         ..*.:  :*:*          : :: ***.  :*.:*: 
 
Papain       IRIKRGTGNSYGVCGLYTSSFYPVKN------ 212 
Cathepsin B  FKILRGQ-DHCGIESEVV-AGIPRTDQYWEKI 261 
Cathepsin K  ILMARNKNNACGIA---NLASFPKM------- 215 
Cathepsin S  IRMARNKGNHCGIA---SFPSYPEI------- 217 
Cathepsin V  VKIAKDKNNHCGIA---TAASYPNV------- 221 
             . : :.  :  *:         *          
 
Identity Matrix 
Papain          100.00   32.85   44.17   42.51   44.93 
Cathepsin B      32.85  100.00   30.95   32.08   33.49 
Cathepsin K      44.17   30.95  100.00   58.41   58.60 
Cathepsin S      42.51   32.08   58.41  100.00   57.87 
Cathepsin V      44.93   33.49   58.60   57.87  100.00 
 
Figure 2.20 Alignment of Cysteine Protease Sequences.  Carica papaya papain 
and human cathepsin B, K, S, and V sequences aligned using Clustal Omega.159  
Only residues present in the X-ray structures were aligned.  Coloring indicates 
sites of interaction with P3 (purple), P2 (blue), P1 (green), or P1' (orange). * 





Figure 2.21 Cysteine Protease Structure Overlay.  Papain (PDB IDs 1BP4, 
salmon, and 1PAD, cyan), Cts B (PDB ID 1GMY, olive), Cts K (PDB ID 1BGO, 
grey), Cts S (PDB ID 1MS6, burgundy), and Cts V (PDB ID 1FHO, wheat) 
structures aligned in MacPyMOL demonstrate that the positioning of key active site 




Figure 2.22 Interactions of Substrate Carbonyls in Papain Active Site.  X-ray 
structure of papain in complex with covalently bound inhibitor (PDB ID 1BP4) 
demonstrates carbonyl interactions of the P1 (green), P1' (orange), P2' (red), and 






Figure 2.23 Interactions of Substrate Carbonyls in Papain Active Site.  X-ray 
structure of papain in complex with covalently bound inhibitor (PDB ID 1PAD) 
demonstrates carbonyl interactions of the P1 (green), P2 (blue), and P3 (purple) 
residues.  Key hydrogen bonding interactions are shown as dashed lines. 
 
 
Figure 2.24 Interactions of Substrate Carbonyls in Cts B Active Site.  X-ray 
structure of Cts B in complex with covalently bound inhibitor (PDB ID 1GMY) 
demonstrates carbonyl interactions of the P1 (green), P2 (blue), and P3 (purple) 





Figure 2.25 Interactions of Substrate Carbonyls in Cts K Active Site.  X-ray 
structure of Cts K in complex with covalently bound inhibitor (PDB ID 1BG0) 
demonstrates carbonyl interactions of the P1 (green) and P2 (blue) residues.  Key 
hydrogen bonding interactions are shown as dashed lines. 
 
 
Figure 2.26 Interactions of Substrate Carbonyls in Cts S Active Site.  X-ray 
structure of Cts S in complex with covalently bound inhibitor (PDB ID 1MS6) 
demonstrates carbonyl interactions of the P1 (green), P2 (blue), and P3 (purple) 




Figure 2.27 Interactions of Substrate Carbonyls in Cts V Active Site.  X-ray 
structure of Cts V in complex with covalently bound inhibitor (PDB ID 1FH0) 
demonstrates carbonyl interactions of the P2 (blue) and P3 (purple) residues.  Key 
hydrogen bonding interactions are shown as dashed lines. 
 
 
Figure 2.28 Papain Structure Overlay.  Papain (PDB IDs 1PPP, dark green; 1PAD, 
cyan; and 1CVZ, teal) structures aligned in MacPyMOL demonstrate that the 
positioning of key active site residues is similar in all structures.  Inhibitor molecules 





Figure 2.29 Interactions of Substrate Carbonyls in Papain Active Site.  X-ray 
structure of papain in complex with covalently bound inhibitor (PDB ID 1PPP) 
demonstrates carbonyl interactions of the P1' (orange), P1 (green), P2 (blue), and 




Figure 2.30 Interactions of Substrate Carbonyls in Papain Active Site.  X-ray 
structure of papain in complex with covalently bound inhibitor (PDB ID 1CVZ) 
demonstrates carbonyl interactions of the P1 (green), P2 (blue), and P3 (purple) 
residues.  In this structure, the P3 carbonyl makes no hydrogen bonds.  Key 




CHAPTER 3 STUDIES OF THIOAMIDE POSITIONAL EFFECTS ON SERINE 
PROTEASE ACTIVITY ENABLE TWO-SITE STABILIZATION OF CANCER 
IMAGING PEPTIDES  
 
Adapted with permission from Barrett, T. M.; Chen, X. S.; Liu, C.; Giannakoulias, 
S.; Phan, H. A. T.; Wang, J.; Keenan, E. K.; Karpowicz, R. J.; Petersson, E. J., 
Studies of Thioamide Effects on Serine Protease Activity Enable Two-Site 
Stabilization of Cancer Imaging Peptides. ACS Chemical Biology 2020, 15 (3), 




§ 3.1 Introduction 
As discussed in previous chapters, backbone thioamides, an oxygen-to-
sulfur substitutions of the peptide bond, have been shown to render peptides 
resistant to cleavage by proteases.102, 104, 106, 108, 115, 117, 125, 129 Previous work in our 
group has utilized this modification in the stabilization of both glucagon-like 
peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP), increasing their half-
lives up to 750-fold against degradation by dipeptidyl peptidase-4 (DPP-4).60 
These peptides activated their cognate receptors comparably to the native all-
amide peptides, and the GLP-1 analog was shown to be active in rats with 
prolonged efficacy compared to GLP-1. A report by Chatterjee and co-workers 
demonstrated that even for macrocyclic peptides, which are already stable, 
thioamide incorporation can increase their serum half-life.56 However, very few 
systematic studies were performed in order to determine which positions are 
sensitive to thioamide substitution for a given protease.129, 160 In Chapter 2, I 
discussed our groups analysis of cathepsin family cysteine proteases.161 We found 
that the effects of thioamide substitution varied with position and protease, in spite 
of up to 60% sequence identity and a highly conserved active site. These findings 
highlight the value of such a systematic approach.  
Here, we report our analysis of trypsin family serine proteases, where 
thioamide positional effects differ not only from those of the cysteine proteases, 
but also between trypsin, chymotrypsin, and kallikrein, in spite of high structural 
similarity and a conserved mechanism. We further show that these results can be 
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used to design in vivo imaging probes stabilized at multiple proteolytic sites with a 
single thioamide modification. 
§ 3.2 Synthesis of Fluorescent Probes 
Previously, our laboratory has created protease sensors that utilize 
thioamide quenching of fluorophores to provide real-time sensors of local protease 
activity.47, 128, 161 Our first-generation sensors contained a thioamide at the P3 
position, based on previous reports that suggested that thioamides nearer to the 
scissile bond could inhibit proteolysis.128 However, inspired by our observation that 
thioamide substitution can dramatically destabilize protein folding,80 as well as 
previous reports of thioamide effects on proteolysis, we have adapted this design 
to systematically study the positional effects of thioamides. 
The design of our sensors builds on our initial 2014 sensor report,128 where 
placing a thioamide and fluorophore on opposite sides of the scissile bond leads 
to a turn-on of fluorescence after cleavage, and is analogous to the design of our 
recently reported cysteine protease substrates.161 In order to investigate positions 
on both sides of the scissile bond, we labelled the peptides with 7-
methoxycoumarin-4-yl-alanine (µ) fluorophores at both ends (Figure 3.1). With this 
design, regardless of the thioamide location, one fluorophore will be separated 
from the thioamide once the. substrate is cleaved. Thus, proteolysis can be 
monitored in real time by a fluorescence change. The amino acid sequence of the 





Figure 3.1. Thioamide Positional Scanning in a Host Substrate Sequence. Top: 
Peptides contain µ residues at both termini, and amide (X=O) or thioamide (X=S) 
residues between. The red line represents the cleavage site.  Amino acid residues 
are denoted P3 to P1 from the N-terminus to the scissile bond, and P1' to P3' from 
the scissile bond to the C-terminus. Bottom: Normalized cleavage data for Arg 
substrates of trypsin (μLLRAAAμ) and Phe substrates of chymotrypsin 
(μKAAFAAAμ). Data for thioamide variants are colored as in the top image, control 
peptides in black.  Note: Chymotrypsin P2 and P1 data overlap. 
 
The first series of peptides prepared were substrates for trypsin: μLLKAAAμ 
and its P3 to P3' thioamide analogs. We denote the position of the thioamide with 
a superscript “S”; for example, the P1 thioamide peptide is μLLKSAAAμ. In order 
to examine the effect of the amino acid sidechain at the scissile bond (a key 
recognition element for serine proteases), we synthesized the corresponding 
μLLRAAAμ series. We also synthesized a series of chymotrypsin substrates: 
µKAAFAAAµ and its analogs with a thioamide incorporated from position P4 to P3'. 
In this case, µKSAAFAAAµ was used as a control peptide due to aggregation of 
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the all-amide peptide. Previous studies showing that thioamides at the P4 position 
are non-perturbing support the use of this peptide as the “Phe control.”117-118, 128 
 
§ 3.3 Positional Effects of Thioamides on Trypsin and Chymotrypsin with and 
Kinetic Analysis 
Using the fluorescence turn-on data, the initial rates of proteolysis were 
determined for each cleavage reaction. As one can see from the example data in 
Figure 3.1 and the relative rates reported in Table 3.1 (primary data are shown in 
Methods and Materials), the effect of thioamidation on proteolysis rate varies 
dramatically with thioamide position and protease. For trypsin, only the P1 
thioamide significantly affects proteolysis, and this is true for both the Lys 
substrates and the more rapidly-cleaved Arg substrates. For chymotrypsin, both 
P2 and P1 thioamidation retard proteolysis by >100-fold. 
 










P3 0.49 ± 0.03 0.55 ± 0.15 0.22 ± 0.03 0.04 ± 0.01 
P2 0.94 ± 0.05 1.04 ± 0.28 <0.01 0.62 ± 0.03 
P1 <0.01b <0.01 <0.01 <0.01 
P1' 0.52 ± 0.05 0.97 ± 0.28 1.66 ± 0.15 0.86 ± 0.11 
P2' 0.60 ± 0.04 1.63 ± 0.44 1.29 ± 0.13 0.95 ± 0.04 
P3' 0.55 ± 0.03 1.49 ± 0.41 1.56 ± 0.12 1.09 ± 0.05 
P3 0.49 ± 0.03 0.55 ± 0.15 0.22 ± 0.03 0.04 ± 0.01 
aAll rates normalized to rate of cleavage of control peptide.  Raw rate data are reported inTable 





To better understand the effects of the thioamide at the scissile bond, we 
generated computational models based on the structure of trypsin bound to bovine 
pancreatic trypsin inhibitor,162 and found that the P1 position has the most 
significant hydrogen bond acceptor role (Figure 3.2 and Figures 3.14-3.16). The 
P1 position features a bifurcated hydrogen bond with the backbone amide N-H 
groups of Gly193 and Ser195, part of the “oxyanion hole.”163 With a longer C=S bond 
length and poorer hydrogen bond acceptor ability, the thioamide is likely to disrupt 
this bifurcated interaction,164 so it is possible that either the thioamide peptide can 
no longer bind to trypsin tightly, or that the interaction with the oxyanion hole is 
disrupted such that the tetrahedral intermediate cannot be stabilized efficiently, 
leading to a decreased turnover rate. In earlier studies, Asbóth and Cho observed 
similar resistance to trypsin cleavage with a thioamide at the P1 position, which 




Figure 3.2. Interactions of Substrate Carbonyls in Trypsin Active Site.  Docked 
structure of LLKAAA peptide (yellow) with trypsin (violet) shows carbonyl 
interactions of the P3 (purple), P2 (blue), P1 (green), P1' (orange), P2' (red), and 
P3' (pink) residues.  Peptide hydrogen bonds shown as dashed lines.  The P1 
carbonyl forms a bifurcated hydrogen bond with Gly193 and Ser195 backbone 
amides.  Computational modelling is described in Methods and Materials.  
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To differentiate the proposed mechanisms, we subjected the Lys P1 and 
Arg P1 trypsin substrates (μLLKSAAAμ and μLLRSAAAμ), as well as the 
corresponding control peptides, to detailed kinetic analysis. We initially attempted 
Michaelis-Menten analysis, but found that the very slow rate of proteolysis and 
solubility limits (~100 µM) of Lys P1 and Arg P1 precluded working at appropriate 
protease/substrate concentrations. Thus, we used higher concentrations of trypsin 
and fit the data using a general mass action model that does not require steady 
state conditions ( (Equation 3.2). We found that k2, the rate constant for catalysis, 
was reduced by at least 100-fold for both the Lys and Arg thioamide substrates. 
Binding rates (k1) were also decreased for the thioamide peptides, and they had 
significant unbinding (k-1) rates, which were negligible for the control peptides. 
These results imply that both binding and catalysis are weaker for P1 thioamide 
peptides, in contrast with Asbóth and Cho’s interpretations, which focused on 
catalysis.106, 129 In our previous studies of DPP-4 cleavage, we have found that 
binding is affected by thoamidation to a greater degree than in studies by other 
laboratories.60, 165 We believe that the apparent contradiction in those studies arose 
from differences in the substrates used, where thioamide analogs of full-length 
protease substrates like GLP-1 and GIP exhibit greater KM effects than short di- or 
tripeptide substrates. Likewise, the longer peptides used here may be responsible 





Table 3.2. Kinetic Parameters for Trypsin Proteolysis.a 
Peptide k1 (µM-1•min-1) k-1 (min-1) k2 (min-1) 
Lys Controlb 0.49 ± 0.03 <2.8 x 10-6 106.2 ± 0.9 
Lys P1b 0.41 ± 0.01 46.6 ± 0.8 1.31 ± 0.01 
Arg Controlb 5.72 ± 0.11 <8.4 x 10-5 273.6 ± 3.1 
Arg P1b 0.44 ± 0.16 2.88 ± 0.96 0.126 ± 0.002 
aCleavage measurements (Figure 3.11 and Figure 3.12) and global fitting data analysis as 
described in Materials and Methods. bSequences: Lys Control (μLLKAAAμ), Lys P1 (μLLKSAAAμ), 
Arg Control μLLRAAAμ), Arg P1 (μLLRSAAAμ). 
 
We further interrogated whether the P1 thiopeptides bound more or less 
tightly to trypsin by testing whether Lys P1 and Arg P1could inhibit proteolysis of 
an alternative trypsin substrate, N-benzoyl-L-arginine-4-nitroanilide (BAPNA). No 
significant differences were observed in kcat or KM for BAPNA proteolysis in the 
presence or absence of 100 µM Lys P1 or 80 µM Arg P1, so the thioamide peptides 
do not effectively act as trypsin competitive inhibitors (Figure 3.13). This result 
supports our above finding that a significant aspect of the thioamide effect is to 
weaken binding to the protease. 
§ 3.4 Positional Effects of Thioamides on Kallikrein 
Having validated the approach with trypsin and chymotrypsin, we next used 
our probes to identify thioamide resistance to a clinically-relevant serine protease, 
kallikrein. Various kallikreins are found in serum and are known to cleave the C-
terminus of neuropeptide Y (NPY), as well as analogs under investigation for the 
imaging of breast tumors.166-167 Kallikreins are characterized as Arg-selective 
trypsin-like proteases,168 so we used our trypsin Arg and Lys substrates to study 
the effects of thioamidation on their activity. While one could potentially design a 
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set of thioamide scanning probes with optimal sequences for kallikreins that might 
be more sensitive to specific thioamide substitutions, we wished to identify general 
patterns of thioamide effects that could be applicable to any kallikrein substrate of 
interest. In addition, determining whether our probes could be used broadly to test 
any protease with a common P1 residue would demonstrate their versatility. We 
tested both the Arg and Lys control peptides and found that only the Arg peptide 
was cleaved, consistent with previous reports of kallikrein as selective for Arg over 
Lys. We then tested the Arg thioamide series.  As we suspected, Arg P1 is resistant 
to proteolysis by a cocktail of human kallikreins (Figure 3.3), consistent with a 
general P1 thioamide effect for serine proteases.  However, what was not 
anticipated from our trypsin and chymotrypsin studies was a retardation of 
proteolysis for the Arg P3 peptide μLSLRAAAμ (Figure 3.3 and Table 3.1). This 
unexpected finding highlights the value of testing each serine protease rather than 
generalizing based on trypsin data. 
 
 
Figure 3.3. Thioamide Effects on Kallikrein Cleavage.  Normalized cleavage data 
for Arg substrates of kallikrein (μLLRAAAμ). Data for thioamide variants are 




§ 3.5 Development and Analysis of TB1-RS6: A Stabilized, NPY1R Specific 
Imaging Probe 
We hypothesized that this two-site resistance to kallikrein proteolysis could 
be exploited to generate stabilized analogs of NPY-based in vivo imaging peptide 
BVD15.169-170 BVD15 is a highly potent antagonist of the Y1 NPY receptor subtype 
(Y1R), but it is still quickly proteolyzed in serum at Arg6 and Arg8 by kallikreins.167 
Incorporation of a thioamide at Arg6 would allow it to serve as a P1 site for Arg6 
and a P3 site for Arg8, protecting both sites with a single modification (Figure 3.4).  
We designed a fluorescein analog of BVD15, termed TB1, and a thioamide-
stabilized version, TB1-RS6. Both peptides were subjected to a stability assay 
where they were incubated at 37 °C in human serum and aliquots were removed 
at various times for chromatographic analysis (Figure 3.4). TB1-RS6 was 
dramatically more stable, with a half-life of >24 h, compared to 1.5 h for TB1. Of 
course, increases in stability are not valuable if potency is weakened, so we next 






Figure 3.4. TB1/TB1-RS6 Serum Stability and Y1R Binding Data. Top: Structures 
of the TB1 and TB1-RS6 peptides. Carboxyfluorescein is attached as a mixture of 
the 5- and 6-isomers. Bottom Left: TB1 or TB1-RS6 were incubated in human serum 
and aliquots removed to measure intact peptide by HPLC. Data are an average of 
three trials with bars representing standard error. Primary data are shown in SI. 
Bottom Right: Dose response curves for TB1 and TB1-RS6. All cellular responses 
were determined using DiscoveRx Y1R reporter cells, which were activated with 
50 nM PYY for 30 min prior to application of TB1 and TB1-RS6. Normalized 
luminescence data are averages of three biological replicates with ≥7 technical 
replicates for all closed symbols, open symbols are averages of three technical 
replicates. Bars represent standard error. 
 
Using a commercial enzyme-linked luminescence assay, we activated the 
Y1R using peptide YY (PYY, a close analog of NPY) and then tested inhibition of 
this activation using varying doses of TB1 or TB1-RS6. We found that the two 
peptides had nearly identical inhibition curves (Figure 3.4) with a less than two-fold 
difference in Y1R affinity (TB1: KI = 53 ± 10 nM, TB1-RS6: KI = 101 ± 24 nM). This 
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is in contrast to a previous attempt to modify BVD15 by substituting Arg6 and Arg8 
with homoarginine, which was successful in increasing serum stability, but lead to 
a nearly 1000-fold decrease in potency.170 
Microscopy studies showed that TB1 and TB1-RS6 bind similarly to Y1R-
expressing MCF-7 breast cancer cells (Figure 3.5 and Figure 3.19). In both cases, 
this binding can be competed with unlabeled NPY peptide, and no binding is 
observed to QBI cells, which do not express Y1R (Figure 3.5). The majority of 
MCF-7 cell fluorescence in is found in internal puncta (Figure 3.5 insets), 
consistent with previous reports that acetylated versions of BVD15-like peptides 
are internalized by endosomes after receptor binding.167 This process seems to be 
unaffected by the thioamide in TB1-RS6. Thus, we are able to use the knowledge 
from our thioamide scanning experiments to effectively stabilize the BVD15 
imaging peptide at two places without compromising its biological activity. We 
observed that TB1-RS6 cells seemed to be less bright than TB1 cells in spite of the 
similar binding affinities demonstrated in our inhibition assays.  Therefore, we 
performed fluorescence lifetime (𝜏) measurements by time correlated single 
photon counting (TCSPC) to determine whether the fluorescein in TB1-RS6 was 
quenched by the thioamide (Figure 3.20).  We found that, in solution, for TB1 𝜏 = 
3.54 ns, whereas for TB1-RS6 𝜏 = 3.13 ns, indicating 12% quenching. It is possible 
that there is a different level of quenching in the bound or internalized forms of the 
peptides if changes in peptide conformation permit more contact-based quenching 
by the thioamide. For future studies, our mechanistic understanding of photo-
induced electron transfer thioamide quenching allows us to select alternate probes 
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based on their spectroscopic and electrochemical properties to generate TB1-RS6 




Figure 3.5. Selective Binding of TB1-RS6 to Y1R-Expressing Cells. MCF-7 (Y1R 
expressing) or QBI (no Y1R) cells were incubated with 250 nM TB1 or TB1-RS6 for 
15 min before imaging. For + NPY conditions, cells were preincubated with 1 µM 
NPY. Detailed protocols are found in ESI, with additional images showing variation 
in signal and NPY blocking. Insets: Zoomed in views of individual cells showing 
puncta of internalized TB1 or TB1-RS6.  Scale bars indicate 50 µm. 
 
§ 3.6 Future Directions 
In summary, we have systematically investigated the positional effects of 
thioamide substitution on serine protease catalysis and identified positions suitable 
for different applications of thioamide modification. Non-perturbing positions can 
be used to make localized proteolysis sensors that will report on native peptide 
cleavage kinetics. Perturbing positions can be used to generate tremendous 
increases in stability for therapeutic peptides (as we have shown previously with 
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GLP-1 and GIP)60 or in vivo imaging probes, as we have shown here with dual site 
stabilization of the BVD15 analog TB1-RS6. The fluorescein derivative TB1-RS6 
was an expedient choice for proof-of-principle experiments. Based on our 
promising results here, we can design other variants with dyes that have higher 
intrinsic extinction coefficients and quantum yields that are not quenched by 
thioamides. Additionally, our thioamide strategy can be translated to NPY 
derivatives used in other imaging modalities such as positron emission 
tomography (PET) for which quenching is not  an issue at all. 
As in our recent cysteine protease research, we have found that thioamide 
effects vary with position and protease, necessitating scanning studies of a 
protease of interest rather than making assumptions for a class of proteases.161 In 
particuarlar, the ability to design protection at both Arg6 and Arg8 with a single 
atom O-to-S substitution in TB1-RS6 shows the value of our scanning approach, as 
the P3/P1 kallikrein effect could not have been anticipated from other serine 
protease studies. While more mechanistic investigation is clearly warranted, our 
experiments thus far indicate that these effects result from compromised binding 
to the protease as well as interference in the chemical steps of proteolysis. We 
have used general substrates that are not optimized for a given protease, relying 
on the identity of the P1 residue alone for recognition by a given protease. It is 
likely that sequence-optimized substrates will show somewhat different effects. In 
fact, we are currently generating larger thioamide-containing libraries in order to 
explore the interplay of sidechain variation and thioamide positonal effects. 
Building on our growing database of thioamide experimental data, we will extend 
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our computational modeling to attempt to predict which positions interfere with 
cleavage for novel proteases. We will also test TB1-RS6 analogs with near infrared 
fluorophores in rodents to truly assess their potential for in vivo imaging of 
receptors over-expressed in tumors. 
 
§ 3.7 Methods and Materials 
General Information. Fmoc-β-(7-methoxycoumarin-4-yl)-Ala-OH was purchased 
from Bachem (Torrance, CA, USA).  All other Fmoc protected amino acids and 2-
(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU) 
were purchased from Novabiochem (currently EMD Millipore; Billerica, MA, USA).  
Piperidine was purchased from American Bioanalytical (Natick, MA, USA). 7-
Azabenzotriazol-1-yloxy)tripyrrolidino-phosphonium hexafluorophosphate 
(PyAOP) was purchased from ChemImpex (Wood Dale, IL, USA). Sigmacote®, 
N,N-diisopropylethylamine (DIPEA), N-benzoyl-L-arginine 4-nitroanilide, trypsin 
(lyophilized powder; from porcine pancreas; Type II-S; 1,000 – 2,000 units/mg dry 
solid), chymotrypsin (lyophilized powder; from bovine pancreas; Type II; greater 
than or equal to 40 units/mg dry solid) and mouse serum (M5905) were ordered 
from Sigma Aldrich.  Kallikrein (in Tris HCl buffer; from human plasma; 15 units/mg 
protein) was ordered from Millipore Sigma. PathHunter® eXpress NPY1R CHO-
K1 β-Arrestin GPCR Assay kits were purchased from DiscoverX (Fremont, CA, 
USA).  All other reagents were purchased from Fisher Scientific (Pittsburgh, PA, 
USA) unless specified otherwise.  Milli-Q filtered (18 MΩ) water was used for all 
solutions (EMD Millipore).  Time-course UV-Vis absorbance and fluorescence data 
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were obtained with a Tecan Infinite® M1000 PRO plate reader (San Jose, CA, 
USA).  Peptides were purified with a Varian ProStar High-Performance Liquid 
Chromatography (HPLC) with a diode array detector (currently Agilent 
Technologies), an Agilent 1260 Infinity II Preparative HPLC system, a Biotage 
Isolera one (Biotage, LLC, Charlotte NC) and analyzed with an Agilent 1100 or 
Agilent 1260 Infinity II Series Analytical HPLC system.  Peptide mass spectrometry 
was collected with a Bruker Ultraflex III MALDI-MS mass spectrometer (Billerica, 
MA, USA).  Nuclear magnetic resonance (NMR) spectra were collected with a 
Bruker DMX 500 MHz instrument (Billerica, MA).  High resolution electrospray 
ionization mass spectra (ESI-HRMS) were obtained on a Waters LCT Premier XE 
liquid chromatograph/mass spectrometer (Milford, MA).  Cellular images were 
obtained using a VT-iSIM confocal microscope (VisiTech International Ltd., 
Sunderland, U.K.).  Fluorescence lifetime measurements were made by time 
correlated single photon counting (TCSPC) using a Photon Technologies 
International (PTI) QuantaMaster40 fluorometer (currently Horiba Scientific, 
Edison, NJ, USA). 
 
Chemical Synthesis and Characterization. 
 




Synthesis of Nα-Fmoc-Nω-Pbf-L-arginine-2-amino-5-nitroanilide (S1).  Under 
argon atmosphere, Fmoc-Arg(Pbf)-OH (6.48 g, 10 mmol, 1 equiv) was dissolved 
in 50 mL of dry tetrahydrofuran (THF) and equilibrated to -10 °C in a salt ice bath 
(NaCl/ice = 1:3).  Under magnetic stirring, N-methylmorpholine (NMM, 2.20 mL, 20 
mmol, 2 equiv) and isobutylchloroformate (IBCF, 1.97 mL, 10 mmol, 1 equiv) were 
added to the solution dropwise by a pipette.  The reaction was allowed to proceed 
for 30 min at -10 °C with stirring.  4-nitro-1,2-pheylenediamine (1.53 g, 10 mmol, 1 
equiv) was added and the reaction was stirred at -10 °C until the ice melted, then 
at room temperature overnight.  After removal of solvent by rotary evaporation, the 
residue was dissolved in 50 mL of ethyl acetate and extracted with 50 mL each of 
1 M Na2HPO4, Brine, and 5% NaHCO3. The organic layer was dried over 
magnesium sulfate and solvent was taken off by rotary evaporation and high 
vacuum. An orange solid was obtained as the final product (6.791 g, 8.67 mmol, 
87% yield) in 75% purity (determined by HPLC).  Rf = 0.51 in 9:1 ethyl 
acetate/hexanes.  1H NMR (500 MHz, DMSO-d6) δ 9.34 (s, 1H), 8.16 (d, J = 2.4 
Hz, 1H), 7.87 – 7.80 (m, 3H), 7.69 (q, J = 6.9 Hz, 3H), 7.37 (t, J = 7.4 Hz, 2H), 7.29 
(t, J = 7.4 Hz, 2H), 6.74 (d, J = 9.1 Hz, 1H), 4.28 (d, J = 7.0 Hz, 2H), 4.24 – 4.17 
(m, 2H), 4.13 (dd, J = 14.3, 6.9 Hz, 2H), 3.09 – 3.01 (m, 2H), 2.46 (p, J = 1.8 Hz, 
31H), 2.39 (s, 3H), 1.95 (s, 3H), 1.35 (s, 6H). 13C NMR (101 MHz, CD3CN) δ 
172.42, 158.89, 157.30, 157.04, 150.51, 144.58, 144.50, 141.69, 138.61, 137.76, 
133.99, 132.82, 128.29, 127.68, 125.78, 125.58, 124.60, 124.26, 121.28, 120.55, 
118.16, 117.88, 117.68, 114.63, 87.09, 78.73, 67.13, 55.80, 47.60, 43.08, 40.55, 
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30.48, 29.05, 28.23, 26.15, 19.16, 17.91, 12.22, 1.52, 1.46, 1.37, 1.31, 1.25, 1.16, 
1.11, 1.05, 1.01, 0.90, 0.84, 0.81, 0.69, 0.63, 0.60, 0.49, 0.39, 0.28.  ESI+-HRMS 
[M+H]+ Calculated: 784.313 m/z, Observed: 784.314 m/z. 
 
Synthesis of Nα-Fmoc-Nω-Pbf-L-thioarginine-2-amino-5-nitroanilide (S2)  
Anhydrous Na2CO3 (0.676 g, 6.38 mmol, 1 equiv) and P4S10 (2.84 g, 6.38 mmol, 1 
equiv) were dissolved in 50 mL of dry THF and stirred at room temperature under 
argon for 30 min until the mixture became a clear pale yellow solution.  The solution 
was then cooled to 0 °C over an ice bath.  Compound S1 (5.00 g, 6.38 mmol, 1 
equiv) was added to the solution and allowed to react under argon atmosphere 
overnight at 0 °C, warming to room temperature.  Upon completion, the solvent 
was removed by rotary evaporation.  The crude reaction mixed was filtered through 
Celite to remove excess phosphorous pentasulfide.  The filtrate was dry packed 
onto a 340 g silica SNAP column from Biotage (Charlotte, NC) and purified by 
normal phase chromatography using an ethyl acetate/hexanes gradient (50% to 
100% ethyl acetate over 12 column volumes) to yield an orange foam (1.518 g, 
1.899 mmol, 30% yield) in 100% purity (determined by HPLC).  Rf = 0.24 in 9:1 
ethyl acetate:hexanes.  1H NMR (500 MHz, DMSO-d6) δ 11.27 (s, 2H), 8.46 (d, J 
= 2.4 Hz, 1H), 7.93 (dd, J = 9.1, 2.6 Hz, 3H), 7.86 (t, J = 9.1 Hz, 9H), 7.78 (dd, J = 
8.7, 2.5 Hz, 1H), 7.70 (dd, J = 15.9, 7.5 Hz, 5H), 7.38 (t, J = 7.4 Hz, 5H), 7.29 (t, J 
= 7.4 Hz, 5H), 6.77 (d, J = 9.1 Hz, 3H), 6.51 (d, J = 8.7 Hz, 2H), 6.32 (s, 4H), 4.40 
(q, J = 6.5 Hz, 2H), 4.34 – 4.26 (m, 3H), 4.25 – 4.17 (m, 5H), 3.99 (dd, J = 8.6, 6.6 
Hz, 3H), 3.72 (qq, J = 7.1, 4.0, 3.6 Hz, 2H), 3.51 – 3.45 (m, 1H), 3.14 (s, 2H), 3.08 
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(q, J = 6.5 Hz, 5H), 2.91 (s, 5H), 2.41 (s, 7H), 1.97 (s, 7H), 1.95 (s, 2H), 1.36 (s, 
15H), 1.14 (t, J = 7.1 Hz, 2H), 1.02 (d, J = 6.7 Hz, 6H), 0.82 (d, J = 6.7 Hz, 1H). 
13C NMR (126 MHz, CDCl3) δ 206.48, 171.40, 159.44, 157.00, 156.46, 148.88, 
143.77, 143.74, 143.69, 141.45, 141.39, 141.34, 138.71, 138.00, 132.59, 128.02, 
127.98, 127.94, 127.36, 127.30, 127.22, 125.55, 125.33, 125.28, 125.19, 125.13, 
122.58, 120.23, 120.20, 118.09, 115.10, 86.91, 86.82, 82.58, 77.42, 67.61, 60.81, 
60.63, 53.64, 47.28, 47.24, 47.14, 43.26, 40.62, 33.08, 32.14, 31.80, 29.92, 29.87, 
29.58, 28.75, 28.49, 28.43, 25.89, 22.91, 22.76, 21.29, 20.34, 19.99, 19.94, 19.55, 
18.21, 14.41, 14.35, 12.73, 12.67, 12.50.  ESI+-HRMS [M+H]+ Calculated: 800.290 
m/z, Observed: 800.2917 m/z. 
 
Synthesis of Nα-Fmoc-Nω-Pbf-L-thioarginine-nitrobenzotriazolide (S3)  
Compound S2 (1.503 g, 1.899 mmol, 1 equiv) was added to 40 mL of neat glacial 
acetic acid at 0 °C and stirred until fully dissolved.  NaNO2 (0.164 g, 2.374 mmol, 
1.25 equiv) was added in small portions with stirring over 5 min.  The reaction was 
allowed to stir for 30 min at 0 °C, then quenched with 200 mL of ice water, resulting 
in an orange precipitate.  The precipitate was collected by filtration, rinsed with cold 
water, and dried overnight by lyophilization.  An orange solid was obtained as the 
final product (1.104 g, 1.363 mmol, 72% yield) in 80% purity (determined by 
HPLC).  1H NMR (500 MHz, Chloroform-d) δ 9.53 (s, 1H), 8.78 (d, J = 8.2 Hz, 1H), 
8.48 – 8.32 (m, 1H), 8.30 (s, 1H), 8.24 – 8.15 (m, 1H), 7.68 (d, J = 7.6 Hz, 2H), 
7.55 (t, J = 7.0 Hz, 3H), 4.41 (d, J = 7.1 Hz, 2H), 4.29 (d, J = 8.5 Hz, 2H), 4.12 (td, 
J = 7.2, 4.1 Hz, 2H), 2.88 (s, 3H), 2.51 (d, J = 12.2 Hz, 4H), 2.44 (d, J = 12.0 Hz, 
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5H), 2.04 (d, J = 12.4 Hz, 7H), 1.42 (s, 10H). 13C NMR (101 MHz, DMSO) δ 202.51, 
176.16, 158.89, 158.74, 157.97, 157.93, 156.53, 156.33, 154.43, 147.42, 145.16, 
144.39, 144.22, 144.01, 143.90, 143.82, 141.26, 141.20, 141.12, 138.93, 138.44, 
137.79, 137.66, 134.61, 134.51, 133.12, 132.61, 132.57, 131.98, 131.94, 131.88, 
131.84, 128.08, 127.53, 125.65, 125.25, 125.22, 124.78, 124.73, 124.69, 121.46, 
120.55, 120.51, 117.25, 117.04, 116.81, 116.76, 116.71, 116.67, 87.21, 87.17, 
86.69, 86.64, 66.21, 55.34, 47.18, 47.13, 42.93, 42.72, 28.69, 28.65, 19.47, 19.43, 
19.38, 18.34, 18.12, 18.05, 12.73, 12.68, 12.66. ESI+-HRMS [M+H]+ Calculated: 
811.270 m/z, Observed: 811.270 m/z. 
 
Synthesis of Other Thioaminoacid Precursors.  Nα-Fmoc-Ne-Boc-L-thiolysine-
nitrobenzo triazolide, Nα-Fmoc-L-thioleucine-nitrobenzotriazolide, Nα-Fmoc-L-
thiophenylalanine-nitrobenzo triazolide, and Nα-Fmoc-L-thioalanine-
nitrobenzotriazolide were synthesized as previously reported by our laboratory.128, 
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Peptide Synthesis, Purification, and Characterization. 
Peptide Synthesis.  Each peptide was manually synthesized on a 25 μmol scale 
on 2-chlorotrityl resin using our established protocols.136  Prior to use, the glass 
peptide reaction vessel (RV) was coated with Sigmacote® and dried under 
vacuum.  For a typical synthesis, 2-chlorotrityl resin was added to a dry RV and 
swelled in 5 mL dimethylformamide (DMF) for 30 min with magnetic stirring.  
Between each reaction, the resin was washed extensively with adequate DMF.  
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For the first amino acid coupling, 5 equiv of amino acid was dissolved in 2 mL of 
DMF and added to the RV, following an addition of 10 equiv of DIPEA.  The 
reaction ran for 30 min under stirring.  After washing, the resin was incubated with 
2 mL of 20% piperidine solution in DMF for 20 min under stirring for deprotection.  
The same deprotection procedure was followed for all the subsequent standard 
amino acids.  For a typical coupling reaction, 5 equiv of amino acid and 5 equiv of 
HBTU or PyAOP was dissolved in DMF, and added to the RV, with an addition of 
10 equiv of DIPEA.  Thioamide residues were coupled and deprotected with 
slightly different procedures.  Thioamides were coupled through pre-activated 
precursors, where 2 equiv of thioamide was dissolved in 1.5 mL of dry 
dichloromethane (DCM) with 2 equiv DIPEA, and stirred for 30 min.  This 
procedure was repeated prior to deprotection. For the deprotection of thioamides, 
2% DBU (1,8-diazabicyclo(5.4.0)undec-7-ene) in DMF was added to the RV and 
reacted three times for two min each with extensive washing with DMF and DCM 
between each deprotection step.  
 
Peptide Cleavage and Purification. Upon completion of the synthesis, the resin 
was dried with DCM under vacuum.  Peptides were cleaved off resin by treatment 
with a 2 mL fresh cleavage cocktail of trifluoroacetic acid (TFA), water, and 
triisopropylsilane (TIPSH) (95:2.5:2.5 v/v) for 45 min with stirring.  After treatment, 
the cocktail solution was expelled from the RV with nitrogen and reduced to a 
volume of less than 1 mL by rotary evaporation.  This TFA solution was then 
treated with over 10 mL of cold ethyl ether in order to precipitate the peptides from 
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the cleavage solution.  This precipitate was redissolved in 2mL 50:50 CH3CN/H2O, 
flash frozen with liquid nitrogen, and evaporated using lyophilization.  The crude 
was diluted in CH3CN/H2O (1:1 v/v) and then purified on a Vydac 218TP C18 prep 
column (Grace/Vydac; Deerfield, IL, USA) by HPLC using the following gradients 
(Table 3.3 and Table 3.4) at a flow rate of 12 mL/min.  MALDI- MS was used to 
confirm peptide identities (Table 3.5).  Purified peptides were dried on a lyophilizer 
(Labconco; Kansas City, MO, USA) or in a vacuum centrifuge (Savant/Thermo 
Scientific; Rockford, IL, USA).  If needed, peptides were subjected to multiple 





Table 3.3.  Peptide Purification Methods and Retention Time.   
 
Peptide Gradient Retention Time 
μLLKAAAμ 1 35 min 
μLSLKAAAμ 1 33 min 
μLLSKAAAμ 1 35 min 
μLLKSAAAμ 1 35 min 
μLLKASAAμ 2 28 min 
μLLKAASAμ 2 28 min 
μLLKAAASμ 2 28 min 
μLLRAAAμ 1 35 min 
μLSLRAAAμ 3 18 min 
μLLSRAAAμ 2 22 min 
μLLRSAAAμ 1 35 min 
μLLRASAAμ 3 21 min 
μLLRAASAμ 3 20 min 
μLLRAAASμ 3 23 min 
μKAAFAAAμ 4 23 min 
μKSAAFAAAμ 5 20 min 
μKASAFAAAμ 5 20 min 
μKAASFAAAμ 5 23 min 
μKAAFSAAAμ 5 22 min 
μKAAFASAAμ 5 22 min 
μKAAFAASAμ 5 23 min 
μKAAFAAASμ 5 24 min 
*  μ: 7-methoxycoumarinylalanine; AS: thioalanine; LS: thioleucine; KS: thiolysine; RS: 




Table 3.4.  HPLC Gradients for Peptide Purification.   
No. Time (min) %B  No. Time (min) %B 
1 00:00 002  2 00:00 002 
06:00 002  06:00 002 
08:00 015  08:00 020 
37:00 040  28:00 040 
40:00 100  31:00 100 
45:00 100  36:00 100 
50:00 002  41:00 002 
3 0:00          10  4 0:00     2 
 2:00          10   6:00 00       2 
 5:00          20   9:00          20 
       25:00          40   24:00          40 
 26:00          40   28:00        100 
 27:00        100   33:00        100 
 30:00        100   48:00            2 
 35:00   10     
5 0:00     2     
 6:00     2     
 8:00  27     
 24:00 35     
 26:00       100     
 31:00       100     
 36:00 2     
 





Table 3.5.  Calculated and Observed Masses of Peptides.   
 
Peptide 
[M+H]+ (m/z) [M+Na]+ (m/z) [M+K]+ (m/z) 
Calculated Observed Calculated Observed Calculated Observed 
μLLKAAAμ 1076.53 1075.81 1098.51 1097.79 1114.49 1113.77 
μLSLKAAAμ 1092.51 1092.44 1114.49 1114.42 1130.46 1130.39 
μLLSKAAAμ 1092.51 1092.42 1114.49 1114.40 1130.46 1130.37 
μLLKSAAAμ 1092.51 1092.87 1114.49 1114.85 1130.46 1130.84 
μLLKASAAμ 1092.51 1092.43 1114.49 1114.41 1130.46 1130.38 
μLLKAASAμ 1092.51 1092.38 1114.49 1114.36 1130.46 1130.43 
μLLKAAASμ 1092.51 1092.52 1114.49 1114.51 1130.46 1130.47 
μLLRAAAμ 1104.54 1104.11 1126.52 1126.11 1142.49 1142.08 
μLSLRAAAμ 1120.51 1120.48 1142.50 1142.57 1158.47 1158.57 
μLLSRAAAμ 1120.51 1120.64 1142.50 1142.61 1158.47 1158.59 
μLLRSAAAμ 1120.51 1120.54 1142.50 1142.53 1158.47 1158.50 
μLLRASAAμ 1120.51 1120.40 1142.50 1142.58 1158.47 1158.41 
μLLRAASAμ 1120.51 1120.42 1142.50 1142.47 1158.47 1158.58 
μLLRAAASμ 1120.51 1120.83 1142.50 1142.88 1158.47 1158.82 
μKAAFAAAμ 1139.50 1139.77 1161.49 1161.80 1177.46 1177.79 
μKSAAFAAAμ 1155.48 1155.54 1177.46 1177.57 1193.44 1193.55 
μKASAFAAAμ 1155.48 1155.68 1177.46 1177.68 1193.44 1193.67 
μKAASFAAAμ 1155.48 1155.12 1177.46 1177.12 1193.44 1193.11 
μKAAFSAAAμ 1155.48 1155.80 1177.46 1177.88 1193.44 1193.93 
μKAAFASAAμ 1155.48 1155.73 1177.46 1177.72 1193.44 1193.68 
μKAAFAASAμ 1155.48 1155.71 1177.46 1177.74 1193.44 1193.73 
μKAAFAAASμ 1155.48 1155.54 1177.46 1177.45 1193.44 1193.72 
*  μ: 7-methoxycoumarinylalanine; AS: thioalanine; LS: thioleucine; KS: thiolysine; RS: 
thioarginine; FS: thiophenylalanine 
 
Sensor Peptide Analysis 
Steady State Protease Assays.  In a typical trial, a 7.5 μM solution of peptide was 
incubated in the presence or absence of 0.2 mg/mL chymotrypsin in 100 mM Tris-
HCl, pH 7.8 at 25 °C, or in the presence or absence of 25 μg/mL trypsin in 67 mM 
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sodium phosphate, pH 7.6 at 25 °C, or in the presence or absence of 4.3 μg/mL 
kallikrein in 20 mM Tris-HCl, 100 mM NaCl, pH 7.5 buffer at 25 °C.  The 
fluorescence was monitored as a function of time at 390 nm with an excitation 
wavelength of 325 nm on the Tecan plate reader.  Three independent trials were 
performed for each assay to ensure reproducibility.  Primary data are shown in 
Figures 3.7-3.10.  The data from the fluorescent trials were averaged and cleavage 
percentages were calculated by dividing the fluorescence change of each time 
point by the fluorescence change of complete cleavage (measured up to 6 h).  
Initial rates were determined by fitting a line to early timepoints (first 2 min) and 
later timepoints (between min 10 to 20) if a biphasic curve was observed.  These 
are reported in Table 3.6 and Table 3.7 (with standard error) and normalized rates 
are given in the main text. 
 







Lys Control 1.900 ± 0.101 Arg Control 3.320 ± 0.902 
Lys P3 0.939 ± 0.037 Arg P3 1.838 ± 0.101 
Lys P2 1.787 ± 0.019 Arg P2 3.458 ± 0.093 
Lys P1 
0.177 ± 0.017a 
Arg P1 0.016 ± 0.001 
0.011 ± 0.002b 
Lys P1' 0.990 ± 0.073 Arg P1' 3.222 ± 0.304 
Lys P2' 1.140 ± 0.031 Arg P2' 5.405 ± 0.125 
Lys P3' 1.048 ± 0.021 Arg P3' 4.953 ± 0.166 
aCleavage rate during first five min.  bCleavage rate during 10-40 min. 
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Table 3.7. Initial Rates of Peptides Cleavage by Serine Proteases. 
Chymotrypsin 
Peptides 
Rate (μM•Min-1) Kallikrein Peptides Rate (μM•Min-1) 
Phe Control 6.049 ± 0.469 Arg Control 0.634 ± 0.021 
Phe P3 1.311 ± 0.181 Arg P3 0.022 ± 0.006 
Phe P2 0.010 ± 0.001 Arg P2 0.390 ± 0.016 
Phe P1 0.012 ± 0.001 Arg P1 0.002 ± 0.001 
Phe P1' 10.050 ± 0.440 Arg P1' 0.544 ± 0.065 
Phe P2' 7.826 ± 0.532 Arg P2' 0.601 ± 0.013 





Figure 3.7.  Trypsin Proteolysis of Lys Peptides Monitored by Fluorescence.  A 7.5 
µM solution of peptide was incubated in the presence or absence of 25 µg/mL of 
trypsin in 67 mM sodium phosphate buffer (pH 7.6) at 25 °C.  Three independent 
trials for each peptide are shown.  Black trace: All amide Lys Control peptide in the 
presence of protease; Colored traces: Lys thioamide peptides in the presence of 
protease; Grey traces: Thioamide peptides or control peptide in the absence of 
protease.  Inset: Normalized cleavage data for control and thioamide peptides 





Figure 3.8.  Trypsin Proteolysis of Arg Peptides Monitored by Fluorescence.  A 7.5 
µM solution of peptide was incubated in the presence or absence of 25 µg/mL of 
trypsin in 67 mM sodium phosphate buffer (pH 7.6) at 25°C.  Three independent 
trials for each peptide are shown.  Black trace: All amide Arg Control peptide in the 
presence of protease; Colored traces: Arg thioamide peptides in the presence of 
protease; Grey traces: Thioamide peptides or control peptide in the absence of 
protease.  Inset: Normalized cleavage data for control and thioamide peptides 






Figure 3.9.  Chymotrypsin Proteolysis of Phe Peptides Monitored by 
Fluorescence.  A 7.5 µM solution of peptide was incubated in the presence or 
absence of 0.2 mg/mL chymotrypsin in 100 mM Tris-HCl, pH 7.8 at 25°C.  Three 
independent trials for each peptide are shown. Black trace: P4 thioamide Phe 
Control peptide in the presence of protease; Colored traces: Phe thioamide 
peptides in the presence of protease; Grey traces: Thioamide peptides or control 
peptide in the absence of protease.  Inset: Normalized cleavage data for control 





Figure 3.10. Kallikrein Proteolysis of Arg Peptides Monitored by Fluorescence.  A 
7.5 µM solution of peptide was incubated in the presence or absence of 4.26 μg/mL 
kallikrein in 20 mM Tris-HCl, 100 mM NaCl, pH 7.5 buffer at 25°C.  Three 
independent trials for each peptide are shown. Black trace: All amide Arg Control 
peptide in the presence of protease; Colored traces: Arg thioamide peptides in the 
presence of protease; Grey traces: Thioamide peptides or control peptide in the 
absence of protease.  Inset: Normalized cleavage data for control and thioamide 




Kinetic Analysis of P1 Thioamide Peptides 
Kinetic Assays at Varying Substrate Concentrations.  Various concentration of 
the Lys or Arg Control peptides were treated with 0.1 μM of trypsin in 67 mM 
sodium phosphate buffer, pH 7.6, at 25 °C in a 96-well plate.  Various 
concentrations of the P1 thiopeptides were treated with 10 μM of trypsin in 67 mM 
sodium phosphate buffer, pH 7.6, at 25°C in a 96-well plate.  The fluorescence of 
the reaction was monitored as a function of time at 390 nm with an excitation 
wavelength of 325 nm on the Tecan plate reader.  Three independent trials were 
performed for each assay to ensure reproducibility.  Data were analyzed by 
subtracting an average of the fluorescence of the no protease control (FMin) from 
the average fluorescence of the plus protease wells at time t, F(t).  Then, 
fluorescence was converted to concentration of product (in μM) using Equation 
3.1, where FMax is the average fluorescence of the plus protease wells over the 
final 1000 s of the assay, and [S]0 is the initial concentration of substrate.  
 
[Product] = [S]0 ×
(F(t) − FMin)
(FMax − FMin)
  (Equation 3.1) 
 
 
Kinetic Parameter Estimation in COPASI. Since limitations in the solubility of 
substrates and the low activity of trypsin toward the thioamide substrates 
precluded using a Michaelis-Menten model, the data were numerically fit using 
COPASI software to a reversible mass action model (Equation 3.2) to determine 
k1 and k-1, and kcat.171  In order to fit the data, progress curves were imported into 
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COPASI, and the Parameter Estimation task was used.  Initial concentrations of 
enzyme (E) and substrate (S) were specified as those used in the experiment, 
while concentrations of the ES complex and product (P) were set to zero.  Initial 
parameter estimations were done using evolutionary programming with 200 
generations and a population size of 20.  The starting values for k1, k-1, and kcat 
were set to 0.1 with upper and lower bounds set to 1 x 10±100.  Once the values 
converged and had a small standard deviation, the parameter estimation was run 
again with 1000 generations and a population size of 100 to confirm the robustness 
of these values.  The goodness of fit can be observed in the relatively small 
standard deviations in the fitted parameters (Table 3.8) and by inspection of Figure 
3.11 and Figure 3.12.  
(Equation 3.2)  
 
 
Table 3.8. Kinetic Parameters Estimated from Mass Action Analysis 
Substrate k1 (µM-1•min-1) k-1 (min-1) k2 (min-1) 
μLLKAAAμ 1.026 ± 0.007 <2.8 x 10-6 106.2 ± 0.9 
μLLKSAAAμ 0.408 ± 0.007 46.56 ± 0.82 1.308 ± 0.014 
μLLRAAAμ 5.724 ± 0.114 <8.4 x 10-5 273.6 ± 3.1 








Figure 3.11.  Kinetic Data Fitting for Control Peptides.  Progress curves with 
COPASI fits of μLLKAAAμ (left) and μLLRAAAμ (right) treated with trypsin.  
Various concentrations of peptide were incubated in the presence of 0.10 µM 
trypsin in 67 mM sodium phosphate buffer (pH 7.6) at 25 °C. [peptide]: 20 µM, 40 
µM, 60 µM, 80 µM, 100 µM, 200 µM in black, purple, lavender, green, orange, and 





Figure 3.12.  Kinetic Data Fitting for P1 Thioamide Peptides.  Progress curves with 
COPASI fits of μLLKSAAAμ (left) and μLLRSAAAμ (right) treated with trypsin. 
Various concentrations of peptide were incubated in the presence of 10 µM trypsin 
in 67 mM sodium phosphate buffer (pH 7.6) at 25 °C. [μLLKSAAAμ]: 7.5, 15, 30, 
50, 75, 100, and 150 µM  in gray, black, purple, lavender, green, orange, and red 
traces, respectively.  [μLLRSAAAμ]: 1.0, 2.5, 4.0, 5.0, 6.0, 7.5, 15, and 25 µM in 




Inhibition Assay.  Various concentrations of trypsin substrate N-benzoyl-L-
arginine-p-nitroanilide (BAPNA) (50 μM, 100 μM, 500 μM, 1 mM, 1.5 mM, 2.0 mM, 
and 3.0 mM) were reacted with 25 μg/mL trypsin in 67 mM sodium phosphate 
buffer, pH 7.6, at 25 °C in a 96-well plate.  For thioamide inhibition, 100 μM of Lys 
P1 or 80 μM Arg P1was incubated with 25 μg/mL trypsin for 15 min at 25 °C to 
allow for full interactions before adding the BAPNA substrates.  The reaction was 
monitored by UV-Vis absorbance at 410 nm by the plate reader.  Three trials were 
performed to ensure reproducibility.  From the extinction coefficient of p-nitroaniline 
(8800 M-1∙cm-1), the absorbance was converted into the product p-nitroaniline 
concentration.  The reaction rate was calculated by extracting the slope of a linear 
fit of the first 2 min of the cleavage reaction.  The average of reaction rates from 
three trials were calculated used to construct a Michaelis-Menten plot (Figure 
3.13).  These curves were fit to Equation 3.3 in Prism to determine VMax and KM.  
Turnover number (kcat) was calculated by dividing VMax by the enzyme 
concentration. 
 
     𝑣0 = 𝑉𝑀𝑎𝑥  
[𝑆]
[𝑆] + /𝐾𝑀
  (Equation 3.3) 
 
Table 3.9. Kinetic Parameters for Trypsin Inhibition by Thioamide Peptides.  
 
Condition kcat (sec
-1) KM (mM) kcat / KM (mM
-1∙sec-1) 
No Inhibitor 0.049 ± 0.0028 1.59 ± 0.32 0.031 ± 0.004 
0100 µM μLLKSAAAμ 0.088 ± 0.0023 2.17 ± 0.62 0.041 ± 0.007 





    
   
Figure 3.13. Trypsin Activity Monitored by Colorimetric Substrate BAPNA.  Left: A 
25 µg/mL trypsin solution was incubated in the presence or absence of thioamide 
peptides, then mixed with various concentrations of BAPNA.  [BAPNA]: 50 µM, 
100 µM, 500 µM, 1 mM, 1.5 mM, 2 mM, and 3 mM in red, orange, yellow, light 
green, dark green, teal, and dark blue, respectively.  Right: Michaelis-Menten 




Structure Analysis: Modeling of LLKAAA Peptide Binding to Trypsin.  The 
interaction between the µLLKAAAµ “Oxo” peptide and trypsin was modeled using 
PyRosetta and the Rosetta Modeling Suite.146-147  The PDB structure 2PTC was 
used as a starting structure of trypsin to simulate its docking interactions with the 
LLKAAA peptide.  The native inhibitor peptide was trimmed both N, and C 
terminally leaving only the VYGGCR 6-mer in the active site of trypsin. This peptide 
was converted to the LLKAAA peptide, using the mutate residue functionality within 
the PyRosetta toolbox. After generation of the target peptide in the active site of 
trypsin, the FlexPepDock refinement protocol within Rosetta was performed on the 
complex. The FlexPepDock protocol is a Monte-Carlo based simulation which 
applies gradient-based energy minimization to optimize the peptide’s rigid body 
orientation relative to receptor protein it is docked with. During this optimization, 
both the peptide and enzyme sidechains and backbones are allowed to flexibly 
explore torsions.144  The refine FlexPepDocking protocol was run using the default 
parameters sampling 1000 decoys with constraints set with a weight of 100 
Rosetta Energy Units (REUs).144  The 10 lowest energy structures, according to 
the FlexPep score, were visualized in PyMOL.144, 148  As shown in Figure 3.14, all 
10 output structures display nearly identical binding interactions spanning the 
entire peptide from positions P3 to P3’. 
Following the FlexPepDock protocol, the lowest energy structure was 
subjected to two relax protocols. The Relax algorithm consists of sidechain 
repacking alongside gradient-based minimization of both backbone and side-chain 
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torsion angles. Initially, the van der Waals repulsion score term is downweighed, 
but increases in weight with each applied cycle, ultimately returning to its default 
weight during the final cycle of the Relax.172 A total of 100 trajectories were 
sampled, performing 10 FastRelax protocol executions per trajectory.172  Both 
protocols were  performed using the “ref2015_cart” score function with the 
dualspace flag set to True. This flag corresponds to the optimization in latter stages 
of the protocol occurring in cartesian space.154 Minimizations were performed 
using the “lbfgs_armigo_nonmonotone” minimization method allowing for 
minimization of the bond angles. The difference between the two protocols was 
that the first included a Flat_Harmonic potential constraint of the active site serine 
oxygen to the P1 amide carbon with an energy of zero from 2 to 4 Å with a standard 
deviation of 1 Å dictating the harmonic profile outside of the zero-energy region).149 
The lowest energy structure from the constrained relaxes was then put into an 
identical relax protocol without the constraint to ensure that the peptide was 
energetically stable in a cleavable orientation without being forced to be. The ten 
lowest energy structures observed during the final search were all practically 
identical in terms of peptide conformation (<0.5 Å RMSD across all peptide atoms).  
These are shown overlaid in Figure 3.15 and are shown separately in Figure 3.16.  
The energy in REU of each of the structures is plotted as a function of RMSD 
relative to the lowest energy structure in Figure 3.16.  The peptide-enzyme 
hydrogen bonds observed in the “Relax” outputs were also observed in the 
FlexPepDock outputs, bolstering our confidence in these simulated docking 
interactions.  The average hydrogen bond distances for all contacts made by the 
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backbone amides in the 10 lowest energy structures are reported in Figure 3.16.  





Figure 3.14. Overlay of Lowest Energy Structures from “FlexPepDock” 
Simulations of Trypsin.  The 10 lowest energy structures of trypsin in complex with 
docked LLKAAA have minimal variations in carbonyl interactions of the P3 
(purple), P2 (blue), P1 (green), P1' (orange), P2' (red), and P3' (pink) residues.  
Note: Protein backbone structure is static in these simulations. 
 
 
Figure 3.15. Overlay of Lowest Energy Structures from “Relax” Simulations of 
Trypsin.  The 10 lowest energy structures of trypsin in complex with docked 
LLKAAA have minimal variations in carbonyl interactions of the P3 (purple), P2 
(blue), P1 (green), P1' (orange), P2' (red), and P3' (pink) residues.  In spite of 





Figure 3.16.  Lowest Energy Structures from “Relax” Simulations of Trypsin.  Top: 
The 10 lowest energy structures of trypsin in complex with docked LLKAAA have 
minimal variations in carbonyl interactions of the P3 (purple), P2 (blue), P1 (green), 
P1' (orange), P2' (red), and P3' (pink) residues.  Bottom Left: A plot of the energy 
(in Rosetta Energy Units, REU) as a function of the RMSD of each structure 
relative to the lowest energy structure from the Relax simulations.  Bottom Right: 




Imaging Peptide Studies 
Serum Stability Assay.  A 25 µL solution of 50 µM TB1 or TB1-RS6 in sterile Mill-
Q water was incubated at 37 °C in the presence of 25 µL mouse serum (Sigma 
Aldrich M5905).  After incubating for the desired time, the serum proteins were 
precipitated by adding 50 µL methanol, and chilled at -20 oC for 10 min.  After 
precipitation, samples were pelleted using an Eppendorf 5415R centrifuge at 
13,000 RPM for 10 min at 4 oC.  Next, 80 µL of supernatant was diluted to 200 µL 
with Milli-Q water and analyzed by HPLC, after the addition of 0.8 µL of a 1.2 mM 
5,6-carboxyfluorescein internal standard solution.  A Phenomenex Luna C8(2) 
analytical column (Torrance, CA, USA) was used to analyze all samples using the 
gradients shown in Table 3.10.  MALDI MS was used to check peptide identities 
(Table 3.11).  The amount of intact peptide was quantified based on peak areas in 
HPLC chromatograms (Figure 3.17).  All peptides were monitored at 484 nm.  The 
internal standard was used to normalize the amount of intact peptide in each 
sample.  For each time point, samples were run in triplicate, and the amount of 
intact peptide was determined to be the average from three separate runs.  To 
determine percent intact peptide, the average ratio of intact peptide to internal 
standard was compared to the ratio at t = 0 for all samples.  Percent intact peptide 




Table 3.10. HPLC Gradient for Serum Stability Assay*. 
 
Time (min) %B 
00:00 002.0 
05:00 002.0 
15:00 0 30.0 




*Solvent A: 0.1 % TFA in water; Solvent B: 0.1 % TFA in acetonitrile 
 
Table 3.11. Retention Times and Masses of TB1 Peptides. 
 
Peptide Retention Time (min) Observed Mass (m/z) 
TB1 026.2 1795.00 
TB1-RS6 027.5 1810.75 
 
 
Figure 3.17. Serum Stability Assay.  Representative HPLC chromatograms.  
Absorbance was monitored at 484 nm. Left: Dark blue curve is at zero min, light 
blue curve is at 90 min, black curve is internal standard alone, and gray curve is 
serum alone; * indicates 5,6-carboxyfluorescein internal standard, • indicates intact 
peptide (observed mass: 1795.9 m/z), § indicates cleavage of TB11-5 (observed 
mass: 1477.4 m/z, theoretical mass: 1475.7 m/z), and † indicates internal standard 
bound to serum proteins (other cleavage product indicated ƒ by could not be 
identified by MALDI MS).  Right: Dark red curve is at zero h, light red curve is at 8 
h, black curve is internal standard (5,6-carboxyfluorescein) alone, and gray curve 
is serum alone; * indicates 5,6-carboxyfluorescein internal standard, • indicates 
intact peptide (observed mass: 1810.6 m/z), and † indicates internal standard 




Neuropeptide Y Y1R Activation Assay.  To determine the Ki of TB1 and TB1-
RS6, a DiscoverX PathHunter® eXpress NPY1R CHO-K1 β-Arrestin GPCR Assay 
was employed.  Provided cells were thawed and plated onto a 96 well plate and 
stored in a 37oC incubator with 5% CO2 for 48 h.  Solutions of both peptides in 
DPBS buffer at varying concentrations were plated into a separate 96 well plate to 
be transferred to the assay plate.  Cells were treated with 5 µL of TB1 or TB1-RS6 
antagonist for 30 min in the incubator (37oC with 5% CO2), followed by treatment 
with 5 µL of 50 nM (final working concentration) peptide YY (PYY) for 1.5 h in in 
the incubator (37oC with 5% CO2).  Next, cells were treated with the detection 
solution provided in the assay kit and allowed to incubate at room temperature for 
1 h.  Finally, the assay plate luminescence was read on a Tecan M1000pro in 
luminescence mode (no filter) with an integration time of 100 ms after incubation 
at 1 h and 3 h post-treatment.  Within each trial, luminescence signal was 
normalized to the maximum (treatment with 50 nM PYY) and the minimum 
(treatment with buffer).  The normalized data were then analyzed by averaging 
data across three independent biological replicates (different batches of cells) on 
different days.  A few data sets or data points were dropped because outlier data 
points at the high or low concentrations made it infeasible to normalize the data in 
a sensible way.  The final data set consisted of 7-8 data points at each 
concentration for both TB1 and TB1-RS6, with at least two trials in every biological 
replicate.  These averaged plots are shown in Figure 4 in the main text.  These 
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averaged data were fit to Equation 3.4 in Kaleidagraph (to determine an IC50 for 
competition with PYY. 
   Norm. Luminescence =  1 −
[L]
[L] + IC50
  (Equation 3.4) 
 
 The IC50 values determined for TB1 and TB1-RS6 (719 ± 143 nM and 1363 
± 323 nM, respectively) were then used to calculate KI values using Equation 3.5, 
where [L] is 50 nM PYY and the EC50 for PYY is 4.1 nM, according to the assay 
manufacturer, DiscoverX (https://www.discoverx.com/getmedia/782b3f48-40b1-45ae-a6c2-
f6827c9d8f5f/93-0397E2CP0M.aspx). 
     𝐾I =  
IC50
1 + [L]/EC50
   (Equation 3.5) 
 KI values of 53.0 ± 10.6 nM and 101 ± 23.9 nM were determined for TB1 







Figure 3.18. Representative TB1 and TB1-RS6 Binding Trials.  Luminescence 
signal after treatment of cells with 50 nM peptide YY followed by various 
concentrations of TB1 or TB1-RS6. Traces shown are averages of three technical 
replicates from one biological replicate of the DiscoverX PathHunter® eXpress 
NPY1R CHO-K1 β-Arrestin GPCR Assay.  Open symbols indicate that only two 
trials were included in final set of 7-8 data sets across all three biological replicates.  
Black curve: TB1, Green curve: TB1-RS6.  
 
Cell Culture and Imaging. The following media were used in cell culture: DMEM 
(Corning), 10% FBS (Atlanta Biologicals), 1% Glutamine Supplement (Gibco), 1% 
Penicillin/Streptomycin (Gibco).  MCF-7 and QBI-293 cultures were synchronized 
prior to experiments.  For cellular imaging, cells were plated onto 35mm MatTek 
dishes, pre-treated with poly-D-lysine containing a 10 mm diameter glass insert 2 
days prior to imaging at 37 °C in 5% CO2.  Immediately prior to the experiment, 
medium was removed by aspiration and wells were washed 1X with 1 mL Hanks 
Balanced Salt Solution (HBSS, Gibco).  Treatments were performed on MCF-7 
and QBI-293 cells in parallel.  All studies were conducted at room temperature.  
For imaging of the peptide alone, 500 μL of HBSS containing Hoechst 33342 was 
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added to the plate, followed by 500 μL of 500 nM TB1 or TB1-RS6 in HBSS for 15 
min (final concentration of 250 nM peptide).  For competition binding studies, 1 µM 
NPY in HBSS was added directly to the plate after HBSS wash and incubated for 
30 min at room temperature before treatment using the conditions above.  At the 
completion of each experiment, wells were washed 3X with HBSS and immediately 
imaged using a VT-iSIM confocal microscope (Hoechst excitation = 405 nm; 
Fluorescein excitation = 488 nm).  Images were compiled using ImageJ (NIH).  For 
each Z-stack, the first 10 stacks were combined into a composite image.  All 
brightness, contrast, etc. settings for the images in the main text and in Figure 3.19 
are normalized to the same values and smoothed.  
 
Figure 3.19. Additional Representative Images of TB1 and TB1-RS6 Cell Binding.  
MCF-7 cells were incubated with 250 nM TB1 or TB1-RS6 for 15 min before 
imaging. For + NPY conditions, cells were preincubated with 1 µM NPY.  Inset: In 
some cases, signal from TB1 or TB1-RS6 was observed in + NPY conditions, 




Fluorescence Lifetime Analysis. TCSPC measurements of fluorescence lifetime 
decays were collected using a pulsed LED with a maximum emission at 486 nm. 
Fluorescence was collected at 515 nm with the slit widths adjusted for each 
measurement to keep the ACD value between 1 - 3 % of the SYNC value. The 
instrument response function (IRF) was collected for each slit width used for 
collection. For these experiments labeled TB1 or TB1-RS6 were diluted to 175 µM 
in water.  Lifetime data were fit using PowerFit10 distributed by PTI. Each decay 
was fit to a single exponential decay where the time regime was selected to 
minimize the chi-squared values and the residuals. 
   
Figure 3.20. Fluorescence Lifetime Measurements of TB1 and TB1-RS6 Peptides.  
TB1 (black) and TB1-RS6 (green) fluorescence decays for 175 µM solutions in 
water.  The instrument response function (IRF) is shown in grey.  IRF-corrected 
single exponential fits to the decay data provide lifetime values of 3.545 ± 0.010 




CHAPTER 4 OPTIMIZATION OF THE TB1-RS6 SCAFFOLD TO MAKE AN 





§ 4.1 Introduction 
As previously discussed in Chapter 3, our laboratory developed TB1-RS6 as 
a stabilized peptide to image the neuropeptide Y1 receptor. This scaffold was 
originally developed as a proof-of-concept to show that thioamide incorporation 
could stabilize peptide-based imaging agents. However, this initial scaffold had 
several issues when we attempted to move into animal models (unpublished data, 
not shown). Some issues that we encountered with the original TB1-RS6 scaffold 
were poor solubility in buffer and rapid internalization of the peptide through 
receptor-mediated endocytosis. In order to develop this scaffold further for future 
imaging applications, we needed to address these concerns. We proposed 
changing three properties of the peptide in order to optimize it for future imaging 
experiments: N-terminal acetylation, the fluorophore identity, and the linker length 
and polarity. In this chapter, I will discuss our efforts towards optimizing the original 
TB1-RS6 scaffold for improved properties for imaging applications.  
 
Figure 4.1 BZ1 peptides, lacking N-terminal acetylation, show coronal staining of 




§ 4.2 Summary of Current Progress 
Currently, we have made a library of peptides to examine how N-terminal 
acetylation and linker identity affect the properties of the TB1 and TB1-RS6 
peptides. We also made a library of oxopeptides to examine the effect of 
fluorophore identity on the solubility of the peptides, as measured by a logP assay. 
These modifications to the TB1 scaffold are summarized in Figure 4.2.  
 
Figure 4.2 Structure of Generic TB1 Scaffold. Areas for optimization are: N-
terminal acetylation or free amino terminus (Z = H or Ac), oxopeptide or thiopeptide 
(X = O or S), linker identity (linker is aminohexanoic acid or PEG), and fluorophore 
identity (purple star = 5,6-carboxyfluorescein, tetramethylrhodamine, or 
indocyanine green). BZ-1 peptide structure is: Z = H, X = O, and fluorophore = 
FAM.  
 
Our initial tests focused on using a library of eight peptides to determine the 
effects of changing N-terminal acetylation and linker identity on the properties of 
the TB1 scaffold. Currently, we have synthesized and purified the peptides shown 





Table 4.1 Table of TB1 constructs for N-terminal acetylation and Linker Testing 
Construct Name 
Ac-TB1-Ahx-FAM (originally TB1) 







Ac: N-terminal acetylation; Ahx: 6-aminohexanoic acid linker; AEEA: ethoxy-ethoxy-acetic acid 
linker; FAM: 5,6-carboxyfluorescein 
 
After synthesis and purification of the peptides in Table 4.1, we wanted to 
determine how these changes to the scaffold affected stability in serum, as any 
changes that decrease serum stability from that of the parent TB1 or TB1-RS6 
scaffold will not be helpful in optimizing these peptides for imaging applications. 
While full serum stability curves are currently being obtained, we can make a 
qualitative assessment from preliminary data. It was determined that having a free-
amino terminus made the peptides more susceptible to cleavage of the N-terminal 
Ile residue (Figure 4.4). In the future, we would like to obtain serum stability curves 
for all eight peptides in order to determine the half-lives and quantitatively compare 
the effect of N-terminal acetylation and linker identity on the stability of the 
peptides.  
 We also made oxopeptides where the identity of the fluorophore was 
changed, in order to determine how this would affect logP of the peptides, a 
measure of their solubility. The original TB1 peptide was labeled with 5,6-
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carboxyfluorescein, and two other constructs were synthesized with a 
tetramethylrhodamine or indocyanine green fluorophore. After synthesis and 
purification, these three peptides were subjected to an HPLC-based assay that 
indirectly measures logP173. We were able to determine that fluorophore identity 
does have a significant impact on the logP of the peptide, and this is an area where 
we can optimize the scaffold for different properties (Table 4.2).  
 
Table 4.2 logP Values for TB1 constructs 
Compound Name log (RT) Calculated logP 
H2N-TB1-Ahx-FAM 1.40 ± 0.01 2.16 
H2N-TB1-Ahx-TAMRA 1.38 ± 0.01 1.99 
H2N-TB1-Ahx-ICG 1.54 ± 0.09 3.34 
FAM = 5,6-carboxyfluorescein, TAMRA = tetramethylrhodamine, ICG = indocyanine green 
 
§ 4.3 Future Directions 
To date, we have obtained data to suggest that N-terminal acetylation and 
linker identity have moderate to significant effects on the stability of these peptides 
in serum. In the future, we would like to obtain full serum stability curves for all the 
peptides in order to make quantitative assessments of the effects of N-terminal 
acetylation and linker identity. It may also be of interest to incorporate a IleS residue 
in peptides that do not have N-terminal acetylation in order to increase the serum 
stability of these peptides. This doubly-thioamidated peptide as well as a TB1-RS6 
peptide without the N-terminal Ile should be examined to determine whether these 
changes affect NPY Y1R affinity. If the shortened peptide is still active, then 
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methods to stabilize the N-terminus are unnecessary to have an active imaging 
peptide.  
Once full serum stability curves have been determined for the peptides in 
Table 4.1, it will also be imperative to determine the KI of each of these peptides 
using the DiscoverX assay described in Chapter 3. If the KI of any given peptide is 
increased, this suggests that the modification made to the peptide may impact its 
interaction with the receptor and will not be helpful in optimizing the TB1 scaffold. 
Eventually, we would also like to use our most potent and soluble TB1 constructs 
to image the NPY Y1R in MCF-7 cells and then in mouse (or other) animal models.  
Our research group is also interested in developing peptide-based imaging 
agents that can target the NPY Y2R, which is overexpressed in a number of brain 
cancers174. Currently, we are developing a cyclic peptide scaffold that we have 
designed to specifically target the Y2R over the Y1R based on previous studies of 
NPY-derived peptides (Figure 4.3)175.  Presently, we have synthesized and purified 
oxo- and thiopeptide versions of the HP2 scaffold with plans to perform serum 




Figure 4.3 Structure of HP2 and HP2-RS10, a NPY Y2R specific imaging peptide. 
Current design includes an aminohexanoic acid linker, 5,6-carboxyfluorescein 
fluorophore, and both oxo- and thiopeptide versions.  
 
§ 4.4 Methods and Materials 
General Information. Fmoc-β-(7-methoxycoumarin-4-yl)-Ala-OH was purchased 
from Bachem (Torrance, CA, USA).  All other Fmoc protected amino acids and 2-
(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU) 
were purchased from Novabiochem (currently EMD Millipore; Billerica, MA, USA).  
Piperidine was purchased from American Bioanalytical (Natick, MA, USA). 7-
Azabenzotriazol-1-yloxy)tripyrrolidino-phosphonium hexafluorophosphate 
(PyAOP) was purchased from ChemImpex (Wood Dale, IL, USA). Sigmacote®, 
N,N-diisopropylethylamine (DIPEA), Mouse serum (M5905) was ordered from 
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Sigma Aldrich. All other reagents were purchased from Fisher Scientific 
(Pittsburgh, PA, USA) unless specified otherwise.  Milli-Q filtered (18 MΩ) water 
was used for all solutions (EMD Millipore).  Peptides were purified with an Agilent 
1260 Infinity II Preparative HPLC system and analyzed with Agilent 1260 Infinity II 
Series Analytical HPLC system.  Peptide mass spectrometry was collected with a 
Bruker Ultraflex III MALDI-MS mass spectrometer (Billerica, MA, USA).  Serum 
stability studies were performed on an Agilent 1100 Series Analytical HPLC 
system.  
 
Synthesis of Nα-Fmoc-Nω-Pbf-L-thioarginine-nitrobenzotriazolide.  Nα-Fmoc-
Nω-Pbf-L-thioarginine-nitrobenzotriazolide was synthesized as previously reported 
by our laboratory176.   
 
Peptide Synthesis, Purification, and Characterization. 
Peptide Synthesis.  Peptides were manually synthesized on scales ranging from 
50-150 μmol rink amide resin using our established protocols136.  Prior to use, the 
glass peptide reaction vessel (RV) was coated with Sigmacote® and dried under 
vacuum.  For a typical synthesis, rink amide resin was added to a dry RV and 
swelled in enough dimethylformamide (DMF) to fully cover the beads for 30 min 
with magnetic stirring (typical volumes range from 4 mL to 8 mL).  Between each 
reaction, the resin was washed extensively with adequate DMF and 
dichloromethane (DCM).  For the first amino acid coupling, 5 equiv of amino acid 
and 5 equiv of PyAOP were dissolved in an appropriate volume of DMF for the 
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scale (50 μmol = 4 mL; 150 μmol = 10 mL) and added to the RV, following an 
addition of 10 equiv of DIPEA.  The reaction ran for 30 min under stirring and was 
performed twice to ensure adequate resin loading.  After washing, the resin was 
incubated with the appropriate volume of 20% piperidine solution in DMF for 20 
min under stirring for deprotection (50 μmol = 4 mL; 150 μmol = 8 mL).  The same 
deprotection procedure was followed for all the subsequent standard amino acids.  
For a typical coupling reaction, 5 equiv of amino acid and 5 equiv of PyAOP were 
dissolved in DMF, and added to the RV, with an addition of 10 equiv of DIPEA. 
This procedure was repeated prior to deprotection to ensure high coupling 
efficiency. Thioamide residues were coupled and deprotected with slightly different 
procedures.  Thioamides were coupled through pre-activated precursors, where 2 
equiv of thioamide was dissolved in 4 mL of dry dichloromethane (DCM) with 2 
equiv DIPEA, and stirred for 30 min.  This procedure was repeated prior to 
deprotection. For the deprotection of thioamides, 2% DBU (1,8-
diazabicyclo(5.4.0)undec-7-ene) in DMF was added to the RV and reacted three 
times for two min each with extensive washing with DMF and DCM between each 
deprotection step.  
 
Peptide Cleavage and Purification. Upon completion of the synthesis, the resin 
was dried with DCM under vacuum.  Peptides were cleaved off resin by treatment 
with a 4 mL fresh cleavage cocktail of trifluoroacetic acid (TFA), water, and 
triisopropylsilane (TIPSH) (95:2.5:2.5 v/v) for 45 min (thiopeptides) or 2 hrs 
(oxopeptides) with stirring.  After treatment, the cocktail solution was expelled from 
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the RV with nitrogen and reduced to a volume of less than 1 mL by rotary 
evaporation.  This TFA solution was then treated with over 10 mL of cold ethyl 
ether in order to precipitate the peptides from the cleavage solution.  This 
precipitate was redissolved in 2mL 50:50 CH3CN/H2O, flash frozen with liquid 
nitrogen, and evaporated using lyophilization.  The crude was diluted in 20-35% 
CH3CN/H2O and then purified on a Phenomenex Luna Omega C18 semiprep 
column (Phenomenex; Torrance, CA, USA) by HPLC using the following gradients 
(Table 4.3 and Table 4.4) at a flow rate of 5 mL/min.  MALDI- MS was used to 
confirm peptide identities (Table 4.5).  Purified peptides were dried on a lyophilizer 
(Labconco; Kansas City, MO, USA) or in a vacuum centrifuge (Savant/Thermo 
Scientific; Rockford, IL, USA).  If needed, peptides were subjected to multiple 
rounds of purification until 99% purity was achieved. 
 
Table 4.3.  Peptide Purification Methods and Retention Time.   
 
Peptide Gradient Retention Time 
Ac-TB1-Ahx-FAM (originally TB1) 1 14.7 min 
Ac-TB1-RS6-Ahx-FAM (originally TB1-RS6) 1 15.3 min 
H2N-TB1-Ahx-FAM 1 16.6 min 
H2N-TB1-RS6-Ahx-FAM 1 13.3 min 
Ac-TB1-AEEA-FAM 1 15.3 min 
Ac-TB1-RS6-AEEA-FAM 1 16.1 min 
H2N-TB1-AEEA-FAM 1 16.6 min 
H2N-TB1-RS6-AEEA-FAM 1 13.3 min 
H2N-TB1-Ahx-TAMRA 1 15.9 min 
H2N-TB1-Ahx-ICG 1 18.2 min 
*RS: thioarginine; Ac: acetylation; Ahx: 6-aminohexanoic acid linker; AEEA: ethoxy-ethoxy-






Table 4.4.  HPLC Gradients for Peptide Purification.   
 
No. Time (min) %B  
1 00:00 020  
03:00 020  
05:00 030  
25:00 050  
27:00   50  
29:00 100  
33:00 020  
 35:00   20  






Table 4.5.  Calculated and Observed Masses of Peptides.   
 
Peptide 
[M+H]+ (m/z) [M+Na]+ (m/z) [M+K]+ (m/z) 










1810.87 1811.94 1832.86 1833.85 1848.38 1849.65 
H2N-TB1-
Ahx-FAM 




1767.86 1769.47 1790.85 N/A 1806.82 1807.81 
Ac-TB1-
AEEA-FAM 
1825.88 1828.18 1848.87 1849.79 1864.85 1866.37 
Ac-TB1-RS6-
AEEA-FAM 
1841.86 1843.27 1864.85 N/A 1880.82 1881.29 
H2N-TB1-
AEEA-FAM 




1799.85 1801.29 1822.84 N/A 1838.81 1838.92 
H2N-TB1-
Ahx-TAMRA 
1806.98 1807.15 1828.84 N/A 1844.82 N/A 
H2N-TB1-
Ahx-ICG 
2094.67 2107.23 2116.87 N/A 2132.81 N/A 
*RS: thioarginine; Ac: acetylation; Ahx: 6-aminohexanoic acid linker; AEEA: ethoxy-ethoxy-acetic 
acid linker; FAM: 5,6-fluorescein; TAMRA: 5,6-tetramethylrhodamine; ICG: indocyanine green 
 
Serum Stability Assay.  A 25 µL solution of 50 µM peptide in sterile Mill-Q 
water was incubated at 37 °C in the presence of 25 µL mouse serum (Sigma 
Aldrich M5905).  After incubating for the desired time, the serum proteins were 
precipitated by adding 50 µL methanol, and chilled at -20 oC for 10 min.  After 
precipitation, samples were pelleted using an Eppendorf 5415R centrifuge at 
13,000 RPM for 10 min at 4 oC.  Next, 80 µL of supernatant was diluted to 200 µL 
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with Milli-Q water and analyzed by HPLC, after the addition of 0.8 µL of a 1.2 mM 
5,6-carboxyfluorescein internal standard solution.  A Phenomenex Luna C8(2) 
analytical column (Torrance, CA, USA) was used to analyze all samples using the 
gradients shown in Table 4.6. The amount of intact peptide was quantified based 
on peak areas in HPLC chromatograms (Figure 4.4).  All peptides were monitored 
at 484 nm.  The internal standard was used to normalize the amount of intact 
peptide in each sample.  For each time point, samples were run in triplicate, and 
the amount of intact peptide was determined to be the average from three separate 
runs.  Due to instrumentation issues, full serum stability curves could not be 
obtained for all peptides. However, we were able to characterize interesting 
degradation products for the H2N-TB1-RS6 peptide series (masses shown in Table 
4.7). 
 
Table 4.6. HPLC Gradient for Serum Stability Assay*. 
 
Time (min) %B 
00:00 002.0 
05:00 002.0 
15:00 0 30.0 








Table 4.7. Retention Times and Masses of H2N-TB1-RS6 Peptides. 
 
Peptide Retention Time (min) Observed Mass (m/z) 
H2N-TB1-RS6-Ahx 24.09 1769.12 
H2N-TB1-RS6-AEEA 23.22 1801.34 
H2N-TB1-RS6-Ahx (-Ile) 23.52 1655.90 
H2N-TB1-RS6-AEEA (-Ile) 22.88 1687.89 
H2N-TB1-RS6-Ahx (-Ile-Asn) 23.21 1493.79 




Figure 4.4. Serum Stability Assay.  Representative HPLC chromatograms.  
Absorbance was monitored at 484 nm. Traces of peptides after treatment with 
serum for four hours; * indicates 5,6-carboxyfluorescein internal standard, § 
indicates cleavage of N-terminal Ile-Tyr amino acids, ƒ indicates cleavage of N-
terminal Ile amino acid, and † indicates internal standard bound to serum proteins. 
Masses for cleavage products are shown in Table 4.7.  
 
logP Assay Protocol In order to determine the indirect logP of some of the TB1 
peptides, as assay adapted from an Environmental Protection Agency (EPA) 
protocol was implemented173. Briefly, four small molecules with known logP values 
were used to create a standard curve of logP versus HPLC retention time.  The 
standards used were naphthalene, benzyl alcohol, toluene, and diphenyl ether. 
These compounds were diluted in acetonitrile and the retention times were 
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determined in triplicate by analytical HPLC analysis on a 1260 Infinity II Series 
Agilent HPLC using the gradient shown in Table 4.8. on a Luna Omega analytical 
C88 column (Phenomenex, Torrance, CA, USA).  A sample HPLC trace of these 
standard compounds can be seen in Figure 4.5. Once a standard curve was 
developed, the TB1 constructs outlined in Table 4.2 were subjected to the same 
indirect measurement of logP and the standard curve was used to determine logP 
for these peptides. Plots of logRT versus logP for these peptides can be seen in 
Figure 4.6. 
 
Table 4.8. logP Assay Gradient. 
Time (min) %B 
00:00 002.0 
05:00 002.0 
10:00 0 10.0 










Figure 4.5. HPLC Traces of logP Standards. Naphthalene (black), benzyl alcohol 
(red), toluene (green), and diphenyl ether (blue) were analyzed using analytical 
HPLC in order to produce a standard curve for indirect logP. 
 
 
Figure 4.6. logP Curves of Standards and TB1 Peptides. Left: standard curve of 
small molecules with known logP values to provide an equation to determine 
indirect logP. Right: log plot of RT and logP showing where the different TB1 





CHAPTER 5 EXPRESSION AND LABELING OF PEPTIDE HORMONES FOR 




§ 5.1 Introduction 
Peptide hormones are an interesting class of potential therapeutics 
because of their intrinsic signaling ability and known activity in the body. Therefore, 
it is important to have tools to study their cellular activity, receptor expression, and 
to image these receptors when they are overexpressed in disease states. Due to 
the size of these peptide hormones (many being >30 amino acids), synthesis, 
derivatization, and purification can be a challenge when developing functionalized 
versions. In order to obtain these peptide hormones for imaging applications, we 
have developed a cell-based platform for expressing peptides and other biological 
targets of interest that allows us to incorporate an unnatural amino acid for 
fluorophore conjugation after expression and purification. Amber suppression 
methods allow for non-canonical amino acids to be incorporated into peptides and 
proteins through cellular expression in E. coli and, to some extent, in mammalian 
cells177-178. Utilizing this methodology, we are hopeful that we can express full-
length peptide hormones and other large, biological targets with reactive amino 
acids as handles for fluorophore conjugation.  
 
§ 5.2 Summary of Current Progress 
Currently, moderate progress has been made on the expression, 
purification, and modification of two peptide hormones – Neuropeptide Y (NPY) 
and Growth Hormone Releasing Hormone (GHRH). The sequences of these 
peptides are shown in Figure 5.1 Sequences of NPY and GHRH. Both peptides 
are C-terminally amidated (denoted by -NH2 at the end of the sequence). 
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Proteolytic cleavage sites of DPP-4 (red) and human Kallikrein (orange) are also 
shown., and are of interest due to the receptors or the peptides themselves 
currently being studied for therapeutic purposes179-180.  
 
 
Figure 5.1 Sequences of NPY and GHRH. Both peptides are C-terminally 
amidated (denoted by -NH2 at the end of the sequence). Proteolytic cleavage sites 
of DPP-4 (red) and human Kallikrein (orange) are also shown.  
 
 
One thing that makes the expression of peptide hormones, and other biologically 
active peptide and proteins, difficult is the amidated C-terminus these biomolecules 
may contain that is necessary for their function. Previously, researchers had 
produced this C-terminal amidation by simply using the appropriate resin when 
generating these peptides by solid phase peptide synthesis. However, it was not 
until recently that researchers found a way to post-translationally modify expressed 
peptides, such that the final target would contain C-terminal amidation181. In order 
to do this, researchers expressed their peptide of interest with an intein at the C-
terminus that would then be converted to a thioester using sodium 2-
mercaptoethanesulfonate (MESNa). Finally, this thioester is converted to the 
amidated C-terminus by aminolysis with a high concentration of ammonium 





Figure 5.2 General Scheme for Peptide Hormone Expression. Peptide hormones 
(POI = protein of interest) will be expressed as intein constructs with a six His tag 
at the C-terminus for purification. In order to remove the intein and reveal an 
amidated C-terminus, the peptide with intein is treated with MESNa to form the 
MESNa thioester and then ammonium carbonate to reveal the amidated C-
terminus.  
 
Once a method for C-terminal amidation was determined, we began to optimize 
the expression of native NPY and GHRH. To date, we have MALDI and SDS gel 
electrophoresis data to suggest the expression, C-terminal amidation, and 







Figure 5.3 SDS-PAGE Gel Electrophoresis and MALDI-TOF from Expression of 
NPY and GHRH. Top: SDS-PAGE Gel of flow-through (FT), Wash #1 (W1), Wash 
#2 (W2), and Elution and Cleavage (Elu) from NPY and GHRH expressions. 
Bottom: MALDI-MS of NPY and GHRH after purification. Calculated mass of 
MIEGR-NPY-NH2: 4858.39 g/mol. Calculated mass of MIEGR-GHRH-NH2: 
5626.36 g/mol. Red star indicates the desired peak. 
 
Currently, we are working towards optimizing a proteolytic cleavage 
reaction to yield the native N-termini of these peptides, as opposed to the Met 
amino acid that would be present after expression in E. coli. We are using Factor 
Xa, a serine endopeptidase that recognizes the sequence Ile-Glu (or Asp)-Gly-
Arg-X and will cleave at the Arg-X bond182. We are optimizing conditions for this 
cleavage reaction in order to cleave Met-Ile-Glu-Gly-Arg/Tyr at the red dashed line 
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to provide us the native NPY peptide. Due to the Arg-rich nature of the C-terminus 
of NPY, we have observed off-target cleavage in this area of the peptide of interest 
(MALDI Data in Table 5.2).  If the off-target effects prove to be too difficult to control 
with Factor Xa, we will use a different enzyme, such as Sumo protease, to produce 
the desired N-terminus.  
 
§ 5.3 Future Directions 
Currently, our laboratory is developing a cell-based platform to express and 
functionalize peptide hormone imaging agents. In order to achieve this goal, there 
are a few key experiments left to perform. First, incorporation of an unnatural 
amino acid needs to be completed. As a proof-of-concept, we are going to 
incorporate propargyl tyrosine (PpY) into several C-terminal positions in NPY in 
order to develop a small library of peptides. Next, we will use this handle to attach 
a fluorophore using copper-catalyzed click chemistry in order to make a full-length 
NPY with site-specific fluorophore incorporation. Once this small library of peptides 
is constructed, we will use circular dichroism to determine if the incorporation of an 
unnatural amino acid has affected the secondary structure. We will also use a 
DiscoverX cell-based assay to determine if these peptides still interact with the 
NPY Y1 and Y2 receptors with similar potency to native NPY. Once this workflow 
has been established, it will be applied to GHRH and other targets of interest. If 
proteolytic stability becomes an issue, we are also considering incorporating 
thioamide modifications through native chemical ligation in order to address this 
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issue. Eventually, the best constructs will be used for animal or cellular imaging 
studies.  
 
§ 5.4 Methods and Materials 
General Information. cOmplete Mini, EDTA-free protease inhibitor tablets were 
purchased from Roche Diagnostics (Mannheim, Germany). High-Density Nickel 
Agarose Beads were purchased from GoldBio (St. Louis, MO, USA). UV-Vis 
absorption measurements were performed on a Thermo Fisher Scientific Genesys 
150 UV/Vis Spectrophotometer (Waltham, MA, USA). Matrix assisted laser 
desorption/ionization with time-of-flight detector (MALDI-TOF) mass spectra were 
acquired on a Bruker Ultraflex III or Microflex LRF instrument. Preparative HPLC 
was performed on an Agilent 1260 Infinity II Prep HPLC system. HPLC columns 
were purchased from Phenomenex (Torrance, CA, USA). The HPLC column used 
were Prep size (250 x 21.2 mm) Luna® Omega 5 μm PS C18 100 Å columns from 
Phenomenex. All PCR reactions were carried out on a T100 thermocycler from 
Bio-Rad (Hercules, CA, USA). Primers and double stranded DNA fragments 
(gBlocks) were purchased from Integrated DNA Technologies (Coralville, IA, 
USA). dNTPs, SYBR Safe DNA gel stain and Agarose were purchased from 
Invitrogen (Waltham, MA, USA). Q5 High-Fidelity DNA152 polymerase, Q5 High-
Fidelity DNA polymerase Master Mix, HiFi DNA Assembly Master Mix, Restriction 
Enzymes, competent High Efficiency E. coli cells (NEB 5-alpha and NEB 10-beta), 
Monarch Gel Extraction Kit was purchased from New England Biolabs (Ipswich, 
MA, USA). Gel Green DNA gel stain was purchased from Biotium (Freemont, CA, 
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USA). DNA Clean & Concentrator Kit and Plasmid Miniprep Kit were purchased 
from Zymo Research (Irvine, CA, USA). DNA concentrations were determined with 
a TECAN Nanoquant plate on an Infinite M1000Pro plate reader (Tecan, 
Männedorf, Switzerland). DNA sequencing (Sanger sequencing) was performed 
at the University of Pennsylvania DNA Sequencing Facility (Philadelphia, PA, 
USA).  
 
Procedure for Deletion PCR. Primers were dissolved in Milli-Q grade water to be 
at a concentration of 50 μM. The amount of plasmid used ranged from 0.1 – 1 ng 
total DNA for amplifications using Q5 polymerase. Primers, plasmid and buffer 
components were mixed according to manufacturer recommendations. PCR was 
carried out for 29 cycles at an annealing of 59 °C for 45 seconds. Following deletion 
of the αS gene, the PCR product was purified using DNA agarose gel 
electrophoresis. The band corresponding to the desired plasmid was cut from the 
gel and isolated using the Monarch DNA Gel Extraction Kit. The DNA was 
quantified using the Nanoqaunt plate and determined to be 38 ng/µL. This plasmid 
was then used in the Gibson Assembly of the NPY and GHRH plasmids for 
expression.  
 
General Procedure for Gibson Assembly. DNA assembly was performed with 
100 ng of vector DNA and 5 equiv of insert DNA using a HiFi DNA Assembly Mix 
according to manufacturer’s protocol. 10 μL of the ligated product were 
transformed in 50 μL competent NEB10β cells according to manufacturer’s 
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instructions and plated on an LB-Agar plate containing appropriate antibiotic. 
Individual colonies were picked, grown up in 5 mL LB-medium and their DNA was 
extracted using a Plasmid Miniprep Kit according to manufacturer’s protocol. 
Quantified DNA was submitted for sanger sequence analysis to verify correct 
sequence. Sequencing primer was provided by Sequencing Center and aligns with 
T7 promoter unless otherwise noted. 
 
Cloning of MIEGR-NPY-MxeGyrA-His6. The plasmid was constructed using 
Gibson Assembly. The Vector donor plasmid was pTXB1 αS-MxeGyrA-His6 and 
construction of this plasmid is described elsewhere183. The insert was purchased 
as a gBlock from IDT. 
Forward Primer for vector: 5’ – TGC ATC ACG GGA GAT GCA – 3’ 
Reverse Complement Primer for vector: 5’ – ATG TAT ATC TCC TTC TTA AAG TTA AAC 
– 3’ 
gBlock: 5’ - TTA ACT TTA AGA AGG AGA TAT ACA TAT G ATT GAG GGC CGC GAT CGA 
GGG TCG TTA TCC GTC TAA ACC CGA TAA CCC AGG GGA GGA TGC TCC TGC GGA AGA 
TAT GGC ACG TTA CTA CTC AGC GCT GCG CCA TTA CAT TAA CTT AAT CAC TCG TCA 
GCG CTA TG CAT CAC GGG AGA TGC ACT AGT TG – 3’ 
 
Cloning of MIEGR-GHRH-MxeGyrA-His6. The plasmid was constructed using 
Gibson Assembly. The Vector donor plasmid was pTXB1 αS-MxeGyrA-His6 and 
construction of this plasmid is described elsewhere183. The insert was purchased 
as gBlock from IDT (Coralville, Iowa, USA). 
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Forward Primer for vector: 5’ – TGC ATC ACG GGA GAT GCA – 3’ 
Reverse Complement Primer for vector: 5’ – ATG TAT ATC TCC TTC TTA AAG TTA AAC 
– 3’ 
gBlock: 5’ – TTA ACT TTA AGA AGG AGA TAT ACA TAT GAT TGA GGG CCG CTA TGC AGA 
TGC GAT CTT CAC AAA TTC GTA TCG TAA AGT TCT GGG CCA GTT ATC CGC ACG CAA 
GCT GTT ACA AGA TAT TAT GTC TCG CCA ACA GGG TGA AAG TAA CCA AGA GCG TGG 
TGC CCG CGC ACG CCT GTG CAT CAC GGG AGA TGC ACT AGT TG – 3’ 
 












General Procedure for Expression of Peptide Hormones.  A single colony was 
picked from an LB/Amp plate used to grow the plasmid of choice and allowed to 
grow for 4-5 in 5 mL LB media supplemented with 100 µg/mL ampicillin (until OD600 
≈ 0.6-0.7). Next, the primary culture was inoculated into a 1 L LB/ampicillin media 
(10 g Tryptone, 10 g NaCl, and 5 g year in 1 L Milli-Water with add 100 µL of 
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100mg/mL Amp stock) and placed in a 37 °C incubator with shaking at 250 rpm 
until OD600 reads 0.7-1.0. Finally, isopropyl-β-D-1-thiogalactopyranoside (IPTG) 
was added to a final concentration of 0.5 mM and the expression was allowed to 
go overnight (16-18 hours) at 18 °C. After protein expression was complete, the 
cells were pelleted by dividing the culture into 500 mL centrifuge bottles and 
centrifuging for 20 minutes at 4 °C utilizing a Sorvall GS-3 rotor at 4,000 rpm. Next, 
the cell pellet was resuspended in 20 mL 540 mM Tris, pH 8.3 with 1 Roche 
protease inhibitor cocktail pill (cOmplete mini tablets, EDTA-free, Easy Pack, 
Roche Cat. #04693159001) and supplemented with 0.1 mM PMSF. Next, the cells 
were lysed by sonication (amplitude 40, 5 minutes total, 1 second on, 1 second 
off). Finally, the cell debris was pelleted off by centrifugation using a Sorvall SS-34 
rotor (14,000 rpm, 20 minutes, 4 °C).  
 
General Procedure for Purification using Ni-NTA Resin. After expression and 
lysis of the cells, the supernatant was allowed to incubate with 3 mL of Ni-NTA 
resin on ice for 1 hour, with shaking. Next, the flow-through was collected, and the 
Ni-NTA resin was treated with a series of washes. The first wash was done with 
15 mL 50 mM HEPES buffer, pH 7.5. The second wash was done with 20 mL 50 
mM HEPES buffer, 5 mM imidazole, pH 7.5. Finally, the protein was eluted with 12 
mL 50 mM HEPES buffer, 300 mM imidazole, pH 8.0. 
 
General Procedure for C-terminal Amidation of Peptide Hormones. Ni-NTA 
column elution was treated with 500mM MESNa, pH 7.5 (400 mg into 12 mL 
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elution) for 48 hours at 4 °C. Once the intein cleavage and C-terminal MESNa 
thioester formation was deemed to be complete by MALDI-MS, 1 M NH4HCO3 (1.0 
g into 12 mL elution), pH 8.5 was added to the elution and treated for 48 hours at 
room temperature. This was then dialyzed into water and purified by Prep HPLC. 
The purification gradient for the MIEGR-NPY-NH2 can be seen in Table 5.1. After 
purification, the peptide was lyophilized to afford a powder for further studies.  
 
Table 5.1 HPLC Gradient for Purification of MIEGR-NPY-NH2* 
 








*Solvent A: 0.1 % TFA in water; Solvent B: 0.1 % TFA in acetonitrile 
 
General Procedure for Factor Xa Cleavage. In order to afford the full-length, 
expressed NPY from MIEGR-NPY-NH2 the Factor Xa protease was used to cleave 
the N-terminal leader peptide MIEGR. Purified MIEGR-NPY-NH2 was dissolved in 
2 mL of Factor Xa Buffer (20 mM Tris, 100 mM NaCl, 2 mM CaCl2, pH 8.0) to a 
concentration of 16.25 µM. 50 µL of this stock (~4 µg/mL peptide) was treated with 
0.02 µg/mL Factor Xa (1 µL of Factor Xa stock diluted with 999 µL Factor Xa 
buffer). The reaction was monitored over time, and after 60 minutes there was no 
reaction, so 10 µL of the 1 µg/mL Factor Xa stock were added and the reaction 
was checked again after another 60 minutes. This reaction was then allowed to 
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proceed overnight, where it was determined by MALDI-MS that the reaction had 
moved forward significantly, but so had a side reaction (proposed to be the 
cleavage of the C-terminal Tyr residue). Further optimization of this reaction 
protocol is needed.  
 
Table 5.2 Observed Masses During Factor Xa Cleavage of MIEGR-NPY-NH2 
 
Proposed Peptide Observed Mass (m/z) Calculated Mass (m/z) 
MIEGR-NPY-NH2 4860.55 4858.39 
IEGR-NPY-NH2 4727.00 4727.02 
NPY-NH2 4274.32 4271.69 
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